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Abstract 
Matrix metalloproteinases (MMPs) network with other biological molecules to 
maintain the extracellular matrix (ECM) in normal physiology and perform 
different roles. Understanding and assigning specific role to each of 24 
members of these endoproteinases is impeded because of lack of specific 
and efficient detection methods in biological samples. Moreover, MMP-based 
anti-cancer drug development has also been challenged because, currently, 
there is no robust methodology to distinguish the inactive pro-enzymes, 
active enzymes or those complexed with endogenous inhibitors in biological 
specimens. The objective of this project is to develop a chemical proteomics 
strategy based on Matrix assisted laser desorption ionization tandem mass 
spectrometry (MALDI-MS/MS) to help identify and discriminate the various 
MMP forms. Firstly, a triazine dye-based ligand immobilized on 
chromatography beads was utilized to assess whether it binds to 
recombinant human MMPs (rhMMPs). The results highlighted that the ligand 
interacts with latent forms of MMPs in agreement with the literature. 
Secondly, the potential of the ligand was assessed using MALDI-MS/MS 
based methodology in in vitro cancer models. Cell line culture supernatants 
were used in amounts to emulate the availability of tumour biopsies in clinical 
settings. The MS/MS spectral peaks specific to MMPs (MMP-2 and MMP-
14), and two endogenous inhibitors TIMP-1 and TIMP-2 were found in affinity 
chromatography eluates of cell culture supernatants with higher Mascot 
scores for the latter. While western blot detected MMP-2 in cell extracts, 
MALDI-MS/MS did not detect MMPs because of amounts below the limit of 
detection (LOD) of the instrument. Although the ligand was found to be 
interacting with MMPs and detergent-free salt elution buffers improved 
MALDI analysis, recovery of MMPs from biological samples was sub-optimal. 
The dye ligand was observed to bind other enzymes and despite various 
strategies to reduce non-specific binding of proteins or enable selective 
elution did not improve MMP enrichment. Further work using methodology 
described in this study is required after scaling up the MMP amounts in 
biological specimen and to resolve the issue of non-specific binding of 
proteins to the ligand by understanding its structure. 
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1.9 Mass Spectrometry͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϯϯ
1.9.1 MALDI-Mass Spectrometry͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϯϱ
1.9.2 MALDI-MS-TOF͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϯϲ
1.10 Proteomics͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϯϵ
1.10.1 Chemical Proteomics͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϬ
1.10.2 Separation Techniques͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϭ
1.10.3 Proteomics Approaches͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϯ
1.11 Aims and Objectives͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϰ
2 Materials and Methods͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϳ
2.1 Reagents & Chemicals͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϳ
2.2 Immobilization of OliveH-7G on Chromatography Beads: H-7G-Sepharose and 
H-7G-Sephadex͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϳ
2.3 Cell Culture͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϴ
2.3.1 Cell Counting͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϴ
2.3.2 Tumour Cell Line Growth Kinetics͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϴ
2.3.3 Collection of Culture Supernatant͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϵ
2.3.4 Harvesting of Cells͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϵ
2.4 Affinity Chromatography of Recombinant, Secreted and Cellular MMPs͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϭ
2.4.1 Salt Elution͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϭ
2.5 Protein Concentration: NAP-5 Columns and Dialysis Method͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϮ
2.6 Bradford Assay for Quantification of Total Proteins͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϰ
V 
2.7 ELISA for Quantification of MMP-2͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϰ
2.8 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϲ
2.8.1 Coomassie Brilliant Blue Staining͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϲ
2.8.2 Silver Staining͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϳ
2.8.3 Western Blotting for MMP-2͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϳ
2.9 Trypsin Digestion͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϴ
2.9.1 Proteomics: In-Solution Trypsin Digestion͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϴ
2.9.2 Proteomics: On-Bead Trypsin Digestion͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϵ
2.10 Desalting of Digested Protein͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϵ
2.10.1 Desalting by Isolute C18 Cartridges͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϵ
2.10.2 Desalt with Zip tips͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϬ
2.10.3 Desalt with Pierce Columns͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϬ
2.11 Manual MALDI-MS of Peptides͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϭ
2.11.1 Instrumentation͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϭ
2.11.2 Matrix Solution Preparation͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϭ
2.11.3 Mass Spectrum Acquisition͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϭ
2.12 nHPLC coupled to MALDI-MS/MS for Protein Identification (LC-MS/MS)͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϮ
2.12.1 Reverse phase nHPLC Fractionation of Modified Peptides͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϮ
2.12.2 nHPLC Gradient Conditions͘ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϮ
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CHAPTER 1 
INTRODUCTION 
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1 Introduction 
1.1 Definition of Cancer  
Cancer is a broad and complex family of diseases that remains one of the 
most frequent causes of death worldwide (Varmus, 2006). Although cancer 
has multiple causes and exhibits a wide range of genetic, physiological and 
histological features, an acceptable clinical definition states that cancer is a 
set of diseases characterized by up-regulated cell growth leading to invasion 
of surrounding tissues and metastasis to different parts of the body (Kinzler 
and Vogelstein, 1996). Cancer research over the last few decades has 
defined cancer to be a disease involving dynamic changes in the genome. 
The discoveries of mutations that produce oncogenes with dominant gain of 
function and tumour suppressor genes with recessive loss of function in 
animal models have set the foundation of cancer research. Several lines of 
investigation suggest that tumourigenesis is a multi-step process where 
alterations at genetic level drive the progressive transformation of normal 
human cells into highly malignant derivatives. These genetic alterations can 
be as subtle as point mutations and as substantial as changes in 
chromosome compliment (Kinzler and Vogelstein, 1996). Cancer cells have 
defects in regulatory circuits that govern normal cell proliferation and 
homeostasis. 
1.2 Hallmarks of Cancer 
Cancer arises from the stepwise accumulation of several genetic alterations 
in a cell over time, resulting in uncontrolled growth, the formation of a tumour 
and the ability of cells from that tumour to metastasize (Fearon and 
Vogelstein, 1990). The uncontrolled cell growth observed in cancers is 
complex and is thought to result from the deregulation of a number of 
features under exquisite control in healthy cells. It has been suggested that 
the successful breaching of anticancer defense mechanisms in each cell is 
achieved by acquiring novel capabilities caused by changes in molecular, 
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biochemical and cellular traits regulating their proliferation, differentiation and 
death (Hanahan and Weinberg, 2000). Hanahan and Weinberg proposed 
that six essential alterations in cell physiology collectively dictate malignant 
growth namely self-sufficiency in growth signals, insensitivity to antigrowth 
signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis and tissue invasion and metastasis (Figure 
1.1). 
1.2.1 Limitless Replicative Potential 
Mammalian cells carry an intrinsic program that limits the replicative potential 
of a cell and the number of divisions it may undergo. Healthy cells stop 
dividing (senescence) once a maximum number of cell doubling has been 
reached. In cancer cells, this senescence mechanism is de-regulated 
resulting in an override of replicative control. This replicative process is 
deregulated via telomeres which are specialized lengths of chromosome 
ends (Hanahan and Weinberg, 2000). As a cell divides, these telomeres 
shorten until eventually chromosomes become unprotected, signaling the 
senescent switch. A major mechanism for overcoming this switch is the up-
regulation of an enzyme called telomerase which is able to renew the length 
of telomeres resulting in a limitless replication (Blackburn, 2005). 
1.2.2 Self Sufficiency and Insensitivity to Antigrowth Signal 
Normal cells in culture require specific mitogenic factors and matrices in 
order to proliferate; this is in contrast to cancer cells which have shown a 
greatly reduced dependency on exogenous growth stimulation. Growth 
signaling autonomy by activation of dominant oncogenes is a feature of 
tumour cells which liberates it from homeostatic mechanisms in tissues 
(Hanahan and Weinberg, 2000). The over-expression of receptors HER-
2/neu has been reported in mammary carcinomas which enables the cancer 
cells to respond to ambient levels of signals which  otherwise will not illicit a 
cellular response (Yarden and Ullrich, 1988). The genetically damaged 
cancer cells are supported by surrounding stromal cells such as inflammatory 
cells which have been reported to promote growth at the site of neoplasia 
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(Hudson et al., 1999). In order to keep dividing to establish the tumour, 
cancer cells devise ways to avoid terminal differentiation. In addition to self-
sufficiency in growth signals, cancer cells have developed a number of 
modifications to become insensitive to growth inhibitory signals. The tumour 
cells become insensitive to antigrowth signals via disrupting various 
mechanisms controlling cell division. Fynan reported that disruption of 
retinoblastoma protein signal circuitry switches the quiescent cells to dividing 
cells (Fynan and Reiss, 1993). One of the strategies followed by tumour cells 
is to shift the balance from myc-mad complex to myc-max complex formation, 
the latter being the anti-differentiation signal which promotes growth (Foley 
and Eisenman, 1999). It too must be disrupted in order for a clone of cells to 
expand to a size that constitute a macroscopic tumour. It has been found that 
a cell achieves limitless replicative potential by escaping senescence, 
multiplying for additional generations to enter crisis state and without limit, 
the trait termed as immortalization (Wright et al., 1989). 
1.2.3 Evasion of Apoptosis 
In healthy cells, inappropriate proliferation is controlled by the tightly 
regulated process of apoptosis, a precisely choreographed series of steps in 
which cell membranes are disrupted, cytoskeletons are broken down, 
chromosomes are degraded and the nucleus is fragmented (Hanahan and 
Weinberg, 2000). All types of cancer cells alter expression of survival and 
death signal receptors on their cell surface to escape programmed cell death 
(Hanahan and Weinberg, 2000). In the event of abnormality such as DNA 
damage, oncogene activation or insufficient survival signals, cell death is 
stimulated (Evan and Littlewood, 1998). Tumour cells grow rapidly by 
decreasing the expression of p53 protein which, as part of the defense 
system of cell, loses its function (Symonds et al., 1994). Resistance to 
apoptosis is acquired by impairing the apoptotic signaling circuitry. It was 
found that lung cancer cells develop non-signaling CD95 (Fas) receptors 
which do not bind Fas death signals hence cells continue to divide and grow 
into a tumour (Pitti et al., 1998). The cell survival signaling pathway PI-3 
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kinase-AKT/PKB is activated in most parts of human tumours (Hanahan and 
Weinberg, 2000). 
1.2.4 Angiogenesis 
Angiogenesis is an invasive process in which new vessels emerge from 
existing endothelial vessels as opposed to vasculogenesis in which vessels 
differentiate from stem cells (Stetler-Stevenson, 1999). Circulatory system 
develops by both vasculogenesis and angiogenesis during embryonic life. 
However, in the adults, with the single exception of the reproductive cycle in 
females, angiogenesis is initiated only in response to a pathologic condition, 
such as inflammation, rheumatoid arthritis, hypoxia and cancer. The rapid 
growth of tumours results in their requirement of their own blood supply and it 
is known that tumours do not grow beyond 1-2mm unless there is a supply of 
oxygen and nutrients (Carmeliet and Jain, 2000). Angiogenesis is a dynamic 
process, controlled by a large number of pro- including vascular endothelial 
growth factor (VEGF) and fibroblast growth factor (FGF) and anti-angiogenic 
factors (including thrombospondin-1 and endostatin) (Bergers and Benjamin, 
2003). In order to maintain a sufficient blood supply carrying nutrients for 
rapidly dividing cells in tumour, it develops more and more blood vessels 
(Folkman, 1997). Various studies at transcriptional level have confirmed the 
down-regulation of antiangiogenic factors during tumour growth such as 
thrombospondin-1 which in turn is regulated by p53 tumour suppressor gene 
(Dameron et al., 1994). An up-regulation of angiogenic inducers such as 
VEGF further supports the idea that tumour promotes neo-vascularisation 
(Volpert et al., 1997). 
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Figure 1.1 Acquired capabilities for the development of cancer cells. 
Taken from (Hanahan and Weinberg, 2011). 
1.2.5 Cancer Invasion and Metastasis 
Metastasis describes both the process of cancer spread, and the resultant 
secondary cancer, the actual metastatic lesion. Since most cancer patients 
present with localized disease that is effectively managed with multimodality 
therapies including surgery, radiation, and chemotherapy, the development of 
metastasis at distant secondary organs must involve the dissemination of 
metastatic cells before patients present with a primary tumour. Based on the 
work of several groups, it is believed that the process of metastasis involves 
tumour cells leaving the primary tumour through well-regulated lyses of 
surrounding stroma. These cells must pass through the tumour basement 
membrane and then through or between endothelial cells in order to enter the 
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circulation. While in the circulation, tumour cells must resist the process of 
anoikis (programmed cell death associated with loss of cellular contact), 
evade immune recognition, cope with the sheer physical stress of the 
circulatory system, and eventually arrest at a distant organ. At the distant 
site, the cell must exit the circulation, survive the stresses of a new and likely 
hostile microenvironment, proliferate, induce angiogenesis and/or co-opt 
existing blood vessels, and then successfully grow into a measurable 
metastatic lesion (Steeg and Theodorescu, 2008). 
The timing, pattern and sites for the spread of cancer are in part defined by 
the specific cancer type. The route of spread of cancer may include blood 
stream (haematogenous), lymphatic vessels, or third space extension i.e., 
ascitic fluid dissemination as seen in ovarian cancer. The site of distant 
metastasis may include regional lymph nodes, or visceral organs such as 
lungs, liver, brain, and bone. Weiss et al. have shown that the primary site of 
metastases tend to occur at the first capillary bed encountered (Weiss et al., 
1988). However, it is increasingly believed that the specific site of distant 
metastasis is not simply due to the anatomical location of the primary tumour 
or proximity to secondary sites, but rather, involves interactions between 
tumour cells and the local micro-environment at the secondary site. For many 
reasons, metastatic lesions are often not amenable to the surgical treatment 
achieved in the management of the primary tumour. Metastasis remains the 
overwhelming cause of approximately 90% deaths for cancer patients 
(Hanahan and Weinberg, 2000). The development of metastases at distant 
secondary organs is often so widespread that surgery is not possible. In 
addition, metastatic lesions themselves demonstrate increased resistance to 
conventional treatment modalities i.e., chemotherapy. This resistance to 
therapy may be acquired as a result of past treatment of the patient or may 
be an innate feature of cells that have successfully negotiated the metastatic 
process. Based on the challenges that metastatic disease presents, new 
treatment options are needed in order to decrease morbidity and mortality. 
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1.3 Matrix Metalloproteinases (MMPs) 
The cancer degradome defines the complete set of protease genes or the 
repertoire of proteases expressed by a certain tissue during cancer (Lopez-
Otin and Overall, 2002). The human degradome is composed of 569 
protease and protease-related genes (Puente and Lopez-Otin, 2004; Puente 
et al., 2003). Human proteases can be divided into five different catalytic 
classes, with metalloproteinases, serine and cysteine proteases being the 
most abundant ones (194, 176 and 150 genes in human genome, 
respectively), while aspartic and threonine proteases are composed of 
smaller numbers (21 and 28, respectively). The family of matrix 
metalloproteinases (MMPs), also known as matrixins, represents a sub-group 
of zinc endopeptidases which mediate both normal and pathological tissue 
remodeling processes. The human genome has 24 matrixin genes which 
include a duplicated MMP23 gene. Thus, there are 23 different MMPs 
(Murphy and Nagase, 2008a). In these endopeptidases, a conserved 
methionine forming a ‘Met-turn’ eight residues downstream of the Zn2+
binding motif HEXXHXXGXXH supports the active site cleft structure around 
the catalytic Zn2+ (Bode et al., 1993).  
In 1962 Gross and Lapiere first reported vertebrate collagenolytic activity in 
tadpole tissues (tailfin, skin, intestine and gill) undergoing metamorphosis 
(Gross and Lapiere, 1962). These tissues are rapidly remodeling the ECM, 
hence triggering apoptosis, cell differentiation and growth (Shi et al., 1998). 
Since degradation of collagen is important in wound healing, tissue 
regeneration and diseases such as arthritis, cancer, atherosclerosis, 
aneurysm and tissue ulcerations, this discovery stimulated many researchers 
to look into human tissues. MMP-1 can degrade a broad range of substrates 
including types I, II, III, VII, VIII, and X collagens as well as casein, gelatin, Į-
1 antitrypsin, myelin basic protein, L-Selectin, pro-TNF, IL-1ȕ, IGFBP-3, 
IGFBP-5, pro-MMP-2 and pro-MMP-9. A significant role of MMP-1 is the 
degradation of fibrillar collagens in ECM remodeling, characterized by the 
cleavage of the interstitial collagen triple helix into ¾, ¼ fragments. MMP-1 is 
expressed by fibroblasts, keratinocytes, endothelial cells, monocytes and 
macrophages. MMP-10 is expressed naturally in keratinocytes, T cells, 
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menstrual endometrium and a few tumour samples. MMP-10 degrades a 
broad range of substrates including gelatin, collagen types III, IV and V, 
fibronectin and aggrecan. MMP-10 can activate other MMPs such as MMP-1 
and MMP-8. MMP-13 has been demonstrated to degrade a range of ECM 
proteins, including collagen types I, II, III, IV, IX, X and XIV, gelatin, 
aggrecan, perlecan and fibronectin. MMP-13 is distinguished from the other 
human collagenases by its efficient degradation of type II collagen. MMP-13 
is expressed by fibroblasts, chrondrocytes and and squamous epithelial cells. 
Over ׽40 years (1962–2001), 28 different MMP genes have been identified. 
The founding member of the MMP family, Xenopus collagenase, now thought 
to be collagenase 4 (MMP-18), was discovered in 1962 by J. Gross and C. 
M. Lapiere (Gross and Lapiere, 1962) and the last member, epilysin (MMP-
28), was reported by Strongin in 2001 (Marchenko et al., 2001). With the 
completion of the genome project, it is clear that all members of this family 
have now been identified (Greenlee et al., 2007). 
1.4 MMPs in Normal Physiology and Degradative Diseases 
These enzymes are present in normal healthy individuals and have been 
shown to play an important role in processes such as wound healing, 
pregnancy and bone resorption. The hallmark of disease involving MMPs 
appears to be a stoichiometric imbalance between active MMPs and tissue 
inhibitor of metalloproteinases (TIMPs), leading to excessive tissue disruption 
and often degradation. MMPs have been implicated in the development or 
progression of several diseases or syndromes. The destructive mechanism 
of cellular damage in myocardial infarction and vascular disease is suggested 
to involve MMP-2, MMP-9 and MMP-14 (Deschamps et al., 2005; 
Hayashidani et al., 2003; Longo et al., 2002; Matsumura et al., 2005). Chase 
and Newby (2003) have proposed that multiple steps of MMP gene induction 
occur in vascular pathologies due to the progressive recruitment of different 
cell types and inductive factors during different phases of the disease (Chase 
and Newby, 2003). In rheumatoid arthritis (RA) and osteoarthritis (OA), the 
MMPs are known to be central to destruction at the synovial membrane 
(Okada et al., 1986). In particular, MMP-1 and MMP-13 are produced by 
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synovial fibroblasts and macrophages, and chondrocytes are rate limiting in 
the process of collagen degradation. Furthermore, the expression of MMPs in 
synovial membranes, cartilage, tendon and bone of synovial joints in both RA 
and OA often correlates with tissue destruction (Murphy and Nagase, 2008b; 
Smeets et al., 2001). MMPs such as MMP-2, MMP-3, MMP-9, MMP-10 and 
MMP-19 are also elevated in arthritis and, along with MMP-13 these 
enzymes degrade non-collagen matrix components of the joints (Cawston 
and Wilson, 2006). Therefore, various diagnostic and therapeutic strategies 
in OA and RA are focused on the involvement of MMPs in these diseases 
(Okada et al., 1990). 
1.5 Role of MMPs in Cancer 
Tumour growth is orchestrated by degradation of the ECM, release of 
sequestered growth factors and/or the generation of bioactive fragments 
(Noel et al., 2008). A number of cancer studies have correlated MMP 
expression and disease outcome (Egeblad and Werb, 2002). For instance, 
MMP-9 mobilizes VEGF from the ECM (Bergers et al., 2000) and cleaves 
type IV collagen to generate tumstatin, an angiogenesis inhibitor (Hamano et 
al., 2003). The MMPs are clearly implicated in angiogenesis. The most direct 
and compelling evidence for this conclusion is that MMP inhibitors, both 
synthetic and endogenous, inhibit angiogenic responses both in vitro and in 
vivo (Hiraoka et al., 1998). Moreover, recent studies provide evidence that 
MMP-deficient mice exhibit delayed or diminished angiogenic responses 
during development or in response to tumour xenografts (Itoh et al., 1998). 
While these studies clearly implicate functional MMP activity in the 
angiogenic response, there is some debate regarding the possible molecular 
targets that are involved and their precise role in angiogenesis. 
Understanding what, where, when, and how MMP activity is involved in the 
angiogenic phenotype has enormous implications for cancer therapy 
because angiogenesis is necessary for tumour growth and metastasis. 
Current therapeutic approaches targeting MMP activity utilize general class 
inhibitors that are selective, but not specific, for some MMP family members. 
This has resulted in moderately severe, but reversible, musculo-skeletal 
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complications. This experience highlights a need for a better understanding 
of the specific MMPs and their precise role in the angiogenic response. In 
this way, we can discern what MMPs to target, and when to target them, with 
the aim of limiting side effects and possible complications. MMPs reportedly 
produced by endothelial cells are MMP-1, MMP-2, MMP-9, and MT-1-MMP. 
Of these, MMP-2 and MT-1-MMP are the most studied for their role in 
angiogenesis (Hiraoka et al., 1998; Zhou et al., 2000). 
The molecular mechanisms underlying the cellular events of angiogenesis 
have been examined utilizing a number of in vitro models. These have been 
helpful in examining the role of proteases in angiogenesis. They include 
growth of endothelial cells or vascular explants in amniotic membranes, fibrin 
clots, type I collagen, or basement membrane matrices. In these assays, 
endothelial cells acquire a migratory or invasive phenotype, reorganize the 
ECM, and in some cases recapitulate the tubular morphology of micro 
vessels complete with lumen formation. In many early studies, the ECM was 
viewed as a barrier to endothelial cell invasion. The principal role of MMP 
activity was to remove this barrier and allow endothelial cell migration. 
Recent studies challenge this notion and suggest that cell–ECM interactions 
profoundly influence cell behavior. These interactions not only influence MMP 
production but are subject to modulation and regulation by MMP activity. In 
this way, MMP activity can directly and indirectly mediate the angiogenic 
response. MMPs work in a complex cascade with other factors in tumour 
progression, promoting invasion, immune escape and many other events. It 
is possible that obtaining a detailed understanding of the potential role of 
MMPs in the different cell types associated with tumours may improve our 
understanding of this disease and aid the design of therapeutic strategies. 
Proteins involved in cancer cell motility and chemotactically-guided 
extravasation of arrested cancer cells at secondary sites are mediated by 
MMPs. 
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1.6 Regulation of MMPs 
MMPs are produced in different cell types under unique conditions, and thus 
distinctive inductive and suppressive factors regulate their expression which 
has been detailed comprehensively in several studies. 
1.6.1 Transcriptional and Translational Regulation 
Transcription factors which can be activators and repressors tightly regulate 
MMPs at the gene expression level (Greenlee et al., 2007). Moreover, mRNA 
stability has been reported to play a role in regulation of MMP-1, MMP-2, and 
MMP-9. (Overall et al., 1991). GATA-1 in endothelial cells and members of 
the AP-1 family, c-Jun, Jun-D, c-Fos, Fos-B, and Fra-1 proteins in lung 
cancer cells activate the MMP-2 promoter (Choi et al., 2005; Han et al., 
2003). Epidermal growth factor receptor (EGFR) activation up-regulates 
MMP-14 in lung fibroblasts (Kheradmand et al., 1998). Chemokines have 
been shown to regulate several members of the MMP family. Indirect 
evidence shows that activation of CCR-1, the receptor for RANTES, MCP-1, 
and CXCL-12, induces secretion of MMP-9 in primary human monocytes 
(Klier et al., 2001). Reactive oxygen species (ROS), including singlet O2, 
hydroxyl radical, superoxide anion, and hydrogen peroxide can affect MMP 
gene expression through activation of several transcription factors. For 
example, H2O2 production by mitochondria can activate MMP-1 gene 
expression through activation of AP-1 and Ets-1 transcription factors (Nelson 
and Melendez, 2004). The role of shear mechanical stress elevates the 
mRNA level of MMP-1, MMP-3, and MMP-13 and the three transcription 
factors c-Fos, Ets-1, and Ets-2, suggesting a new mechanism for tissue 
degradation in rheumatic joints (Sun and Yokota, 2001). 
1.6.2 Post-Translational Regulation 
MMP activity is kept in check by post-translational modification (PTM) of 
MMPs mediated through activation of latent MMPs and 
compartmentalization. 
13 
1.6.2.1 Activation of MMPs 
The MMPs are synthesized and secreted as pre-pro-enzymes and the signal 
peptide is removed during translation to generate pro-MMPs (Overall and 
Lopez-Otin, 2002). MMPs can be activated both proteolytically (in vivo and in 
vitro) by other proteases or by autolysis, and non-proteolytically by chemical 
agents (in vitro). Chemical agents such as APMA (4-aminophenylmercuric 
acetate), HgCl2, SDS, chaotropic agents, reactive agents and even heat 
treatment or low pH cause activation in vitro (Visse and Nagase, 2003). The 
pro-peptides have the ‘cysteine switch’ motif PRCGXPD in which the 
cysteine residue coordinates with the catalytic Zn2+ in the catalytic domain, 
keeping the pro-MMPs inactive (Van Wart and Birkedal-Hansen, 1990). The 
stepwise activation proceeds as an intramolecular reaction to cleave the Cys 
switch-Zn2+ interaction and subsequent hydrolysis of exposed Zn+2 ions. This 
intermediate could be activated by removal of pro-peptide either by other 
activated MMPs or chemical agents (Nagase et al., 1990). For regulation of 
these activated enzymes to avoid destruction within a cell, TIMPs bind with 
intermediates before the MMP is fully activated. Intracellular activation of  
pro-MMP-11 by furin and its secretion as an active protease demands 
endogenous inhibition for regulation of its activity (Pei and Weiss, 1995). 
MMP-26 is unique enzyme distinguished by the presence of histidine in place 
of arginine in highly conserved sequence of pro-petide domain PRCGV/NPD. 
Arginine residue is positively charged in the physiological pH range. In 
contrast, histidine is only positively charged at pH values below 7. This 
intrinsic feature of histidine may make MMP-26 more sensitive to pH 
changes; affect the stability and possibly the activation mechanisms of the 
MMP-26 zymogen (Marchenko et al., 2001). 
Several MMPs are exception to this rule. An alternatively spliced transcript of 
MMP-11 lacking the signal peptide and the pro-peptide domain encodes an 
active intracellular form, but its function is not known (Luo et al., 2002). Cell 
surface activation of pro-MMP-2 is mediated by MT-1-MMP and TIMP-2 
facilitated by hemopexin domain of MT-1-MMP (Itoh et al., 2001). Membrane 
bound MMPs all have a furin-like pro-protein convertase recognition 
sequence RX[R/K]R at the C-terminus of the pro-peptide. Pericellular 
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activation of MMP-2 on the cell surface is achieved by the interaction of pro-
MMP-2 to MMP-14 and TIMP-2. This complex tethers the zymogen in place 
and allows a second active MMP-14 to cleave the pro-domain and liberate 
the activated MMP2 (Strongin et al., 1995). 
1.6.2.2 Localization of MMPs 
MMPs can be either free in the cytosol or bound to the surface of a cell such 
as the compartmentalization of MMPs in inflammatory cells. For example, 
pro-MMP-8, pro-MMP-9, and pro-MMP-25 are packaged into granules within 
neutrophils to be released upon leukocyte activation (Eickelberg et al., 1999). 
The cell surface expression pattern of MMP-14 is one potential regulator of 
MMP-2 activity, since MMP-2 activation would then be dependent on co-
localization with MMP-14 (Haas, 2005). MMP-9 is secreted but also has a 
cell surface-bound form which is expressed on neutrophils in response to 
pro-inflammatory mediators and can cleave gelatin, type IV collagen, elastin, 
and Į-1 proteinase inhibitor in vitro (Owen et al., 2003) The cell surface 
activation of MMP-2 and MMP-7 suggest that localization of MMPs to the cell 
surface is a general means of regulating MMP activity. 
Figure 1.3 Conversion from latent to active MMP. 
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1.6.3 Regulation by Protease Inhibitors and other Factors 
1.6.3.1 Natural Inhibitors 
MMPs have several naturally occurring inhibitors (Murphy and Nagase, 
2008a). To date, four members of the family have been characterized TIMP-
1, TIMP-2, TIMP-3, and TIMP-4 of which TIMP-1 and TIMP-3 are 
glycoproteins. TIMP-2 has been shown to inhibit tumour growth, 
angiogenesis, invasion, and metastasis in experimental models, an 
observation consistent with a role of MMP activity in these processes. 
Studies have shown that TIMP-3 is a major regulator not only of matrix 
metalloproteinases but ADAMS (Wang et al., 2006) including ADAM-10 
(Amour et al., 2000). Crystal structures for TIMP-1 in complex with MMP-3 
have been described (Gomis-Ruth et al., 1997). TIMPs bind with their edge 
into the entire length of the active site cleft of MMPs when forming complexes 
(Gomis-Ruth et al., 1997). It has also been shown that TIMP-2 has a bi-
functional effect on MMP-2 since MT-MMP-mediated pro-MMP-2 activation 
requires a small amount of TIMP-2 to make activation progress, whereas a 
greater concentration of TIMP-2 inhibits MMP-2 (Kinoshita et al., 1998). TGF-
ȕ1 increases the mRNA of both TIMP-1 and TIMP-3 in human chondrocytes 
and rat osteoblasts (Wang et al., 2006). TIMP-4 is a good inhibitor for all 
classes of MMPs without notable preference for specific MMPs (Stratmann et 
al., 2001). 
1.6.3.2 Synthetic Inhibitors 
A number of small molecules are also good inhibitors of MMPs activities (Mix 
et al., 2001), (Bernardo et al., 2002). There are broad-spectrum inhibitors 
which interfere with most MMPs and specific inhibitors working on only one 
or two members. Due to redundancy of MMPs, inhibition effects are not easy 
to predict, making synthetic inhibitors poor candidates for therapeutic use. In 
a clinical trial of merimastat, serious musculo-skeletal side effects in cancer 
patients were observed. In addition, other clinical trials were stopped due to 
decreased survival or no survival benefit detected. On the other hand, more 
promising, specific MMP inhibitors are in preliminary stages of research. A 
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specific inhibitor with affinity for MMP-2 and MMP-9, ONO-4817, has been 
shown to decrease neutrophil migration. The potential involvement of any of 
the 24 MMPs in both normal tissue maintenance and the destructive or 
reparative aspects of many diseases has produced numerous challenges 
when considering the potential application of MMP inhibitors as therapeutic 
agents. A detailed understanding of MMP expression patterns, in terms of 
both cellular origins and timing is essential. Furthermore, some knowledge of 
the precise role of an individual MMP within each context is important. This 
needs to be coupled with the ability to generate specific inhibitors, either 
targeting the active site or other interaction sites. 
1.7 MMP Structure 
Numerous 3D structures of MMPs have been determined both by X-ray 
crystallography and NMR spectroscopy (Maskos, 2005) including full-length 
pro-MMP-1 (Jozic et al., 2005), pro-MMP-2 (Morgunova et al., 1999), the pro-
MMP-2-TIMP-2 complex (Morgunova et al., 2002), pro-MMP-3 without the 
linker region and the hemopexin domain (Becker et al., 1995) and pro-MMP-
9 without the linker region and the hemopexin domain (Elkins et al., 2002). 
Figure 1.4 shows the structure of pro-MMP-2-TIMP-2 complex and individual 
domain structures. The overall polypeptide folds of pro-peptide domains, 
catalytic domains and hemopexin domains from other MMPs are essentially 
super-imposable. Typically MMPs consist of a pro-peptide of about 80 amino 
acids, a catalytic domain of about 170 amino acids, a linker peptide of 
variable lengths (also called the ‘hinge region’ and a hemopexin domain of 
about 200 amino acids. MMP-7 (matrilysin-1), MMP-26 (matrilysin-2) and 
MMP-23 are exceptions as they lack the linker peptide and the hemopexin 
domain. MMP-23 has a unique C-terminal cysteine-rich domain and an 
immunoglobulin-like domain immediately after the C-terminus of the catalytic 
domain. 
1.7.1 Pro-peptide Domain 
The signature of matrixins ‘cysteine switch’ motif PRCGXPD is found in the 
pro-peptide. The pro-peptide consists of three Į-chains and connecting loops 
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(Figure 1.4). The cysteine switch sequence lies in the substrate binding site, 
but the orientation of this segment is opposite from that of a peptide 
substrate. The proteinase susceptible ‘bait region’ is located between helix-1 
and helix-2, but the structure of this region has not been resolved in the case 
of pro-MMP-1, pro-MMP-3 and pro-MMP-9 due to its lack of rigidity for X-ray 
crystallography. This region of pro-MMP-2 is however stabilized by a 
disulphide bond. The SH group of cysteine interacts with the catalytic zinc 
ion. Upon activation the interaction of Cys-Zn2+ is disrupted, which allows a 
water molecule to bind to the zinc atom (Figure 1.3). The pro-peptide 
domains of MMPs may also play an important role in folding the pro-enzymes 
during synthesis. 
1.7.2 Catalytic Domain 
Binding of a peptide substrate to the enzyme is primarily dictated by the 
structure of the substrate binding site of the catalytic domain, including a 
hydrophobic pocket called the ‘S1 pocket’ located to the right of the zinc 
atom. This pocket varies in depth in different MMPs. It is therefore one of the 
determining factors of substrate specificity of MMPs. The catalytic domain 
consists of a 5-stranded ȕ-pleated sheet, three Į-helices and a connective 
loops (Figure 1.4). It contains two zinc ions; one catalytic and one structural. 
Usually three calcium ions are found which are thought to stabilize the 
structure. MT-1-MMP (MMP-14), MT-2-MMP (MMP-15), MT-3-MMP (MMP-
16) and MT-5-MMP (MMP-24) have a membrane tethered loop, an additional 
8 residues between ȕ-strand II and III. This loop is critical for activation of 
pro-MMP-2 in the case of MT-1-MMP (English et al., 2001). Non-catalytic 
domains also help protein substrate recognition interaction. Binding of a 
substrate to the active enzyme displaces the water molecule from the zinc, 
and peptide bond hydrolysis is facilitated by the carboxylate group of the 
glutamate in the active site which draws a proton from the displaced water 
and allows a nucleophilic attack of the polarized water on the carbonyl 
carbon of the peptide bond. 
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1.7.3 Fibronectin Type II Domains 
Fibronectin type II (FN II) domains are inserted in the loop between the fifth 
ȕ-strand and the second helix of the catalytic domains of gelatinases (Figure 
1.4) The FN II domains in MMP-2 and MMP-9 have a similar conformation. 
They consist of two anti-parallel ȕ-sheets connected with a short Į-helix and 
stabilized by two disulfide bonds, however, the sequence position of the FN II 
domains in the two gelatinases are significantly different. After super-
imposing the catalytic domains of pro-MMP-2 and pro-MMP-9, FN II domain-
1 and domain-3 fall roughly in the same places, but the position of domain-2 
differs. Domain-2 of pro-MMP-2 has an area that interacts with the catalytic 
domain, but the corresponding domain of pro-MMP-9 is rotated and twisted 
away from the catalytic domain without making contact (Elkins et al., 2002) 
Domain-3 in both pro-gelatinases makes contact with the pro-peptide and 
with the catalytic domain (Morgunova et al., 1999) and (Elkins et al., 2002). 
1.7.4 The Linker Region 
Two domains, hemopexin and catalytic, are connected by the linker region. 
This region is considered to be flexible for MMP-9 (Rosenblum et al., 2007), 
but a number of prolines are found (Iyer et al., 2006; Jozic et al., 2005; 
Morgunova et al., 1999). This suggests that this region has structural 
constraint suited for specific functions. Mutation of this region in MMP-1 
(Tsukada and Pourmotabbed, 2002) and MMP-8 (Knauper et al., 1997) 
reduced the collagenolytic activity, supporting the notion that the correct 
movement and arrangement between the catalytic domain and the 
hemopexin domain is important for this activity. Studies of MMP-9 and MMP-
14 have found that the linker region can be extensively and heterogeneously 
N- and O-glycosylated and that these sugar chains have significant effects on 
the cellular biochemistry of these MMPs (Van den Steen et al., 2006; Wu et 
al., 2004). 
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1.7.5 Hemopexin Domain 
The hemopexin domain has a 4-bladed ȕ-propeller structure with a single 
disulfide bond between the first and the fourth blades (Figure 1.4) (Gomis-
Ruth et al., 1996) The centre of the propeller generally contains one calcium 
ion and a chloride. The hemopexin domains are essential for collagenases to 
express their triple helical collagen degrading activity and for MT-1-MMP to 
dimerize on the cell surface. The latter event is essential for MT-1-MMP to 
activate pro-MMP-2 (Itoh et al., 2001) and to cleave collagen (Itoh et al., 
2006). The cooperation between the catalytic and hemopexin domains is 
considered to be important for the expression of collagenolytic activity of 
collagenases (Chung et al., 2004). 
1.8 Purification of MMPs 
MMPs operate in concert with many other proteins such as chemokines, 
growth factors, substrates, hormones, cofactors, receptors and cleavage 
products creating a protease web. More than 35 chemokines involved in 
macrophage and neutrophil infiltration have been shown to be regulated by 
MMPs (Butler and Overall, 2009). Various proteomic approaches are being 
used to tease out this network to identify the roles played by each protein and 
their potential for therapeutic modification. MMP inhibitor-based therapy 
failure was a consequence of an incomplete picture of MMP biology resulting 
from inadequate knowledge of substrate repertoires and physiological 
pathways under MMP control and that individual members of the MMP family 
have unique functions that render broad-spectrum inhibition undesirable and 
even advantageous for tumourigenesis and metastasis (Butler and Overall, 
2009). 
A great deal of research was dedicated to understanding the MMP biology for 
which purification methods for MMPs are a central requirement. These 
studies highlighted various characteristics of MMPs which were not clear 
before such as site of action, redundancy, regulatory effects, diagnostic value 
and therapeutic potential. For instance, in proteomic screens, identification of 
intracellular substrates for MMPs such as Hsp-90Į has changed the idea that 
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MMPs work only extracellularly (Butler et al., 2008). High-content screens 
such as LC-MALDI, isotope tag for relative absolute quantitation (iTRAQ), 
isotope coded affinity tag (iCAT), two dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) and differential in-gel electrophoresis (DIGE) 
often lead to the identification of more than one MMP substrates within a 
given pathway (Butler and Overall, 2009). MMP-7 was identified as a serum 
biomarker for renal cell carcinoma proteomically (Sarkissian et al., 2008). 
The lethality of the double knock out approach for inhibiting MMP functions 
highlights the importance of using system-wide proteomic analysis to 
elucidate the network in which a protease lies in order to identify alternate up-
stream or down-stream non-MMP targets that might be more easily and 
specifically modulated (Butler et al., 2008). A highly specific MMP-12 inhibitor 
belonging to phosphinic peptide library may have important therapeutic 
applications in diseases such as aortic abdominal aneurysm and 
atherosclerosis (Devel et al., 2006). 
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1.8.1 Conventional MMP Purification Methods 
Before the emergence of proteomics, a number of MMPs and their inhibitors 
were purified using multi-step conventional protein purification methods. In an 
attempt to isolate the two neutrophil metalloproteinases, collagenase and 
gelatinase, separation and further purification was done by sequential gel 
filtration chromatography, DEAE-cellulose, heparin-Sepharose, and 
Sephadex G-50 chromatography (Murphy et al., 1982). The precursor of 
human MMP-3 (pro-MMP-3) was purified from rheumatoid synovial 
fibroblasts to investigate steps of its activation by an endopeptidase and 
mercurial compound amino phenyl mercurial acetate (APMA). The latent 
form of MMP-3 was purified starting from gel filtration chromatography, 
elution with concanavalin A-Sepharose and removal of unbound pro-MMP-3 
by passing the filtrate through anti-collagenase immuno-adsorbant column 
(Okada et al., 1988). The fact that gelatin shows specificity towards 
fibronectin, forms the basis of gelatin-Sepharose affinity chromatography and 
is therefore used to purifiy gelatinases (pro-MM-2 and pro-MMP-9) in 
combination with other chromatography methods. In an attempt to study 
activation and interactions with other MMPs, stromelysin-2 (MMP-10) was 
separated from pro-MMP-2 and pro-MMP-9 using gelatin-Sepharose 
columns (Nakamura et al., 1998). MMPs remain associated with Inter-
photoreceptor retinoid binding protein (IRBP) by procedures commonly used 
for its purification, including ion exchange, concanavalin A affinity and gel 
filtration chromatographies. Through each step of the purification both 
gelatinase and caseinase (stromelysin) activities were detected by 
zymography with IRBP prepared from bovine interphotoreceptor matrix. 
However, inclusion of gelatin affinity chromatography did not totally remove 
the gelatinases. 
Much of this activity was latent and was only revealed following fractionation 
or by pre-activation before zymography (Plantner and Quinn, 1997). Pro-
collagenase-activator (stromelysin) was purified by DEAE-cellulose, Ultrogel 
AcA-44, and zinc chelate sepharose chromatographies, from the culture 
medium of the guinea pig carrageenin granuloma model. On SDS-PAGE, the 
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activator migrated as a principal band of approximately 44kDa. The molecule 
when tested on pro-collagenase from human lung fibroblasts in a 
concentration dependent manner, an enhancement of collagenase activity of 
trypsin-treated crude culture medium was observed. A loss of about 50% of 
its activity occured after heating. In addition, this activator degraded gelatin 
and casein (Pardo et al., 1991). 
1.8.2 Synthetic Inhibitors-Based Methods 
Highly potent inhibitors of MMPs have been developed by grafting a zinc-
binding moiety such as a hydroxamate (CONH-O-), a carboxylate (COO-), a 
thiolate (S-), or a phosphinyl (PO2-) to a suitable peptide sequence. One of 
the very effective hydroxamate based inhibitors, BB-94, has been found to 
show poor selectivity (Cuniasse et al., 2005). Recombinant mouse MT-5-
MMP products have been purified and characterized using BB-94 Q-
Sepharose column and eluted with a gradient of 0.15-1M NaCl (Wang et al., 
1999). Several N-carboxyalkyl peptides were synthesized and tested as 
inhibitors of pig synovial MMP-1, MMP-2, and MMP-3. The most potent of the 
series, CH3CH2CH2(R,S)CH(COOH)-NH-Leu-Phe-Ala-NH2, competitively 
inhibited cleavage of dinitrophenyl-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH2 at 
the Gly-Leu bond by MMP-1 and MMP-2. A similar inhibitory potency was 
found for MMP-1 with soluble Type I collagen and MMP-3 with substance-P 
as substrate. The inhibitor was coupled to EAH-Sepharose 4B through a C-
terminal amide. In the presence of 2M NaCl (pH 7.2), this matrix bound 
MMP-1, MMP-2, and MMP-3 from concentrated culture medium of pig 
synovial membranes. The enzymes co-eluted at pH 4.1 and subsequently 
were resolved by chromatography on DEAE-Sephacel and heparin-
Sepharose. This procedure provided a rapid means of obtaining all three 
MMPs from one source in approximately 15% yield each (Stack et al., 1991). 
1.8.3 Activity Based Probes for Proteomic Profiling (ABPP) 
Failure of conventional proteomic methods for functional analysis and of 
clinical trials of MMPs due to unknown toxicity mechanisms led to the 
fashioning of activity based proteomic probes. The need to develop activity 
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based probes was stressed since post-translational changes affect function 
of proteins so only quantitation does not establish specific roles (Jessani and 
Cravatt, 2004). Since metalloproteinases are a diverse class of enzymes with 
some common structural features, ABPP probes have been designed which 
incorporate hydroxamate and a benzophenone photo cross-linking group to 
enhance selectivity. An ABPP HxBP-rh has been shown to bind to active and 
not the zymogen or inhibitor bound form of MMP-2, MMP-7 and MMP-9 
added to mouse kidney proteome (Saghatelian et al., 2004). 
1.8.4 Affinity Chromatography 
Affinity chromatography that was first described by Cuatrecasas 
(Cuatrecasas and Wilchek, 1968; Cuatrecasas et al., 1968) involved 
reversible adsorption of a protein to a specific ligand immobilized on 
chromatography beads and is based on bio-specific interactions. The mixture 
containing protein of interest is applied to the chromatography system. The 
target protein binds to the ligand immobilized on solid surface which is eluted 
using buffers to reverse the binding (Figure 1.5). The definition of affinity 
chromatography can be broad. Often it includes immobilized metal ion affinity 
chromatography (IMAC), covalent chromatography, and biomimetic ligands 
(dyes). In a more narrow definition only biological functional pairs are 
included such as receptor/ligand, antibody/antigen, enzyme/inhibitor, 
hormone/receptor, nucleic acid/nucleic acid-binding protein, and 
lectin/glycoprotein. The use of these functional pairs often also requires 
production of the adsorbent (ligand) that is immobilized to the matrix. A vast 
array of chromatography systems currently exist and these are tailor-made 
for each adsorbent. In addition, pre-activated gel matrices for ligand 
immobilization are commercially available from several suppliers. The same 
suppliers also offer ready-to-use affinity matrices for a wide variety of 
functional pairs as gels or pre-packed columns. Combinatorial methods can 
also be employed to find new ligands to a vast array of different targets. 
Additionally, synthetic ligands can be designed using structural information of 
the target (Li et al., 1998). 
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To facilitate the purification of recombinant proteins a large number of 
different affinity fusion systems are available, each relying on a specific 
interaction to a ligand (Ford et al., 1991). Fusion system is a genetically 
engineered protein to contain a carboxy- or amino-terminal which forms the 
biochemical basis for affinity chromatography. A variety of fusion tags have 
been developed such as oligo-histidines for recovery by IMAC, carbohydrate 
binding proteins recognized by lectins and a biotin binding domain for in vivo
biotinylation which creates affinity of a fusion protein for avidin or streptavidin. 
It must be stressed, however, that different applications may have demands 
on removal of the fusion moiety, achieved by site-specific cleavage. In 
addition to the specific affinity addressed to the fusion moiety, decreased 
protease susceptibility and increased or decreased solubility of the target 
protein can sometimes be achieved (Stahl and Nygren, 1997). 
Affinity chromatography has several inherent advantages over the classical 
means of protein purification. The technique offers high selectivity and high 
capacity. Since the method eliminates steps the equipment e.g.; columns, 
cartridges etc, can be down-sized, thereby improving the process economics. 
Furthermore, it can preferably be used early in the capture process and the 
protein is concentrated during the process thus, allowing large volumes to be 
loaded. However, large scale affinity chromatography of proteins suffers from 
problems dealing with regulatory compliance. 
Problems concerning ligand leakage and sensitivity towards cleaning 
procedures must be solved. Stromelysin has been proposed to play a major 
role in the pathologic degradation of diseased cartilage of OA and RA 
patients. A truncated, recombinant form of this enzyme, with the sequence 
Phe83 to Thr260 (mSL-t) was expressed and purified from E. coli to 
investigate its biochemical and biophysical properties, and to develop 
inhibitors for arthritis treatment. LC-ESI-MS technique was utilized for the 
characterization of mSL-t. The mass spectra of mSL-t showed the presence 
of a number of different protein components in addition to the full-length 
mSL-t form. The full length mSL-t was successfully separated from auto-
degradation products using affinity chromatography and detected by LC-ESI-
MS (Qoronfleh et al., 1997). 
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Figure 1.5 Principle of affinity chromatography. 
1.8.4.1 Dye-Ligand Chromatography 
A number of textile dyes, known as reactive dyes, have been used for protein 
purification in dye-ligand affinity systems, since they were found to bind 
proteins in a selective and reversible manner. Reactive dyes are colored 
compounds capable of forming covalent bonds with the hydroxyl groups of 
cellulosic fibers, with the amino, hydroxyl and mercapto groups of protein 
fibers and with the amino groups of polyamides (Zollinger, 1991). An 
experimental evidence for such bonds being formed by hydroxyl groups of 
cellulose was given by Zollinger’s group in the early 1960’s. With dyeing of a 
dichlorotriazine dye, evidence was found in the same group by micro-
biological degradation to products containing the dye bound to a glucose unit 
(Zollinger, 1961). Di- and monochlorotriazine reactive dyes were the first 
reactive dyes for cellulosic fibers (Rattee and Stephen, 1954); they were 
introduced commercially in 1956 and 1957, respectively (Zollinger, 1991)  
For selectivity of a dye towards its target protein there has to be a precise fit 
between dye structure and an acceptor site on protein surface (Madhusudan 
and Vijayan, 1992). Roschlau and Hess were first to immobilize covalently 
Cibacron Blue on Sephadex G-200 directly and to purify yeast pyruvate 
kinase with this affinity sorbent (Roschlau and Hess, 1972). The polycyclic 
anionic ligand Cibacron Blue dye affinity ligand that interacts with proteins is 
thought to be due to it acting as a mimic of NAD+ and NADP+, or through 
non-specific electrostatic, hydrophobic, and other forces. The fractionation of 
human plasma of 27 different plasma proteins on immobilized Cibacron Blue 
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F3-GA has been studied. The column was eluted using first, a low molarity 
buffer (30mM H3P04/Na3PO4, then a linear salt gradient (0-1M NaCl in the 
buffer above) was applied. Finally, bound proteins were recovered with 0.5M 
NaSCN. The recovery of individual proteins ranged between 52 and >95% 
(Gianazza and Arnaud, 1982). Reactive dyes are all synthetic in nature, and 
interact mostly with the active sites of proteins by mimicking the structure of 
the substrates, cofactors, or binding agents for those proteins (Denizli and 
Piskin, 2001). A large number of proteins have been purified taking 
advantage of these interactions of proteins with dyes but there are relatively 
few proteases among them. In a study to understand the role played by 
stromelysin in OA, dog synovial fibroblasts were stimulated to express canine 
pro-stromelysin. The APMA-activatable metalloproteinase present in the 
culture supernatants was purified using a combination of ion-exchange and 
dye-ligand affinity chromatography. The purified canine stromelysin showed 
similar characteristics as shown by recombinant pro-MMP-3 such as both co-
migrated on reducing SDS-PAGE as a doublet with apparent molecular 
masses of 54 and 56kDa and both inhibited by 1,10-phenanthroline or 
recombinant human TIMPs (Bayne et al., 1992). 
Initially, dye ligands were pursued for their biomimetic function and they were 
readily available from major chemical companies; they were cheap, non-toxic 
and stable when attached to a support matrix. Synthetic ligands based on 
triazine chemistry have some similarities with their dye predecessors display 
significant stability and resistance to both chemical and biological 
degradation. This property also confers long-term stability and re-usability, 
and synthetic ligand adsorbents can be used for at least 100 cycles. These 
affinity adsorbents display dynamic protein-binding capacities in the range 5-
40 mg/mL. The triazines are symmetrical hexameric rings of alternating 
carbons and nitrogens. Chlorotriazine derivatives such as atrazine were used 
as herbicides and Agency for Toxic Substance and Disease Registry 
(ATSDR) concluded that atrazine is not a likely human carcinogen. 
(www.atsdr.cdc.gov). 
Dye ligands such as Cibacron Blue quickly found application in investigations 
of plasma fractionation and the recovery of albumin (Watson et al., 1978). 
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Procion Blue and Red triazine derivatives have been compared in the 
purification of Į-1-proteinase inhibitor with the finding that a Procion Red 
Fractogel was more effective (Gunzer and Hennrich, 1984). A study by Datar 
et al. reports on use of lysine-agarose to the recovery of tissue plasminogen 
activators (tPA) expressed in E. coli (Datar et al., 1993). 
Affinity chromatography was applied to cytokine purification, tissue necrosis 
factors, and tPA purification (Werner and Berthold, 1988; Zoon et al., 1979). 
Blue-agarose and a mimetic green adsorbant were used to purify Interferon-Į
(Swaminathan and Khanna, 1999). With ever increasing demands on purity, 
yield, and reliability, repeatability and consistency, synthetic ligand 
chromatography is set to assume a significant position in the bio-separations 
armory. 
1.8.4.1.1 Immobilized Reactive Red-120 for the Purification of Proteases 
Many matrix metalloproteinases have been purified either from animal or 
human tissues, from cultured cell lines or from eukaryotic cells expressing 
recombinant enzymes using Reactive Red-120 as immobilized ligand 
(Murphy et al., 1992). The above mentioned dye ligand bound collagenase 
from the crude extract from human buffy coats which was eluted by 1M NaCl. 
Yields ranged from 53-100% of applied collagenase depending upon the 
amount of contaminating haemoglobin (Mookhtiar and Van Wart, 1990). The 
two recombinant forms of stromelysin, with molecular weight 57kDa and 
60kDa (glycosylated) (Okada et al., 1988) were purified from C127 cell 
culture supernatants using Procion Red-Sepharose. Both forms were heat-
activated and displayed similar specific activities with respect to many 
different substrates. The important finding of the study was that a large part 
of the C-terminal portion is not necessary for enzyme activity. Natural pro-
MMP-3 was purified from human gingival fibroblast culture medium (6L) 
initially by binding to dextran sulphate beads equilibrated with buffer (pH 8.5) 
containing 0.15M NaCl. All metalloproteinases bound to this matrix were 
eluted with column buffer containing 1M NaCl. The eluate was 
chromatographed on DEAE-Sepharose to bind gelatinase to this matrix, 
whereas collagenase and stromelysin did not. The column flow-through was 
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loaded directly on to heparin-Sepharose (Pharmacia) to bind collagenase. 
Finally the pool containing pro-MMP-3 activity was chromatographed on 
Procion Red-Sepharose (Pharmacia). The enzyme was eluted with a 
gradient of 0-1M NaCl Fractions containing pro-MMP-3 were finally 
chromatographed on Ultrogel AcA44, from which enzyme was eluted as a 
single protein and activity peak (Koklitis et al., 1991). 
1.8.4.1.2 Purification of Metalloproteinases on Dyematrex Green A 
Since an influential work in 1985 by J.L. Seltzer (Seltzer et al., 1985), several 
reports on purification of matrix metalloproteinases from diverse starting 
materials with Dyematrex Reactive Green A (Green A is also known as 
Procion Olive H-7G) have been published (Enghild et al., 1989; Imai and 
Okada, 2008; Lark et al., 1990; Okada et al., 1990; Okada et al., 1986). A 
number of MMPs have been purified using immobilized triazine dyes as part 
of a sequence of chromatography steps to isolate each enzyme. In a study to 
confirm the pro-MMP-3 mechanism activation , concanavalin A-Sepharose 
(bound glycosylated pro-MMP-3), DEAE-Cellulose, gelatin-Sepharose 
(removed pro-MMP-2), anti-human MMP-3-Sepharose, Green A Dyematrex 
gel and Ultrogel AcA44 were used to purify the protease from culture medium 
of human rheumatoid (Okada et al., 1988). pro-MMP-7 (matrilysin-1) was 
purified by a five-step protocol from culture medium of CaR-1 human rectal 
carcinoma cells using DEAE-cellulose, Green A Dyematrex gel, DEAE-
cellulose, chelating Sepharose  and Ultrogel AcA44 to yield a single protein 
band (28kDa) of pro-MMP-7 on SDS-PAGE (Imai et al., 1995). In another 
study pro-MMP-10 was purified from the culture media of OSC-2 cells 
derived from a moderately differentiated squamous cell carcinoma of the 
tongue (Nakamura et al., 1998) using DEAE-cellulose followed by Green A 
Dyematrex gel (a linear gradient of NaCl,0.15-2M, eluted pro-MMP-1, pro-
MMP-2, pro-MMP-3, pro-MMP-9 and pro-MMP-10. 
The gelatinases (pro-MMP-2 and 9) were subsequently purified by gelatin-
Sepharose, pro-MMP-1 and pro-MMP-3 by immuno-affinity columns and the 
pro-MMP-10 (56kDa on SDS-PAGE) recovered in unbound fractions for 
further chromatography on DEAE-Cellulose and Ultrogel AcA44. Also, though 
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soluble C-terminus MMP-14 (MT1-MMP) has been successfully purified, 
there are no reports showing purification of full-length membrane-anchored 
pro-MMP-14 from cell membranes. However, these processes are extremely 
laborious and time-consuming (summarized in Figure 1.6). MMPs could be 
purified by immuno-purification but this would require production of specific 
antibodies, in significant large quantities (mg), for each MMP and prove 
prohibitively expensive. (Imai and Okada, 2008). Retained proteases were 
eluted through ionic strength increase e.g., Okada, purified MMP-3 and its 
pro- form (pro-MMP-3) from culture supernatant of human rheumatoid 
synovial fibroblasts (Okada et al., 1986). Partially purified enzyme was 
loaded on a Green A column equilibrated with 50mM Tris-HCl buffer, 0.15M 
NaCl and 5mM CaCl2. The column was developed with 0.3M NaCl and 
0.05% Brij-35 in the same buffer which successfully eluted pro-MMP-3 and 
with 2M NaCl which eluted two proteases, pro-MMP-1 and pro-MMP-2. They 
reported furthermore that MMP-3 activated by APMA was no longer retained 
when reloaded on Green A column. This underscores that immobilized dyes 
can be selective. Reported yields and purification factors for these MMPs 
were variable depending on purification starting material. For example canine 
pro-stromelysin from cultured synoviocytes was purified to electrophoretic 
purity by only a DEAE-Sepharose step followed by immobilized Green A 
(Bayen, 1992). Gelatin-Sepharose chromatography was used for isolation of 
pro-MMP-2 (72kDa) and pro-MMP-9 (92kDa) from human plasma. For further 
separation of MMP-2 gel filtration chromatography was followed. 
Stromelysin-1 was isolated from plasma by Matrex Green A affinity 
chromatography. 
Immuno-blotting of plasma fractions with antibodies to unique peptide regions 
of human gelatinases differentiated the 72kDa gelatinase from the 92kDa 
gelatinase and identified human stromelysin as a 57kDa. TIMP-1 (28kDa) 
and TIMP-2 (21kDa) were also identified by immune-blotting of gelatin-
Sepharose bound plasma proteins using non-crossreacting antibodies to 
each protein (Moutsiakis et al., 1992). Pharmacia Blue sepharose and 
Amicon Green sepharose were used for the purification of gelatinases from 
human skin, maintained in serum-free organ culture. The dialyzed and 
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lyophilized medium was fractionated with ammonium sulfate, and applied to 
Pharmacia Blue sepharose in a batch step. The 0.4NaCl eluate was then 
subjected to gel filtration on sephacryl S-200, followed by gradient elution 
from Amicon Green sepharose. The fractions with gelatinolytic activity are 
applied to a Bio-Rad TSK-Phenyl-5PW HPLC column and finally applied to a 
Pharmacia Mono-Q FPLC column and eluted with a gradient of sodium 
chloride. The enzyme appeared as two bands, corresponding to enzymatic 
activity zymograms on SDS-PAGE (Seltzer et al., 1985). 
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1.9 Mass Spectrometry 
A major advance that enabled examination of protein structure by MS and 
MS/MS was the introduction of soft ionization techniques to ‘volatilize’ bio-
molecules, in particular electrospray ionization (ESI) and matrix assisted 
laser desorption/ionization (MALDI). In MALDI, samples are co-crystallized 
onto a sample plate with a small organic matrix compound that usually has a 
conjugated aromatic ring structure, and thus can absorb the wavelength of 
the laser (Muddiman et al., 1997). The matrix provides energy to molecules 
for vaporization to be ionized. Although multiply charged ions can be 
produced, more typically, only singly charged ions are observed in MALDI. 
Mass spectrometry and tandem mass spectrometry (MS/MS) experiments 
are major tools used in protein identification. Mass spectrometers measure 
the mass-to-charge (m/z) of analytes; for protein studies, this can include 
intact proteins and protein complexes (Sobott et al., 2002), fragment ions 
produced by gas-phase activation of protein ions (top-down sequencing) 
(Kelleher, 2004), peptides produced by enzymatic or chemical digestion of 
proteins (mass mapping) (Kleno et al., 2004), and fragment ions produced by 
gas-phase activation of mass-selected peptide ions (bottom-up sequencing) 
(Yates, 1998). 
The application of mass spectrometry and MS/MS to proteomics takes 
advantage of the vast and growing array of genome and protein data stored 
in databases. The information produced by the mass spectrometer, lists of 
peak intensities and m/z values, can be compared with lists generated from 
‘theoretical’ digestion of a protein or ‘theoretical’ fragmentation of a peptide. 
Applications to analyze smaller quantities of sample (such as biopsies) or the 
detection of low abundance proteins (LAP) are driving the development of 
more sensitive mass spectrometers, as well as high resolution separation 
technologies, to provide structural information on individual components in 
complex mixtures of proteins derived from biological samples. Protein 
identification by mass spectrometry requires an interplay between mass 
spectrometry instrumentation (how molecules are ionized, activated, and 
detected) and gas-phase peptide chemistry (which bonds are broken, at what 
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rate) and how cleavage depends on factors such as peptide/protein charge 
state, size, amino acid composition and sequence. Upon detection, the ion 
intensity vs. their m/z is determined by the mass spectrometer, generating 
the mass spectra. Selected peptides, named ‘precursor ions’ are subjected to 
collision-induced dissociation (CID) in the mass spectrometer. The m/z of the 
fragmentation products is then measured. This step is the second dimension 
of the mass spectrometer cycle, which produces the MS/MS spectra for each 
selected precursor ion. The MS/MS spectra obtained are searched against 
databases containing the in-silico-generated MS/MS spectra of each possible 
peptide of the selected organism’s proteome. This leads to the identification 
of the proteins populating the analyzed sample. However, even this 
database-derived information is neither complete (only about 15–30% of 
MS/MS are identified), nor quantitative. Peptides must be able to co-
crystallize efficiently with the matrix, for instance, with Į-cyano-4-
hydroxycinnamic acid (CHCA) matrix, the majority of the ions observed are 
800–1800Da, while with sinapinic acid (SA) matrix larger ions give better 
signals. 
Mass spectrometry is not a quantitative technique because different peptides 
have different ionization efficiencies, meaning that two different peptides at 
the same abundance will generate different signal intensities. To circumvent 
this, different strategies have been developed to overcome this problem and 
many groups have reviewed this subject extensively (Overall and Blobel, 
2007; Overall and Dean, 2006; Tao and Aebersold, 2003). Most of the 
methods achieve relative quantification by comparing protein abundance in 
two or more samples. Results are expressed as fold of increased or 
decreased abundance. Two method classes were developed: isotopic 
labeling or label-free based quantification. The methods using labels rely on 
the inclusion of stable isotopes in the label, which has the exact same 
molecular structure, but different mass. Proteins and peptides can be labeled 
metabolically in cell culture by incorporation of isotope-containing amino 
acids and has been termed stable isotope labeling by amino acids in cell 
cultures (SILAC) (Ong et al., 2002). Alternatively, labels can be chemically 
incorporated after protein isolation. Good examples of such labels are the 
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ICAT (Gygi et al., 1999)  and the iTRAQ (Ross et al., 2004). After the labeling 
step, peptides from the different samples are mixed and analyzed in a single 
MS/MS analysis. In the case of SILAC and ICAT, identified peptides produce 
precursor ions in the MS spectra represented by a peak doublet separated 
the mass difference of the labels (Griffin et al., 2001). Peak area evaluation in 
the MS spectra allows for relative quantification. iTRAQ is fundamentally 
different. Here, the iTRAQ tags are all of the same molecular mass, but upon 
fragmentation they present reporter ions of different mass in the MS/MS 
spectra. The MS/MS peaks are used for relative or absolute quantification 
(Ross et al., 2004). In label-free relative quantification, each sample is 
submitted to mass spectrometry analysis separately and the peak area of 
individual peptides precursor ion found in the different runs are matched and 
used to evaluate the relative abundance of proteins (Cutillas and 
Vanhaesebroeck, 2007). The label-free quantification has no limitation for the 
number of samples that can be compared, but is less accurate than iTRAQ 
for quantification. 
1.9.1 MALDI-Mass Spectrometry 
The first report on MALDI-MS was published in 1985 describing the principle 
and calling the method as ‘matrix assisted desorption’ (Karas, 1985). Over 
the past years, MALDI has developed into indispensable tool in analytical 
biochemistry in particular. As with most of new technologies, MALDI evolved 
from a diversity of prior knowledge. During late 1960’s Beckey introduced 
Field desorption (FD), the first technique which opened a small road into the 
territory of mass spectrometry (MS) of bio-organic molecules. It was in this 
context, in conjunction with the first attempt to desorb organic molecules with 
laser irradiation, that concept of ‘matrix’ as a means of facilitating desorption 
and enhancing ion yield was born (Kaiser et al., 1991). The first attempts to 
use laser radiation to generate ions for a mass spectrometric analysis were 
published few years after the invention of laser. Vistola and Pirone had 
already demonstrated the spectra of organic compound with time of flight 
(TOF) mass spectrometer. Several groups continued to pursue this line of 
research, mainly R. Cotter at John Hopkins University in USA and P. 
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Kistemaker in FOM institute in Amsterdam, the Netherlands with the latter 
group analyzing underavatized digitonin at mass 1251Da (M + Na), using a 
CO2 laser at a wavelength of 10.6μm in the far infrared (Posathumus, 1978). 
1.9.2 MALDI-MS-TOF 
Various combinations of ion sources (MALDI, FAB and ESI) and mass 
analyzers (quadruple, time-of-flight, fourier transform and ion trap) are 
constructed for accurate mass spectrum analyses of bio-molecules. Time-of-
flight mass analyzers are coupled with MALDI due to complimentary pulsed 
nature of both the ion source and mass analyzer. Time-of-flight is a mass 
analyzer employed in modern proteomics which separates ions using time 
and distance as opposed to frequency used in others like quadrople, ion trap 
and fourier transform. Moreover, high resolution, mass accuracy and 
unlimited mass range detection are offered by TOF mass analyzers. A simple 
linear TOF mass analyzer works on the principle that if ions are accelerated 
with the same potential at a fixed point and a fixed initial time and are allowed 
to drift, the ions will separate according to their m/z. Ions strike the detector 
at different times depending on the m/z. A data system controls instrument 
parameters, acquires signal vs. time, and processes the data. In a reflector 
TOF mass analyzer the reflector acts as an ion mirror, extending the flight 
length without increasing the instrument size. The reflector also compensates 
for the initial energy spread of ions having the same mass showing improved 
resolution. 
In a Bruker MALDI, TOF1 ranges from the MALDI ion source to the LIFT cell, 
TOF2 from the second accelerator stage in the LIFT cell to the reflector 
(Figure 1.7). The spots are individually targeted with a laser beam, which 
excites the matrix molecules. These matrix molecules then transfer energy to 
the peptides, leading to peptide ionization. Because the peptides are 
crystallized on a solid support, the same spot can be analyzed several times. 
However, when a spot contains too many peptides, the matrix energy is 
distributed over the entire sample and not enough energy is received by each 
peptide to ionize. This is called the ‘ionization suppression effect’ and also 
leads to under sampling. 
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1.9.2.1 Calibration 
Internal and external calibration of mass spectrometer is important. In 
addition to the samples of interest, a standard protein for which expected 
spectrum is known is run, allowing the operator to externally calibrate the 
system and determine how well the instrument is calibrated. If trypsin is used 
then the advantage of this is that the masses of the resulting peptides are 
known exactly and can be used for internal mass calibration. Being a 
substrate for itself, trypsin is auto-digested into peptides that also contribute 
with signals in the spectra. If the trypsin peaks are found in the spectrum 
internal calibration should be chosen instead of external calibration. Routinely 
an accuracy of 50ppm (parts per million) can be obtained meaning that the 
differences between the measured and the exact masses are less than 
0.005% of the particular peptide mass. The disadvantage of internal 
calibration using trypsin is that the peaks are only seen if the amount of 
trypsin is high enough (compared to the amount of peptides from the 
sample). However, too much trypsin can result in a spectrum where the 
signals from the interesting peptides are suppressed by the trypsin auto-
digest peaks or just too low to be useful. This means that estimation of the 
correct amount of trypsin vs. sample is very important. The two most 
common intensive peptides from the porcine trypsin auto-digest are most 
often the peaks with the m/z values of 842.51 and 2211.10 (charge state 
MH+), respectively. In addition, a trypsin peptide giving a signal at 1045.56 
can be used if either of the other two peaks is missing. 
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Figure 1.7 Schematic diagram of LIFT TOF/TOF MS. 
Taken from Bruker Daltonics Manual. 
1.9.2.2 Sequence Databases 
MS and MS/MS data is transferred to a search engine such as Mascot, which 
then compares experimental and theoretical (in-silico) information in 
sequence databases. SwissProt developed by the SWISS-PROT groups at 
Swiss Institute of Bioinformatics (SIB) and European Bioinformatics Institute 
(EBI) is a protein sequence database that provides a description of the 
function of a protein, its domains structure, post-translational modifications, 
variants, etc., a minimal level of redundancy and high level of integration with 
other databases. The major available sequence databases are maintained at 
NCBI, EBI, SwissProt, UniProt etc. neXtProt is a resource that contains a 
wealth of high-quality data on all the human proteins that are produced by the 
20,000 protein-coding genes found in the human genome. The content of 
neXtProt is continuously extended so as to provide many more carefully 
selected data sets and analysis tools. 
The protein summary page on Mascot includes the accession number, the 
mass of the protein matched, the score, the number of peptides significantly 
matched ( 0.05), the protein name, the sequence of the peptides matched 
and their scores values and mass error values. By clicking on the accession 
number, a separate page ‘protein viewis given, from which the isoelectric 
point (pI) and percentage sequence coverage is gained. The Mascot search 
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results may also give ‘proteins matching the same set of peptides’or may 
give other protein matches with lower scores or number of peptides matched. 
The most appropriate protein identification can be elucidated by comparing 
protein masses, pI and the number of peptides in the sample matched to that 
protein. By clicking on the query number for a peptide, the ‘peptide view’ is 
given which shows a mass spectrum with labeled fragment ions and a table 
containing the matched fragment ions. Protein identification may be 
presented as a single peptide match, or may show several matched peptides. 
The greater number of peptides matched represents more confident protein 
identification. If protein identification with a single peptide match is not 
sufficient, extra information can be given as supporting evidence. This may 
include annotated spectra and/or lists of fragment ions, which can be 
obtained from ProteinScape within Mascot. 
1.10 Proteomics 
During past 5 decades research into protein biochemistry and molecular cell 
biology has led to the elucidation of the function and structure of many 
proteins. Proteins have been and continue to be explored for use in 
pharmacology, biotechnology and biomedical applications. Modern analytical 
technologies are applied to discover and develop new protein based 
biotechnology products. Techniques aiming at identifying the complete 
protein pool found in a biological sample at a given time and under a 
controlled set of conditions are termed ‘proteomics’ techniques. The set of 
proteins found in that biological sample is named its proteome. In the case of 
MMPs, detection of proteases and protease inhibitors at the mRNA level 
using microarrays gives a good indication of whether they might be found in a 
given biological sample. However, there is not always a good correlation 
between the mRNA transcript level and the protein level found in the same 
tissue, confirmation of expression is required at the protein level (Greenbaum 
et al., 2003). 
For example, this is most easily seen for neutrophils storing proteases in 
granules and releasing these upon activation without involving mRNA 
synthesis (Owen and Campbell, 1999). Also, mRNA levels do not provide 
40 
any information about the levels of pre-pro-, pro- and active MMPs that are 
important to understand their physiological roles. Proteomics is defined by a 
number of new and established protein separation methods/procedures, 
most frequently employed in combination with mass spectrometry, for high-
throughput protein identification. A number of strategies/workflows have been 
developed to study whole biological systems or sub-cellular organelles and 
quantify changes in protein expression in response external stimuli (e.g. drug 
administration to a cell line) or determine protein-protein interactions, post-
translational modifications (PTM), etc. Some of these techniques are 
described briefly below. 
1.10.1 Chemical Proteomics 
In last few decades targeted proteome analyses has replaced global 
proteomic analyses with the availability of more sensitive mass 
spectrometers. Targeted proteomics makes use of affinity capture and 
termed chemical proteomics. It comprises the design of drug, cofactors, 
substrate or inhibitor analogues which can be immobilized on a suitable 
matrix support to trap specific proteins, sub-groups or families of target 
proteins. Affinity chromatography has been used in the past for protein 
isolation as part of workflows. With the advent of proteomics, like many 
traditional protein biochemistry techniques, affinity chromatography almost 
disappeared. However, as part of the advancement from global proteomics to 
hypothesis-driven investigation, affinity enrichment to access specific groups 
of proteins for mass spectrometry characterization has re-surfaced as a 
valuable technique (Sutton, 2011). 
Different types of affinity media are commercially available, including triazine 
dyes (albumin, dehydrogenases), nucleotide (kinases), lectin (glycoproteins), 
lysine/gelatin (proteases), heparin (DNA binding proteins, growth factors, 
coagulation factors), Protein G/Protein A (antibodies), antibody-based 
(immuno-affinity and immuno-precipitation), immobilized metal affinity 
chromatography or IMAC (phosphopeptides), that are being used to enrich 
sub-proteomes based on function (Lee and Lee, 2004). One of the key 
differences between current affinity chromatography or chemical proteomics 
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and the traditional methods is scale; in general, the amounts of samples and 
chromatography materials are substantially lower (microlitres instead of 
millilitres or even litres) due to the availability of sensitive mass 
spectrometers and western blotting to analyze captured proteins. For 
chemical proteomics retaining protein functionality during protein 
extract/sample preparation is important. Hence, mechanical methods of 
protein extraction from cells and tissues such as sonication, vortexing, 
maceration, homogenization, extrusion are preferable to chemical methods 
using denaturants such as urea and guanidine, acid precipitation, and some 
detergents, e.g. SDS (Sutton, 2011). 
The information of primary sequence of protein, type of phosphorylation 
(serine/threonine vs. tyrosine), or predicted phosphoacceptor sites 
(consensus peptide that is targeted by a kinase can be used to predict 
precursor and fragment ion m/z values for a multiple reaction monitoring 
(MRM) experiment. This highly sensitive MRM method of monitoring protein 
phosphorylation at specific phosphoacceptor sites may prove useful in 
understanding the physiological regulation of protein function. 
1.10.2 Separation Techniques 
Proteomics mass spectrometry is highly dependent on separation 
technologies that simplify incredibly complex biological samples prior to mass 
analysis. Selection of appropriate separation methods is the first step in 
designing the proteomic application to detect LAP that would otherwise be 
over-shadowed by a higher abundance signal. Therefore, both accuracy and 
sensitivity of a mass spectrometric experiment rely on efficient separation. 
Two major approaches to separation widely used in proteomics are gel-
based and gel-free. Gel-based method, 2D-PAGE, have been traditionally 
used with pulsed ionization MALDI instruments in which the protein band can 
be excised, digested, and off-line sampled with MALDI source (Eckerskorn et 
al., 1992). 
42 
1.10.2.1 Reverse-phase High Pressure Liquid Chromatography (RP-
HPLC) 
Because in a mass spectrometer, proteins are identified by the m/z of their 
peptides and fragments, adequate separation is required for increased 
identifications. The reverse-phase high pressure liquid chromatography is as 
essential to LC-MS as 2D-PAGE is to gel-based proteomics. Peptides bind to 
beads packed into a column and binding is via hydrophobic interactions with 
alkyl-terminating chains covalently bound to the beads. Reverse-phase 
resins (C18) separate peptides based on their hydrophobicity, and a 
significant advantage of RP-LC is that the buffers used are compatible with 
MALDI. It has been shown that packing long, narrow capillary RP columns 
greatly improves loading capacity, sensitivity, and dynamic range of the RP-
LC (Shen et al., 2005). Shen et al. have introduced long, small-particle-size 
(1.4ȝm) RP-LC columns with high peak capacity (1500 and higher, compared 
with an average of 400) operated in an ultra-high pressure regime (20kpsi). 
Using only RP-LC, they identified more than 2000 proteins that vary over six-
orders of magnitude from human plasma in a single experiment. The small 
particle size of RP material (1.5ȝm) allows improved peak capacity, 
resolution, and reduced analysis time (Anspach et al., 2007) when using an 
ultra-high pressure regime. 
1.10.2.2 Multidimensional Protein Identification Technology 
(MudPIT) 
Multidimensional separation is used to address high sample complexity. By 
definition, the multidimensional separation approach combines several 
separation techniques joined to improve the resolving power. An important 
consideration for multidimensional separation is the orthogonality of the 
individual separation methods (Giddings, 1984) in which each dimension 
uses different (orthogonal) molecular properties of molecules as a basis for 
separation. One of the first 2D setups featured cation exchange 
chromatography coupled to a reverse phase column in line with a mass 
spectrometer (Opiteck et al., 1997) used for separation of E. coli proteins. 
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The overall peak capacity of the method was in excess of 2500, with 
femtomolar sensitivity. 
1.10.3 Proteomics Approaches 
Two proteomics approaches are in use based on sample preparation in 
which proteins are either enzymatically digested into peptides (bottom-up 
analysis) (Chait, 2006) or analyzed intact (top-down analysis) (Breuker et al., 
2008). 
1.10.3.1 Bottom-Up Analysis (LC-MALDI) 
In a traditional bottom-up proteomics experiment, proteins are extracted from 
biological samples and digested using a specific protease, usually trypsin. 
The ensuing tryptic peptides are separated by chromatography techniques 
(described above) and submitted to tandem mass spectrometry (MS/MS), 
identifying proteins. In the case of LC-based MALDI-MS analysis, the 
peptides are injected in a capillary containing RP C18 beads and eluted 
using a gradient. The eluting peptides are co-deposited with MALDI matrix as 
discrete sequential droplets (fractions), on a MALDI target with an array of 
384 spots and allowed to dry. The plate is then loaded into the mass 
spectrometer. 
The most widely used method for bottom-up tandem MS data identification is 
the database search in which experimental MS/MS data are compared with 
the predicted, in-silico generated fragmentation patterns of the peptides 
under investigation. Many methods have been developed that address some 
of the computational challenges associated with bottom-up proteomics. 
Some of these developments include using probabilistic scoring schemes 
(Sadygov and Yates, 2003) incorporating additional search criteria. LC-
MALDI provides the ability to separate complex peptide mixtures into discrete 
fractions for more thorough analysis. Drawbacks of the bottom-up approach 
include limited protein sequence coverage by identified peptides, loss of 
labile PTMs, and ambiguity of the origin for redundant peptide sequences 
(Yates et al., 2009). 
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1.10.3.2 Top-Down Proteomics Approach 
Top-down is for the analysis of PTMs which often occur in different 
combinations on individual proteins, and understanding these combinations 
is crucial for understanding biological regulation. Top-down mass 
spectrometry strives to preserve the post-translationally modified forms of 
proteins present in vivo by measuring them intact, rather than measuring 
peptides produced from them by proteolysis. 
1.11 Aims and Objectives 
To date MMP purification has been challenging due to the multiple steps 
required for each member resulting in low yields of proteins which are 
already low in abundance in biological samples. Targeted methods are 
emerging based on a chemical proteomics strategy for active forms of 
specific MMPs, however, there has been no method development for the 
purification of latent pre/pro-forms which would provide critical insights to the 
expression levels of these therapeutically important proteases. MMPs can be 
detected by antibody-based assays such as ELISA; however, these assays 
do not differentiate active and pro-forms. Profiling MMPs by quantifying 
mRNA does not predict protein activity. A shortcoming of antibody-based 
methods is possibility of cross-reactivity of antibodies and lack of 24 specific 
antibodies for each MMP. The study of active MMPs with activity assays is 
not 100% reliable because of the lack of specificity of substrates used. 
Recent advances in sensitivity and resolution of high-throughput mass 
spectrometric based proteomics allows detection of low abundance proteins 
(LAP). Hence, latent and active forms of MMPs may be detected 
simultaneously (Figure 1.8). Considering the number and diversity in function 
of MMPs, innovative approaches and tools are needed to profile expressed 
enzymes on a tissue-wide scale, particularly when valuable biopsies are 
limited in availability. 
This study aims to evaluate a product, which is no longer commercially 
available in conjunction with proteomics methods. Procion Olive H-7G dye 
(Olive H-7G) has previously been used as part of a series of chromatography 
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steps used to purify pro-MMPs in the 80’s and 90’s but before proteomics 
techniques were widely available for MS-based identification. This project 
represents an opportunity to evaluate the traditional affinity purification 
method in conjunction with a modern LC-MALDI proteomics strategy to 
characterize a therapeutically important group of proteins in cancer samples. 
• The first aim of the study was to optimize the preparation of a 
chromatography medium by immobilization of the Olive H-7G on 
various soft gels and magnetic beads. 
• Further, to assist identification of MMPs from valuable biological 
samples, MS and MS/MS were performed to obtain characteristic 
peptide fingerprints/peptide signatures using recombinant human pro-
MMPs (rhMMPs) following trypsin digestion. 
• The Olive H-7G chromatography medium was screened against 
commercially available rhMMPs from various classes to establish the 
dye selectivity.  
• In order to assess chromatographic performance of the Olive H-7G 
medium a series of complimentary and accessory techniques (SDS-
PAGE, western blotting, Coomassie brilliant blue and silver staining 
and ELISA-based activity assays) for the analysis of MMPs from cell 
lines were established and optimized. 
Once the pro-MMPs have been characterized and the methods optimized, 
protein preparations from cell lines will be applied to the chromatographic 
medium as a preliminary assessment of the potential for method to enable 
MMP enrichment from biopsies. The development of a new affinity capture 
tool for pro-MMPs and their subsequent MS-based characterization will 
provide a useful insight into their regulation prior to secretion and possible 
identify strategies to prevent their activation in a range of tissues and 
diseases. 
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Figure 1.8 Challenges for MMP enrichment.
Antibodies
Immuno-precipitation 
assays
Activity 
assays  
Zymography 
Problems with MMP Purification
mRNA
PROTEOMICS
Recent advances in sensitivity and resolution 
of mass spectrometric based proteomics
high-throughput techniques allow
detection of low abundance proteins (LAP)
So Latent/ Active MMP levels could be detected 
simultaneously
(24 Ab, Cross-reactivity)(Does NOT predict protein activity) (NO specific substrate)
Multiple steps are involved.
Some MMPs have not been purified.
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How to Profile MMPs?
CHAPTER 2 
MATERIALS AND METHODS 
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2 Materials and Methods 
2.1 Reagents & Chemicals 
For all proteomics work, polypropylene micro-centrifuge tubes were used, to 
minimize contaminations from plastics and to prevent proteins/peptides being 
retained on the surface of the tubes. HPLC grade water was used 
throughout. All chemicals were purchased from Sigma-Aldrich (Dorset, UK) 
unless stated. 
2.2 Immobilization of OliveH-7G on Chromatography Beads: H-7G-
Sepharose and H-7G-Sephadex 
The Procion Olive H-7G dye (Amicon) ligand was immobilized to Sepharose-
6B beads (45-165ȝm; fractionation range of 1x103-4x106 Da for globular 
proteins) following the previously described method of Dean and Watson 
(Dean and Watson, 1979). The Procion Olive H-7G dye (10mg/mL) was 
added to Sepharose-6B (0.2mg/mL final) to a total volume of 25mL in HPLC 
grade water and mixed via rotation for 5minutes. NaCl was then added to a 
final concentration of 0.2mg/mL and the solution incubated at room 
temperature with mixing for a further 30 minutes. Following the addition of 
Na2CO3 (final concentration 333mM) the solution was incubated for 40hours 
at 45°C with constant mixing. After immobilization, the gel solution was 
poured onto a sintered glass funnel (Supelco Mobile Phase Filtration 
Apparatus 2) and washed with HPLC grade water under suction to remove all 
traces of the azide preservative from the sepharose beads. Suction was 
applied gently until the surface of the gel cracked. Any unbound dye was 
removed by washing with 1M KCl, 4M urea, and then extensive washing with 
HPLC grade water. The prepared beads were stored wet at 4°C in the 
presence of 0.1% (w/v) sodium azide when not in use. Hereafter the 
chromatography beads will be termed as H-7G-Sepharose or Olive H7G 
chromatography beads. 
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H-7G-Sephadex or Olive H-7G chromatography beads were synthesized 
using same method as described above. Sephadex bead size is 50-150μm 
with a bead volume of 4-6mL/g and fractionation range of 1x103-5x103 Da. 
2.3 Cell Culture 
The cell lines were selected to represent tissue and tumour types. The 
human fibrosarcoma cell line (HT1080) and colon adenocarcinoma cell line 
(HT29) were obtained from the Institute’s in-house cell line bank. Cells were 
grown in monolayer culture in 75mL non-vented flasks containing 50mL 
Rosewell Park Memorial Institute (RPMI-1640) medium supplemented with 
10% foetal calf serum (FCS), 2mM L-glutamine, and 1mM sodium pyruvate 
(termed complete medium). The cells were maintained at 37°C in a 
humidified atmosphere of 5% CO2 Haraeus Incubator (DJB Labcare Ltd, UK). 
Cells were grown to a maximum of 80% confluence before being passaged. 
2.3.1 Cell Counting 
Cells were detached using 0.25% trypsin-EDTA solution from one flask and 
counted using a haemocytometer. Briefly, 10μL of cell suspension was 
placed into the chamber of a Neubauer haemocytometer and the mean 
number of cells per grid of the chamber calculated, the resulting count being 
equivalent to the number of cells x 104 per mL. Cell numbers were expressed 
as (mean cell count) x 104 per mL. 
2.3.2 Tumour Cell Line Growth Kinetics 
To determine cell growth kinetics, cells were lifted, counted as described 
above and plated at a density of 1 x 103 cells per 25cm2 cell culture flask per 
time-point. Cells were counted every 24 hour for a total of 7 days. These 
values were plotted against time to generate a growth curve and determine 
the log phase growth period of the HT1080 and HT29 cell line. Growth curves 
were plotted as a mean of 3 growth curves. 
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2.3.3 Collection of Culture Supernatant  
Cell media and the subsequent cells were collected under both serum-
containing and serum-free conditions for analysis of MMP production Cells 
were grown to sub-confluence in complete RPMI-1640 medium (containing 
10% FCS); the resultant media (henceforth referred to as serum-containing 
culture supernatant or S+CS) was then collected and stored at -20°C. The 
cell monolayer was then washed twice with Hanks balanced salt solution 
(HBSS) to remove residual serum prior to being incubated in serum-free 
RPMI-1640, containing 2mM L-glutamine and 1mM sodium pyruvate. 
Following further 48hours incubation at 37°C in a humidified atmosphere of 
5% CO2, media was collected (henceforth referred to as serum-free culture 
supernatant or SFCS) and stored at -20°C. 
2.3.4 Harvesting of Cells 
Cell monolayer was harvested using 0.25% trypsin-EDTA and split into 
further tissue culture flasks at the required density if needs to be passaged. 
For further protein expression studies, cell pellets were resuspended in 10mL 
of 1X PBS solution, centrifuged at 1000rpm for 5minutes. The supernatant 
was discarded and the washing was repeated until supernatant is free of the 
entire medium contents. The cell pellets were stored at -20°C. 
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2.4 Affinity Chromatography of Recombinant, Secreted and Cellular 
MMPs 
An aliquot of Olive H-7G chromatography bead suspension (containing 
approximately 0.5mL wet volume of Olive H-7G chromatography beads) was 
transferred to a 15mL centrifuge tube. The chromatography beads were first 
equilibrated via incubation for 10-30 minutes in the following buffer: 50mM 
Tris-HCl (pH 7.5), 0.15M NaCl, 10mM CaCl2, 0.02% (w/v) Na3N before being 
centrifuged at 1200g at 4°C for 10minutes. The resultant supernatant was 
discarded and equilibration buffer added to the Olive H-7G chromatography 
beads at a final volume of 1mL. Samples (starting material or SM) were 
added to the Olive H-7G chromatography bead suspension and mixed with 
rotation for 1-4 hour at 4°C to affinity bind proteins to the Olive H-7G 
chromatography beads. The sample was then centrifuged at 1200g for 5-
10minutes and the resultant equilibration flow-through (FT) collected. The 
bead-protein complex was washed 3-times in equilibration buffer (1mL each) 
and the individual washes collected (termed wash flow-through FT1a, FT1b 
and FT1c and were pooled in FT). The bead-protein complex was then 
washed twice with a further 10mL of equilibration buffer and the resultant FT 
discarded. 
2.4.1 Salt Elution 
Proteins were then eluted from the Olive H-7G chromatography beads via 
incubation for 10minutes at room temperature in 0.3M elution buffer 
containing: 50mM Tris-HCl (pH 7.5); 0.3M NaCl; 10mM CaCl2; 0.02% (w/v) 
Na3N, 0.05% (v/v) Brij-35 (if added), followed by centrifugation for 10minutes 
at 4°C. This was repeated 3-times and the resultant supernatants termed 
E1a-c. A further elution was performed in elution buffer containing high salt 
concentration (2M or 5M as opposed to 0.3M). This was repeated 3-times 
and the flow-throughs termed E2a-c. The beads were then washed twice with 
a further 10mL of elution buffer and the resultant FT discarded. In latter 
experiments the elution buffers were used without the detergent Brij-35, as 
described in the results. Finally, the Olive H-7G chromatography beads were 
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collected and stored at 4°C in 0.1% NaN3 solution (Figure 2.2). The fractions 
were desalted and concentrated using NAP-5 columns (Materials and 
Methods section 2.5) and 10mM NH4HCO3 + EDTA was used to avoid 
autolytic degradation of MMPs during the process. The same sequence of 
steps of equilibration, washing and elution procedures were followed for each 
type of samples (recombinant human MMPs, serum-containing culture 
media; serum-free culture media; NaCl extract; dimethylsulfoxide (DMSO) 
extract and urea extract from lysed cells) used. 
2.5 Protein Concentration: NAP-5 Columns and Dialysis Method 
Illustrate NAP-5 columns (GE Healthcare, Piscataway, NJ, USA) were used 
to desalt samples. Each column was equilibrated with 3-volumes of 10mM 
ammonium bicarbonate solution (ambic), 0.5mL of sample added, and the 
desalted protein eluted and collected by loading 1mL of 10mM ambic 
solution. Samples were then lyophilized using Genevac EZ-Plus 2 
Evaporator at 37° C, using aqueous conditions setting. The 0.5-3.0mL Slide-
A-Lyzer cassettes (Thermo Scientific, USA) with a molecular weight cut off 
(MWCO) value of 3500Da were used for sample concentration. The 
cassettes slipped into the grooves of the buoy, were hydrated by immersion 
in 1L of 1X CAB dialysis buffer (Appendix 1). Samples were injected into the 
cassette using an 18-gauge needle syringe. Air was withdrawn by pulling up 
the syringe piston. Samples were dialyzed in dialysis buffer for 2hours at 4°C, 
a further 2hours in fresh buffer and then overnight in fresh buffer at 4°C. To 
extract the sample, air was discharged into the cassette cavity to separate 
membranes and the sample was withdrawn into the syringe and its volume 
was measured. 
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Figure 2.2 Flowchart for affinity chromatography. 
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2.6 Bradford Assay for Quantification of Total Proteins  
Protein concentration was ascertained using the Bradford Assay (Bradford, 1976). 
Serial dilutions for six protein standards (62.5μg/mL-1.0mg/mL) were made up using 
2mg/mL bovine serum albumin (BSA) dissolved in distilled water. These standards 
formed a standard curve (Figure 2.3) from which sample protein concentrations could 
be calculated. Each tube was vortexed and absorbance at 595nm read immediately on 
a spectrophotometer (Cary 50 Bio UV-Visible) using a disposable plastic cuvette. 
2.7 ELISA for Quantification of MMP-2 
MMP-2 amounts (pro and active) were quantified using an ELISA-based assay (R&D 
systems, MN, USA). The assay kit contains CHO cell expressed recombinant human 
MMP-2 and antibodies raised against the recombinant factor. This assay specifically 
recognizes recombinant and natural human MMP-2 as well as recombinant MMP-2 
complexed with TIMP-2.  
The mean minimum detectable dose (MDD) of MMP-2 is 0.16ng/mL. The assay was 
performed as per kit instructions. Briefly, serial dilutions of MMP-2 standards from 
0.78ng/mL-50ng/mL were prepared in RD5-32 diluent provided in the kit. 50µL of each 
protein standard was applied in duplicate onto an anti-MMP2 coated microplate. Diluent 
RD5-32 (50μL) was used as a zero control standard and 50µL aliquots of the unknown 
samples were applied in duplicate into the appropriate wells. 
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Figure 2.3 Standard curve for BSA standards. 
A linear relationship between protein concentration and absorbance was confirmed 
between 62.5μg/mL and 1mg/mL. 
The plate was then covered and shaken gently for 2hours at room temperature. All 
wells were washed 4-times with wash buffer and the plate blotted to remove any 
residual wash buffer before adding 200µL of detection antibody against MMP-2 
conjugated to horseradish peroxidase to each well and incubation for a further 2hours 
at room temperature. Following washing, the colorimetric detection reagent 
(tetramethylbenzidine [TMB] and hydrogen peroxide [H2O2]) which is a substrate for 
horseradish peroxidase was added and incubated for 30 minutes at room temperature 
in the dark. The reaction was stopped via addition of H2SO4 (1N). The plate was then 
read at 450nm (Labsystems Multiscan Ex) to obtain the absorbance of blue product 
synthesized in each well. Readings were normalized by subtraction of non-specific 
absorbance at 540nm. Standard curves were constructed from the readings of the 
MMP-2 standards (Figure 2.4) and the concentrations of the unknowns calculated from 
these curves. 
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Figure 2.4 Standard curve for ELISA standards. 
A linear relationship between protein concentration and absorbance was confirmed 
between 0.78ng/mL and 50ng/mL. 
2.8 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were separated through 10% polyacrylamide SDS gels (Bio-Rad, 
Hertfordshire, UK). The gel was immersed in 1X running buffer (Appendix 1). Samples 
equivalent to 30μg protein were diluted in SDS loading buffer (Appendix 1) and were 
then heated at 95°C for 5minutes followed by rapid incubation on ice to denature 
proteins. Samples were loaded into wells at a volume of 20μL. Full range rainbow 
marker were loaded into the first and last well of the gel to allow for later mass 
determination. The electrophoresis was run at 50V until the samples reached the 
resolving gel, then, 125V for a further hour to separate proteins. 
2.8.1 Coomassie Brilliant Blue Staining 
Proteins separated on SDS-polyacrylamide gels were immersed in Coomassie brilliant 
blue solution (Methanol: H20 [1:1 v/v] with 10% acetic acid) which fixed and stained it 
simultaneously for 1 hour. After staining the gels, a destaining solution (40% Methanol/ 
10% acetic acid/ 50% water) was used to remove excess stain. Destained gels were 
sealed in plastic bags in water after being scanned (HP scan jet 2400). 
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2.8.2 Silver Staining 
Gels were fully destained after Coomassie blue staining. Dodeca silver stain kit (Bio-
Rad, Hertfordshire, UK) was used. Since silver salts are sensitive to temperature 
staining was performed at 23°C or above. After washing the gel with distilled water, a 
Fixing solution (8mL acetic acid, 32mL ethanol and 40mL water) was added and left for 
30 minutes on a rocker. Sensitizing solution (8mL Bio-Rad SC reagent, 24mL ethanol, 
800μL Bio-Rad BRC reagent and 47.2mL water) immediately after removing fixing 
solution was added and left on rocker for another 30 minutes at room temperature. 
Following three washes with 80mL of distilled water, staining solution (1.6mL Bio-Rad 
SRC reagent and 78.4mL water) was added and container was covered completely 
with aluminum foil. The gel was left on rocker for 20minutes. After removing staining 
solution and rinsing container quickly for few seconds with 80mL water and replacing 
with another 80mL of water, the gel was left for maximum of 1minute and then 
removed. Developing solution, (8mL Bio-Rad DBC reagent, 16μL Bio-Rad IDC reagent, 
4μL Bio-Rad BRC reagent and 72mL water) was added onto the gel and left on shaker 
for 5-30 minutes depending on the formation of bands. The reaction was terminated by 
adding stopping solution (4mL acetic acid and 76mL water). The gel in container was 
left on shaker for 10minutes and then washed with 80mL water on the shaker for 
10minutes. Water was replaced for storage. 
2.8.3 Western Blotting for MMP-2 
Western blotting protocol was optimized for primary antibodies for human MMP-2. The 
MMP-2 antibody utilized in this study was raised to bind to amino acid 107-117 of the 
protein. Proteins were transferred from the acrylamide gel to PVDF membrane using a 
Biorad transfer kit immersed in 1X transfer buffer (Appendix 1). Protein transfer was run 
at 300mA for 1 hour in the electrophoresis kit placed in an ice bath. After the transfer 
PVDF membrane was immersed in Ponceau solution to verify protein transfer. PVDF 
membrane was washed with 1X TBS and  blocked overnight at 4°C with 10% (w/v) non-
fat dried milk in Tris-buffered saline (1X TBS)-0.1%(v/v) TWEEN®20 (10X TBS: 
Appendix 1). 
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2.8.3.1 Antibody Incubations 
The membrane was washed in 1X TBS without TWEEN®20 for a few seconds and then 
incubated with 1:1000 polyclonal rabbit anti-MMP-2 antibody in 5% (w/v) non-fat dried 
milk/ 1X TBS-TWEEN®20 for 2hours at room temperature. After rinsing thrice with 1X 
TBS-TWEEN®20, membranes were incubated with 1:2000 dilution of horseradish 
peroxidase conjugated polyclonal goat anti-rabbit antibody in 5% (w/v) BSA in 1X TBS-
TWEEN®20 for 2hours at room temperature. The membrane was rinsed with 1X TBS-
TWEEN®20 for 5minutes 3-times before protein detection. The same procedure was 
used for experiments set up to detect minimum amount of MMP-2 detected by using 
commercially available recombinant human MMP-2. 
2.8.3.2 Protein Detection 
The ECL plus western blotting detection system reagents A and B (Amersham™ GE 
Healthcare, Buckinghamshire, UK) were mixed in a 40:1 ratio and applied onto 
membrane for 5minutes. The membrane was then sealed using Saran™ wrap before 
being exposed to the Kodak scientific imaging film in dark room. Exposure times varied 
from 20minutes to overnight. Films were developed using Optimax X-ray film processor 
or in case of manual developing, developing in Ilford rapid multigrade developer (1/10 
dilution) for 3minutes, rinsing with water and fixing in Ilford rapid film and paper fixer 
solution (1/10 dilution) for 3minutes. 
2.9 Trypsin Digestion 
In addition to using samples (HT1080 or HT29 culture supernatants, cell extracts, 
recombinant human MMPs and their corresponding affinity chromatography fractions) 
for total protein concentration measurement and activity assays, aliquots were used for 
proteomics analysis. 
2.9.1 Proteomics: In-Solution Trypsin Digestion 
The amounts of 8M urea, 50mM dithiothreitol (DTT) and 100mM iodoacetamide (IAC) 
were added depending upon the amount of protein present in the samples and will be 
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explained in corresponding chapters. To protein solution 8M urea in 100mM ambic was 
added to give a final concentration of 7.42M, vortexed and centrifuged. DTT (50mM) 
was added to give a final concentration of 1.85mM, vortexed and heated between 50-
80oC in water for 20minutes and centrifuged for 1minute. After bringing it to room 
temperature, 100mM IAC was added to a final concentration of 3.57mM, vortexed spun 
and incubated for 20minutes in the dark. HPLC grade water was added to dilute the 
urea concentration to 2M. Trypsin solution (20μg/mL) was added in a protein to trypsin 
ration of 20:1 (w/w) and incubated at 37oC overnight. The reaction was stopped by 
freezing at -20°C. The controls -horse heart myoglobin + trypsin, myoglobin alone and 
trypsin alone were treated the same as the samples. Lyophilized protein samples were 
digested as described above, except resuspended directly in 8M urea buffer. 
2.9.2 Proteomics: On-Bead Trypsin Digestion 
Olive H-7G chromatography beads (100μL wet volume of Olive H-7G chromatography 
beads in 1:1 suspension in buffer) were equilibrated twice with 1mL of 25mM ambic, To 
the beads, urea was added to give an 8M concentration and vortexed. Then 50μL of 
50mM DTT were added, mixed and heated to 50oC for 15minutes. After bringing it to 
room temperature 50μL of 100mM IAC were added, vortexed, centrifuged and 
incubated for 15-20 minutes at room temperature in dark. To dilute the urea 
concentration to 2M, 50μL of HPLC grade water, were added. This was followed by the 
addition of 80μL of trypsin solution (20μg/mL) and incubated at 28oC for 18hours. The 
reaction was stopped by freezing at -20°C. 
2.10 Desalting of Digested Protein 
Following devices were used to remove chemicals specifically detergents and salts 
likely to interfere with protein identification: 
2.10.1 Desalting by Isolute C18 Cartridges 
Digested protein samples were desalted to remove contaminants interfering with 
protein identification using Isolute C18 columns (Biotage, Kinesis Ltd.). To equilibrate 
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the column, 1mL methanol was added using a 1000μL pipette. A syringe and adaptor 
was attached to column to slowly force methanol through column into waste beaker 
stopping pressure just before total volume is eluted to prevent any air being forced 
through. The same process was repeated 2X with 1mL solvent A (2% CH3CN with 
0.05% triflouroacetic acid [TFA]). Then protein sample was added to column followed 
by toping it up to 2X with 1mL solvent A. Finally collected the sample into a labeled 
1.5mL eppendorf tube by eluting with 1mL solvent B (80% CH3CN with 0.05% TFA). 
Centrifuged and lyophilized the eluate at the end of the process. 
2.10.2 Desalt with Zip tips 
Zip tips with a C4 or C18 filter were used for desalting small volumes of fractions or for 
loading 2μL samples on target plate for MALDI-MS analyses. Using Gilson pipette of 
capacity from 2-20μL, zip tips were washed with 20μL methanol by forcing, stopping 
pressure just before total volume is eluted to prevent any air being forced through. The 
same process was repeated 2X with 20μL solvent A (2% CH3CN with 0.05% TFA). 
Then 2μL protein sample was picked in zip tip followed by toping it up to 20μL with 
solvent A and repeated 2X with same volume of solvent A. Finally collected the sample 
on target plate by eluting with 2μL solvent B (80% CH3CN with 0.05% TFA). 
2.10.3 Desalt with Pierce Columns 
Peptides were desalted using Pierce detergent removal spin columns (Thermo 
Scientific, Rockford, USA) to remove detergents which cause deleterious effects by 
forming adducts with peptides in MALDI-MS analyses. A 125μL spin column was 
placed into a 2mL collection tube. To equilibrate the column, 100μL of 10mM ambic 
was added using a 200μL pipette. The buffer was discarded after centrifugation at 
1000g for 1minute at room temperature. As instructed, a mark was placed on the side 
of the column where compacted resin was slanted upwards. In all subsequent 
centrifugation steps, the mark was faced outwards in fixed-angle rotors since an 
improper orientation results in reduced detergent removal efficiency. The same process 
was repeated 2X with 10mM ambic. After placing the column in a new 1.5mL eppendorf 
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tube 10-25μL protein sample was slowly added to the top of compact resin bed and 
incubated for 2minutes at room temperature. The detergent free sample was collected 
into labeled 1.5mL eppendorf tube by centrifugating at 1000g for 2minutes. 
2.11 Manual MALDI-MS of Peptides 
2.11.1 Instrumentation 
Mass spectrometry was performed on an UltraflexTM II MALDI-TOF/TOF instrument 
(Bruker Daltonics, Bremen, Germany). The MALDI-TOF-MS used a 200Hz pulsed 
337nm nitrogen laser. Mass spectra were obtained after in-solution or on-bead trypsin 
digestion. 
2.11.2 Matrix Solution Preparation 
Į-Cyano-4-hydroxycinnamic acid (CHCA) was used as the matrix of choice. Stock 
matrix solution was prepared by weighing CHCA (10mg) in a 1.5mL eppendorf tube,
dissolved in 1mL of 30% CH3CN + 0.1% TFA, vortexed for few minutes and then 
sonicated for 30 minutes. Stock matrix was stored at 4°C. 
2.11.3 Mass Spectrum Acquisition 
Samples were applied on One piece Aluminium Target with transponder MTP384 
(Bruker Daltonics, Billerica, MA, USA) after cleaning the well positions with 0.5μL of 
10mg/mL of CHCA. Once it was dried, each fraction (10ȝL) was desalted using C18 zip 
tips. Desalted peptides were eluted in 2ȝL of 80% CH3CN + 0.05% TFA onto MTP 384 
massive target plate and 0.5ȝL of matrix solution (10mg/mL CHCA) was applied on top 
of it. It was allowed to dry before placing in the mass spectrometer. A standard peptide 
mixture was used for calibration. Mass spectra were acquired by keeping the 
instrument at positive reflectron mode in the mass range of 700-4000Da using laser 
power from 50-80% firing 500 shots. For each sample and controls analyzed at least 
5000 laser shots were added. Data was acquired by FlexControl software. 
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2.12 nHPLC coupled to MALDI-MS/MS for Protein Identification (LC-MS/MS) 
2.12.1 Reverse phase nHPLC Fractionation of Modified Peptides 
Fractions were desalted using Isolute C18 1mL columns and peptides were eluted 
using 1mL of 80% CH3CN + 0.05% TFA and lyophilized. A nanoHPLC Dionex Ultimate 
3000 system was used for fractionation of trypsin-digested peptides from selected 
chromatography fractions. The above mentioned system consists of stacked 
autosampler, flow manager, detector, pump and solvent rack modules. Samples were 
resuspended in 10% CH3CN and (6.5μL) were transferred to Dionex vials and placed 
on the autosampler unit. The silica needle aspirated 5μL of sample after piercing the 
vial cap with a separate puncture needle. A 25μL syringe fixed at the opposite end of 
puncture needle helps this sample collection by creating suction. Once collected, 
sample was injected into the LC system via a sample loop (carrier solvent) onto a C18, 
300ȝm x 5mm, 5ȝm, 100ǖ PepMap pre-column (LC Packings, Sunnyvale, CA). Once 
on the pre-column the sample was washed for 3.5minutes at a flow rate of 
300nL/minute, with the carrier solvent. The sample was then transferred onto a C18, 
75ȝm x 15cm, 3ȝm, 100ǖ PepMap column (LC Packings) which was equilibrated with 
2% CH3CN with 0.05% TFA (mobile phase A). 
2.12.2 nHPLC Gradient Conditions 
The peptides in the aqueous mobile phase A bind to the stationary phase in reverse 
phase nHPLC column. Column development (elution) was performed in a gradient 
manner in increasing CH3CN buffer concentration. As autosampler injected 5μL of 
sample into micropump at a flow rate of 300nL/minute, 80% CH3CN + 0.05% TFA 
(mobile phase B) increased by 10% in 6minutes. Between 6-81minutes it keeps 
increasing from 10-40% in linear fashion. At 81.1minutes it finally reaches 100%. This 
mobile phase composition is maintained for 5minutes and then changed to 100% 
mobile phase A to re-equilibrate column until the end of run at 100minutes post-
injection. The detector used deuterium lamp and measured the wavelength of eluents 
simultaneously at two different wavelengths of 280nm and 215nm. The profile of 
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peptides was visualized on computer connected to the system using Hystar 3.2 
software (Bruker Daltonics, Gmbh). 
2.12.3 Fraction Collection 
2.12.3.1 MALDI Matrix 
A stock solution was prepared by solubilizing CHCA in 1mL of 30% (v/v) CH3CN with 
0.1% (v/v) TFA. CHCA was solubilized by vortexing for 2minutes and sonicating for 30 
minutes to generate a saturated solution. From the stock solution a working solution is 
prepared by adding 1.056mL ethanol-acetone (2:1), 120μL of matrix stock supernatant, 
12μL 100mM ammonium phosphate and after vortexing mixture 12μL 10% TFA was 
added. Working matrix solution was stored at room temperature with lid closed to 
prevent evaporation. The fractions (384) were collected onto a MTP AnchorChip 
800/384 target plate (Bruker Daltonics, Bremen, Germany) using Proteineerfc FC 
fraction collector (Bruker Daltonics, Gmbh). The xyz coordinates of the robot arm were 
adjusted using Hystar 3.2 software. The eluate fraction volume spotted by Proteineerfc 
robot arm every 15seconds on each well is 1.2μL CHCA matrix + 75nL of sample. 
2.12.3.2 External Calibration for MS 
Peptide Calibration Standard II (Bruker Daltonics, Bremen, Germany), comprising 
Angiotensin I, Angiotensin II, Substrate P, Bombesin, ACTH clip 1-17, ACTH clip 18-39, 
Somatostatin-28, Bradykinin fragment 1-7 and Renin Substrate Tetradecapeptide 
porcine; covering the mass range 700-3200Da, was used for external calibration of 
mass spectrometer. After the collection of fractions, 0.3μL of a 1/15 dilution of Peptide 
Calibrant Standard II in 70% CH3CN + 0.1%TFA was spotted between every four wells 
on target plate. After the calibrant dried, 1.3μL of CHCA working matrix solution was 
applied on top of it. 
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2.12.4 Mass Spectrum Acquisition 
For automated MALDI-MS/MS 800 shots of laser were fired for parent ion and 1200 for 
the fragment ions in UltraflexTM II MALDI-TOF/TOF instrument. The details about what 
precursors were selected and mass range for data collection will be described in 
various chapters. 
2.12.5 WARP-LC and Database searching 
WARP-LC is a software platform for qualitative and quantitative LC-MS/MS-based 
protein and proteomics analysis for all ESI and MALDI mass spectrometers 
manufactured by Bruker, Daltonics. WARP-LC is an acronym for Workflow 
Administration by Result-driven Processing. Figure 2.6 shows how peaks for 
compounds with a certain m/z are selected and sent to Mascot search engine and the 
results are displayed on ProteinBrowser. Mass lists from MS/MS spectra of peptides 
were submitted to a Mascot (Matrix Science, Boston, MA) query search which used 
Mascot software (Perkins et al., 1999) searching against the SwissProt protein 
database using the Bruker Biotools (version 3.2) interface. Within the Mascot search 
engine, the MS tolerance was ±0.7Da and mass tolerance was 100 parts per million 
(ppm). The criteria also included  2partials, taxonomy human, enzyme trypsin and the 
variables modifications allowed were methionine oxidation and carbamidomethylation of 
cysteine. No global variations were selected. A 95% confidence threshold was set 
(p<0.05) for searching the MS/MS data against SwissProt. A Mascot score threshold of 
30 was used for positive protein identification. 
65
 
Fi
gu
re
 2
.5
 L
C
-M
S/
M
S 
w
or
kf
lo
w
. 
Wƌ
Žƚ
ĞŝŶ
^Ă
ŵ
ƉůĞ
WĞ
Ɖƚ
ŝĚĞ
Ɛ
Tr
yp
si
n 
D
ig
es
tio
n
WĞ
Ɖƚ
ŝĚĞ
^Ğ
ƉĂ
ƌĂ
ƚŝŽ
Ŷď
ǇŶ
,W
>
D
at
ab
as
e 
S
ea
rc
hi
ng
P
ro
te
in
 id
en
tif
ic
at
io
n
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
T
im
e
 [
m
in
]
01234
In
te
n
s.
[m
A
U
]
M
A
LD
I-M
S
M
A
LD
I-M
S
/M
S
C
18
 
D
es
al
t
8
7
8
.9
1
4
1
3
13
.4
8
7
2
95
3
.9
4
9
1
0
5
8
.3
9
4
2
4
9
7.
7
9
0
1
4
63
.5
6
9
1
7
6
5.
4
7
1
M
M
P
-1
4
 
012344
x1
0
Intens. [a.u.]
1
00
0
15
00
2
00
0
2
50
0
3
00
0
35
66 
Figure 2.6 LC-MS/MS workflow supported by WARP-LC.
One MS measurement for each LC fraction on MALDI target
MS spectra acquisition and peak picking
Calculation of MALDI compound list
Generation of MS/MS acquisition requests, one for 
each qualified compound. Extension of the 
AutoXecute run with acquisition requests
Generation of 
compound list 
for Database 
search in 
ProteinScape
Generation of 
compound list 
for Mascot 
search in 
BioTools
Display Mascot 
search result in 
ProteinBrowser
MS/MS spectra 
acquisition
Optional:
Use identification 
results of previous 
MALDI-MS/MS
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CHAPTER 3 
PROCION OLIVE H-7G DYE 
CHARECTERISTICS 
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3 Procion Olive H-7G Dye Characteristics 
3.1 Introduction  
Dyematrex Reactive Green A is an azo-anthraquinone immobilized dye 
marketed by Amicon (Lexington, MA, USA) (Fulton, 1980) but this product is 
no longer commercially available. There is considerable evidence that pro-
MMPs can be purified using conventional column chromatography in which 
the Green A Dyematrix plays an important role. This ligand had previously 
been demonstrated to have affinity for MMPs, specifically, pro-MMP-1, pro-
MMP-2, pro-MMP-3 (Okada et al., 1986), pro-MMP-7 (Imai et al., 1995), pro-
MMP-9 (Okada et al., 1992) and pro-MMP-10 (Nakamura et al., 1998). Since 
studies have shown that Green A Dyematrex Gel (Procion Olive H-7G or 
Olive H-7G) can be used for capturing multiple pro-MMPs, it suggests that 
there is a common binding moiety within the family of enzymes. Therefore, a 
detailed analysis of Olive H-7G was made to explore if it will bind other 
MMPs and can be used to purify all MMPs in biological sample, particularly if 
applied as an adjunct to proteomics methods such as MALDI mass 
spectrometry analysis and protein identification. A good amount of Procion 
Olive H-7G, the active ligand in Dyematrex Reactive Green A, is available at 
ICT and was provided by Millipore Inc (who acquired Amicon Inc) for these 
studies. Bound proteins are eluted with high salt concentrations as has been 
described in the literature (Imai and Okada, 2008).  
This chapter comprises of experiments to determine some of the 
characteristics of the dye. Olive H-7G comprises of an anthraquinone moiety 
(Figure 3.1) with two sulphonic acid groups and an amine group. The 
sulphonic groups provide the desired solubility of the molecule in aqueous 
media (Denizli and Piskin, 2001). These groups are negatively charged at all 
pH values. Sodium ions increase the solubility of this dye in water. This 
anthraquinone moiety is linked to an azo functional group which in turn is 
linked to a reactive group mono-chlorotriazine ring (Figure 3.1). The 
presence of aromatic backbone renders it hydrophobic and helps develop 
interactions with hydrophobic surfaces of proteins. Like other reactive dyes, 
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an additional support is provided by the ionic interactions between other polar 
interactions of amino acid side chains with dye substituent (Denizli and 
Piskin, 2001). Olive H-7G is soluble in water and not soluble in methanol or 
ethanol. Olive H-7G dye is immobilized onto a solid support (matrix) by direct 
reaction between hydroxyl groups of the polysaccharide gels such as 
agarose or sepharose and the chloride atom on triazinyl group of the dye. 
This pairing is achieved at alkaline conditions by nucleophilic substitution of 
hydroxyl groups with the reactive chlorine on the dye molecules (Figure 3.2). 
The linkage between the matrix and ligand is stable during the protein 
absorption and elution steps of affinity chromatography. Nucleophiles are 
generated by the high pH, which promotes the ionization of the matrix 
hydroxyl groups, but pH>12 should be avoided as hydrolysis of the 
chlorotriazines in the aqueous media occurs (Denizli and Piskin, 2001). 
Figure 3.1 Structure of Procion Olive H-7G. 
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Figure 3.2 Coupling of triazinyl dyes to the matrix bearing hydroxyl 
groups. 
Taken from (Denizli and Piskin, 2001). 
3.1.1 Aims 
The specific aims of this chapter are: 
• To determine photometric absorbance of Olive H-7G.
• To determine limit of detection of Olive H-7G by MALDI-MS. 
• To determine absorbance of Olive H-7G using nHPLC.
3.2 Materials and Methods 
3.2.1 Spectrophotometery 
Absorbance of Olive H-7G serial dilutions (1nM-10mM) was scanned over a 
range of wavelength (200nm-1000nm) with a step size of 5nm. Each dilution 
was vortexed and absorbance was scanned immediately on UV 
spectrophotometer (Multiskan Spectrum v1.2) using a disposable plastic 
cuvette with a path length of 1cm. 
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3.2.2 MALDI-MS of Olive H-7G 
Mass spectrometry was performed on in-house UltraflexTM II MALDI-
TOF/TOF instrument (Bruker Daltonics, Bremen, Germany) (see Chapter 2 
for details) operating in reflectron, positive ion mode. The Olive H-7G 
dilutions (1nM-10mM) were spotted with CHCA (10mg/mL) matrix and 5000-
15000 laser shots were acquired for various dilutions to achieve a stronger 
mass spectra. 
3.2.3 nHPLC of Olive H-7G (Analytical Runs) 
A nanoHPLC Dionex Ultimate 3000 system was used for Olive H-7G dilutions 
(0nM, 2nM, 4nM, 6nM, 8nM, 10nM, 20nM, 40nM and 80nM). Olive H-7G 
solutions (10μL) were transferred to Dionex vial (plastic) and placed on the 
autosampler unit and 2μL of samples is loaded onto the column. Elution was 
performed for various Olive H-7G dilutions in gradient manner using different 
times and increasing acetonitrile buffer concentration. The mobile phase B 
(80% CH3CN + 0.05% TFA) increased finally reaching 100% and this mobile 
phase was changed to 100% mobile phase A (2% CH3CN + 0.05% TFA) as 
shown in Table 3.1. The detector used deuterium lamp and measured the 
wavelength of eluents simultaneously at three different wavelengths of 
215nm, 250nm and 445nm. The profiles of Olive H-7G solutions were 
visualized on computer connected to the system using Hystar 3.2 software 
(Bruker Daltonics, Gmbh). 
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Table 3.1 HPLC gradient parameters for analytical runs of Olive H-7G. 
3.3 Results 
3.3.1 Spectrophotometery of Olive H-7G 
Photometric absorbance scanning showed wavelengths at maximum 
absorbance (Ȝmax) of 250nm and 445nm in 100μM Olive H-7G solution 
(Figure 3.3). The multiple peaks in the 100μM dilution are because of the 
presence of aromatic rings in the structure of the dye. The absorbance of 
1mM and 10mM dilutions was complicated and lower concentrations (1nM-
1μM) were not detectable by the scanner (results not shown). 
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Figure 3.3 Photometric scanning (200-1000nm) of Olive H-7G to 
measure absorption Ȝ (n=5). 
3.3.2 Olive H-7G Molecular Mass Confirmation by MALDI-MS 
Since matrix CHCA also shows low mass fragments, it was analyzed neat 
across a spectral range 700-4000 as shown in Figure 3.4. The calculated 
molecular mass of Olive H-7G is 869.1 and CHCA matrix did not show any 
fragment with this mass. Figure 3.5 shows that at this spectral range, Olive 
H-7G (10mM) showed a peak at 864.697, Olive H-7G (1mM) showed a peak 
at 864.873 and Olive H-7G (0.1mM) showed very weak intensity peak at this 
mass (result not shown). All lower concentrations (10μM-1nM) did not show 
any significant peaks which imply that limit of detection (LOD) of Olive H-7G 
compound is 0.1mM (869ng/mL). The same Olive H-7G serial dilutions were 
then analyzed setting a spectral range from 200-2000 and 500-1000 so that a 
close observation of the smaller fragments could be made. The CHCA matrix 
showed smaller mass peaks but no significant peak near calculated mass of 
Olive H-7G. 
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Figure 3.4 MALDI mass spectrum of CHCA matrix (spectral range 700-
4000). 
Figure 3.5 MALDI mass spectra of Olive H-7G (spectral range 700-
4000). 
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3.3.3 nHPLC Profiles of Olive H-7G 
Olive H-7G was analyzed by C18 reverse phase nanoHPLC with on-line UV 
detection at 215nm, 250nm and 445 over the concentration range 0-80nM. 
The set of parameters for HPLC analytical run are given in Table 3.1. Since 
Olive H-7G is more soluble in water, the gradient parameters were set so that 
solvent A (2% CH3CN + 0.05% TFA) is 100% for longer time to elute the 
Olive H-7G dye off the HPLC column if it is bound. Within 2.5minutes solvent 
B (80% CH3CN + 0.05% TFA) percentage was increased from 0-90 and then 
in next 12.5minutes it reached 100%. After keeping it 100% for 5minutes, 
solvent B percentage was decreased to 0 at time-point 25.1minute. A 
discrete peak was observed between 37-39minutes possibly indicating that 
Olive H-7G is pure and eluting in higher concentration of solvent A (2% 
CH3CN + 0.05% TFA). It is also worth noticing that there is a delay in elution 
of a compound and its detection by UV detector in HPLC system. Once 
optimized, above mentioned settings were used for 80nM Olive H-7G 
concentration to see if discrete peak could be obtained. A more intense and 
similar profile was observed in three individual runs. The 80nM Olive H-7G 
solution shows better UV profile than for lower concentrations. The Olive H-
7G did not show absorbance at 445nm. 
Figure 3.6 HPLC profile of 80nM Olive H-7G (n=3). 
0 5 10 15 20 25 30 35 40 T ime [min]
0
2
4
6
8
10
Intens.
[mAU ] HPLC profile 80nM H-7G 
Solution
UV 215nm
UV 250nm
UV 445nm
75 
3.4 Discussion 
Simple, economical and reproducible spectrophotometric methods are 
compared with HPLC methods for the estimation of number of components in 
a product to find out difference in efficiency. So that if HPLC is not available, 
spectrophotometer could be used. These methods were successfully applied 
for the determination of the two binary combinations in synthetic mixtures and 
in commercial tablets and syrup containing several light absorbing recipients 
(el-Gindy, 2003). An attempt was made to develop a UV spectrophotometric 
and nHPLC method for simultaneous estimation of components present in 
Procion Olive H-7G dye. For estimation with spectroscopy, the scanning was 
performed at a wavelength range from 200-1000nm. The Developed HPLC 
method is reverse phase chromatographic method using C18 column and 
acetonitrile as mobile phase. The first method involving multi-wavelength 
spectroscopy is specific to the instrument having software for provision of 
such determination. The selection of proper sampling wavelengths and 
concentration of components in solution is critical. Since calculations are 
done by the instrument itself, chances of manual error are nil; furthermore, 
the method is quite rapid. For nHPLC run time per sample was 48minute and 
it used UV detector even for visible range wavelength 445nm. Photometric 
absorbance scanning produced multiple wavelengths for the maximum 
absorbances (Ȝmax) at 250nm and 445nm because Olive H-7G has aromatic 
rings in its structure. 
Based on the results of spectrophotometry three different wavelengths were 
set in HPLC system to detect the absorbance profile of various structural 
components of Olive H-7G. The appearance of peaks at 215nm and 250nm 
indicates the presence of aromatic rings. When 8nM Olive H-7G solution was 
fractionated using HPLC, collected on target plate and analyzed by MALDI-
MS to confirm calculated mass (869.1) of Olive H-7G, very complex set of 
data was obtained and any conclusive observation could not be made. In 
HPLC, the dye was well separated and gave discrete peaks as shown in the 
representative chromatograms (Figure 3.6). The spectrophotometric 
absorbance of 100μM H-7G solution showed a profile specific to aromatic 
ring containing compounds and detection of discrete peaks in HPLC 
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chromatogram for 80nM H-7G solution might suggest that Procion Olive H-
7G has one active component. However, this can not be stated with certainity 
that the peak at 445nm is specific to the dye. This could be attributed to 
weaker chromophore within the structure of the dye, low concentration of H-
7G or the instrument was not specific enough. 
The Olive H-7G peak profile determined by MALDI-MS did not show specific 
peak at 869.1+1. The dye was also analysed by ESI (facility available at IPI 
University of Bradford) but a conclusive result confirming structure of the dye 
could not be obtained suggesting complex nature of the compound.
CHAPTER 4 
CHARECTERIZATION OF RECOMBINANT 
HUMAN MMPs (rhMMPs) BY MALDI-MS 
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4 Characterization of Recombinant Human MMPs (rhMMPs) by 
MALDI-MS 
4.1 Introduction 
Identification of specific peptides that are characteristic of specific proteins is 
one of the key principles of MS-based proteomics. In the present study 
MALDI-MS based strategies were used for the characterization of proteins 
(Figure 4.1). The MALDI-MS is suitable for purified proteins, thus any 
discrepancies in mass of intact purified protein from that of calculated mass 
as determined by amino acid sequence predicted from the cognate gene can 
be revealed. The individual proteins/peptides are ionized and identified 
searching the acquired m/z data against databases. The protein identification 
is confirmed by a score calculated by relating experimental and theoretical 
data. The proteins of interest for the present study are MMPs. As explained 
in the Introduction diverse physiological roles are played by various members 
of this family of enzymes in turnover of most types of the ECM proteins 
making them a suitable drug target for prevention of pathological tissue 
damage. Some of the characteristics of MMPs are summarized in Table 4.1. 
4.1.1 Aims 
A number of recombinant forms of human pro-MMPs (rhMMPs) are available 
commercially. Before studying H-7G-Sepharose chromatography for the 
purification of MMPs from biological samples, a set of preliminary 
experiments with rhMMPs using MALDI mass spectrometry for detection and 
identification were performed. 
The aims of these experiments explained in this chapter were: 
• To characterize rhMMPs by mass spectrometry using amounts 
equivalent to those anticipated in biological samples (a) to confirm the 
intact protein had the expected molecular weight and (b) to identify 
characteristic peptides for the ‘pro’ and ‘active’ regions of each 
rhMMPs after digestion with trypsin. 
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• Having established characteristic profiles, the region of MMPs that 
binds Olive H-7G dye will be identified by comparing MS spectra of 
trypsin-digested rhMMP in the presence and absence of soluble dye. 
Figure 4.1 Applications of MALDI-MS in proteomics. 
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4.2 Materials and Methods 
4.2.1 MALDI-MS of Intact Proteins 
4.2.1.1 Desalting rhMMPs 
Since stock rhMMPs (R & D) are in a solution containing Brij-35, C4 zip tips 
were used to remove the detergent where protein mass peaks were masked 
by detergent related peaks as will be described in Chapter 6. Depending on 
molecular mass and structural properties, 2-50pmoles of purified protein is 
required for comprehensive molecular analysis by MALDI-MS including intact 
mass determination. 
4.2.1.2 Matrix Solution Preparation 
Sinapinic acid (SA) was used as matrix. A stock solution of SA matrix 
(10mg/mL) was prepared in 70% CH3CN + 0.1% TFA. rhMMPs samples 
(0.5μL), with or without desalting, were applied on One-piece Aluminum 
Target with transponder MTP384 (Bruker Daltonics, Billerica, MA, USA) and 
0.5ȝL of matrix solution on top of it. It was allowed to dry before placing in the 
mass spectrometer. 
4.2.1.3 Mass Spectrum Acquisition 
Mass spectrometry was performed on an UltraflexTM II MALDI-TOF/TOF 
instrument (Bruker Daltonics, Bremen, Germany) (see Chapter 2 for details). 
A manual analysis was performed by keeping the instrument at positive linear 
mode using laser power from 70-90% firing 500 shots. For each rhMMP and 
controls analyzed, at least 5000 laser shots were added at a mass range of 
10,000-200,000. Data was acquired by FlexControl software. The 
recombinant MMPs volume analyzed, stock concentrations and the volume 
of SA used is given in Table 4.2. All intact protein samples were analyzed 
before and after desalting using C4 zip tips. 
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Table 4.2 Concentration of intact rhMMPs for molecular mass 
determination. 
4.2.2 Theoretical Digests for MMPs (SequenceEditor Software) 
SequenceEditor 3.2 (Bruker Daltonics, Gmbh, Germany) was used to 
perform in-silico trypsin digestion on sequences of human MMP protein. The 
potential peptides can be created with no modifications or by selecting 
cysteine modification reduced (SH), oxidised (SS), carbamidomethyl (C), N-
terminal end (free hydrogen) and C-terminal side chain (free acid/ amide). 
The enzyme to perform the digest on protein sequence can be selected from 
a list of enzymes given in tab ‘Edit Enzyme’ in tool bar. The interface window 
of the software provides options to define the cleavage rules for the enzyme 
selected. For example, if trypsin enzyme is selected for cleaving the protein 
sequence, it is defined as ‘allow cut after lysine (K) or arginine (R)’ and 
‘proline (P) is not allowed after the cut’. This defines cleavage rule for trypsin 
as {X [K, R]Œ[X X]ˆ[P]} where X can be any amino acid. Once enzyme 
cleavage rules are defined, in-silico protein digestion can be performed by 
setting the extended options of mass range limit, peptide mass tolerance, 
partials (20), positive or negative ion mode, mono-isotopic or average m/z
values as required. For present study, trypsin enzyme was selected to 
generate theoretical tryptic digests and no mass limit was selected with 0-2 
partials. This in-silico digestion identified the correct amino acid sequence 
and m/z. since +1 charge was selected so it generated a list of theoretical 
masses of mono-isotopic tryptic peptides (MH+) of MMPs. 
rhMMP Concentration(μM)
Volume
(μL)
Matrix Volume
(μL)
MMP-1 1.9 0.26 0.50
MMP-2 5.1 0.97 0.50
MMP-3 1.79 2.00 0.50
MMP-7 17.85 0.56 0.50
MMP-8 1.96 2.00 0.50
MMP-9 2.59 1.54 0.50
MMP-10 1.92 2.00 0.50
MMP-13 3.85 0.56 0.50
MMP-14 16.12 0.56 0.50
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4.2.3 MALDI-MS of Trypsin Digests 
4.2.3.1 Preparation of rhMMPs Peptides 
For the characterization study rhMMPs were prepared as described. To each 
rhMMP solution (in buffer provided by R&D), 4μL of 8M urea were added, 
vortexed and centrifuged. To each rhMMP, 1μL of 50mM DTT was added as 
a reducing agent, vortexed and heated between 50-80oC in water for 15-
20minutes and centrifuged for 1minute. After bringing it to room temperature,
1μL of 100mM IAC was added for alkylation, vortexed spun and incubated for 
15-20minutes at room temperature in dark. To dilute the urea concentration 
to 2M, at which concentration trypsin works very effectively, 13μL of distilled 
water, were added. This was followed by the addition of 0.5μL of trypsin 
solution (20μg/mL) and incubated at 28oC for 18hours. The reaction was 
stopped by freezing at -20°C. The controls horse heart myoglobin + trypsin, 
myoglobin alone and trypsin alone were treated the same as samples to 
assure the efficiency of trypsin enzyme. 
4.2.3.2 Removal of Detergents from Peptide Solution
The peptide solutions were desalted using C18 zip tips as described in 
Materials and Methods section 2.10.2. 
4.2.3.3 Mass Spectrum Acquisition 
Mass spectra of peptides were obtained after in-solution trypsin digestion 
using CHCA as matrix. A manual analysis was performed by keeping the 
UltraflexTM II MALDI-TOF/TOF instrument (Bruker Daltonics, Bremen, 
Germany) (see Chapter 2 for details) at positive reflectron mode using laser 
power from 50-80% firing 500 shots. For each sample and controls analyzed 
at least 5000 laser shots were added at a mass range of 700-4000. Data was 
acquired by FlexControl software. External calibration of instrument was 
done as explained in Materials and Methods section 2.12.3.2. 
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4.2.4 Manual MALDI-MS/MS of rhMMP Peptides 
For manual MALDI-MS/MS 800 shots of laser were fired for parent ion and 
1200 for the fragment ions. The compound list of the m/z of parent and 
daughter ions were sent to Biotools manually to generate protein hit 
confirming the signature peptides for corresponding MMP. 
4.2.5 Interaction between rhMMP-14/rhMMP-2 and Olive H-7G 
Solutions of Olive H-7G (1nM), rhMMP-2 (52nM) and rhMMP-14 (33.3nM) 
were prepared. Constituents were added as shown in Table 4.3 to give a 
protein-to-dye ratio of 1:10, including horse heart myoglobin and trypsin 
controls and incubated on a carousel at 4°C for 4 hour. 
Table 4.3 Protein to dye ratios for reaction. 
4.2.6 Interaction between rhMMP Mixture and Olive H-7G 
A mixture of 11 rhMMPs was reacted with 100μM Olive H-7G solution (a 
border-line concentration detected by MALDI-MS). To observe changes in
m/z at peptide level, the Olive H-7G-MMPs complex was lyophilized at 37°C 
using evaporator. It was then trypsinized as described in Materials and 
Methods section 2.9.1 using trypsin (20ng/μL). The determination of mass 
peak shifts of Olive H-7G was accomplished by MALDI-MS of tryptic digests 
both with and without C18 zip tipping. In case when no zip tipping performed, 
1μL of sample was spotted on MALDI target plate and 2μL when zip tipped. 
Sample
rhMMP-2 rhMMP-2
+
Olive H-7G
rhMMP-14 rhMMP-14
+
Olive H-7G
Myo
+
Olive H-7G
Try
+
Olive H-7G
Myo + Try
+
Olive H-7G
Myo + Try
Component μL μL μL μL μL μL μL μL
rhMMP-2        (52nM) 19.5 19.5 - - - - - -
rhMMP-14      (33nM) - - 24 24 - - - -
Olive H-7G    (1nM) - 1 - 1 1 1 1 -
Myo (1mM) - - - - 2 - 2 2
Try                (205nM) 1 1 1 1 - 2 2 2
Ambic (100mM) 1 - 1 - 2 2 - 1
Total Volume 21.5 21.5 26 26 5 5 5 5
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The instrument was calibrated using a standard mixture of proteins and mass 
spectrum was acquired in a mass range of 700-4000 as described in 
Materials and Methods section 2.12.3.2. 
4.3 Results 
4.3.1 Molecular Mass of Intact rhMMPs by MALDI-MS 
Table 4.4 shows the accurate molecular masses of MMPs as determined by 
MALDI-MS in current study and predicted molecular masses calculated 
based on amino acid residue recombinant protein expressed in cloned cell 
lines. The MALDI data for intact MMPs were obtained and shown in Figure 
4.2. These mass peaks were only detectable for MMP-3, MMP-7, MMP-10 
and MMP-14. No intact masses were obtained for MMP-1, MMP-2, MMP-8, 
MMP-9 and MMP-13. No significant results could be found after an attempt to 
remove the detergent using C4 zip tips. 
Table 4.4 MMP theoretical and molecular masses by MALDI-MS. 
*Predicted information is from R & D. 
MMP
rhMMP
Molecular Mass
(Predicted)
(kDa)
MMP
Theoretical Mass
(Predicted)
(kDa)
rhMMP
Molecular 
Mass
(MALDI-MS)
(kDa)
MMP-1 52 54.007 -
MMP-2 71 73.882 -
MMP-3 52 53.977 53.16
MMP-7 20 & 28 29.677 27.70
MMP-8 51 53.412 -
MMP-9 77 78.458 -
MMP-10 43 & 52 54.51 56.09
MMP-13 52 53.820 -
MMP-14 31 65.894 31.00
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Figure 4.2 MALDI mass spectra for intact rhMMP-3, rhMMP-7, rhMMP-10 
and rhMMP-14. 
4.3.2 Mass Spectra for Controls in Trypsin Digestion 
To assure the efficiency of trypsin, three controls (myoglobin + trypsin, 
myoglobin alone and trypsin alone) were run in parallel with digestion of 
rhMMPs for mass spectrometric analyses. Theoretical digest products of 
Horse heart myoglobin were generated using SequenceEditor 3.2 (Appendix 
3) and masses of peaks specific to singly-charged ions were matched with 
those of found in analysis of digested protein samples (Figure 4.3). Horse 
heart myoglobin naturally removes N-terminus methionine hence first two 
peptides products with m/z 1815.90 (for peptide 2-17) and 34.03.49 (for 
peptide 2-32) were observed after deduction of 131Da from theoretically 
calculated values. There was no autolytic degradation of trypsin or 
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myoglobin. The mass peaks below 1000 (810.361 and 941.482) are 
fragments from matrix. 
Figure 4.3 Mass spectra for Myo, Try and Myo + Try controls. 
4.3.3 Peptide Mass Fingerprints (PMF) of rhMMPs 
Signature peptides or PMF of MMPs were identified experimentally by 
manual MALDI-MS (Materials and Methods section 2.11). Several peaks 
were found in mass spectra of the peptides generated from rhMMP-1, 
rhMMP-2, rhMMP-3, rhMMP-7, rhMMP-8, rhMMP-9, rhMMP-10, rhMMP-13 
and rhMMP-14 after trypsin digestion was performed. For rhMMP-12 and 
rhMMP-16, significant number of peaks could not be generated. 
4.3.3.1 MMP-1 
From the trypsin digestion of rhMMP-1, 34 signals were observed (Figure 
4.4A) in the mass range of m/z 830.55-1900.22 (Appendix 5). The theoretical 
m/z of peptides from human MMP-1 generated by SequenceEditor 3.2 is 
labeled T1-T53 (Appendix 4) and matched experimental m/z (Figure 4.4B) 
highlighted red in Figure 4.4C. A number of signals corresponded to tryptic 
peptides were generated for the theoretical sequence. Of these peptide 
products, 2 were partials. The rhMMP-1 was constructed without the pre-
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region (amino acids 1-19) in Murine myeloma cell line so the expressed 
enzyme was from Phe20-Asn469. Two peptides were detected within ‘pro’ 
region (20-99), one a partial (T2/3, m/z 1232.41) when trypsin skips one 
cleavage site (lysine in this case) and one complete (T10, m/z of 1127.51) 
(Figure 4.4C) which suggests that MMP-1 in use was not ‘active’ or degraded 
form of the enzyme before it was subjected to trypsin digestion. Other signals 
were detected within hemopexin-like 3 region (377-424) towards C-terminus 
of the active sequence but no signal was observed from the mid-section with 
active site residue E219 (Figure 4.4C). 
4.3.3.2 MMP-2 
From the trypsin digestion of rhMMP-2, 34 signals were observed (Figure 
4.5A) in the mass range of m/z 843.38-3309.91 (Appendix 5). The theoretical 
m/z of peptides from human MMP-2 generated by SequenceEditor 3.2 is 
labeled T1-T68 (Appendix 4) and matched experimental m/z (Figure 4.5B) 
highlighted red in Figure 4.5C. A number of signals corresponded to tryptic 
peptides were generated for the theoretical sequence with a mass tolerance 
upto 0.33daltons. Of these peptide products, 4 were partials (T46/47, T15/16, 
T57/58 and T32/33) and two were with carbamidomethylation of cysteine in 
the sequence (T13 and T31). As there are many lysine and arginine residues 
in the ‘pre-pro’ region (1-109), many possible products of trypsin digestion 
could be produced (Figure 4.5C). However, this would result in many 
peptides with m/z less than 700 hence difficult to be detected by MALDI-MS. 
These low molecular weight molecules can also be from the matrix in use or 
autolytic digestion of trypsin. Two peptides were detected in ‘pre-pro’ region 
suggesting the enzyme was not active or degraded form (Figure 4.5C). Other 
signals corresponded to the fibronectin type-II 2 (286-334), hemopexin-like 1 
(475-518), hemopexin-like 2 (520-563) and hemopexin-like 3 (568-615) of the 
active sequence were observed. But no signal was observed from 
collagenase-like 2 region with active site reside E404 (Green and enboxed in 
Figure 4.5C). Some tryptic peptides labeled TX could be from unexpected 
partials or modifications or non-trypsin cleavage products. 
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4.3.3.3 MMP-3 
From the trypsin digestion of rhMMP-3, 65 signals were observed (Figure 
4.6A) in the mass range of m/z 707.20-2184.74 (Appendix 5). The theoretical 
m/z of peptides from human MMP-3 generated by SequenceEditor 3.2 is 
labeled T1-T56 (Appendix 4) and matched experimental m/z (Figure 4.6B) 
highlighted red in Figure 4.6C. The accuracy of the peptide products was 
upto 0.34daltons. Of these peptide products, 8 were with 1 partial and one 
(T4-6) was with 2 partial. As there are many lysine and arginine residues in 
the ‘pro’ region (18-99), 15 possible products of trypsin digestion could be 
produced (Figure 4.6C). Two peptides were detected within ‘pro’ region, one 
a partial (T14/15, m/z 2122.84) when trypsin skips one cleavage site (lysine 
in this case) and one complete (T15, m/z of 1178.43) when trypsin does not 
skip its cleavage site (Figure 4.6C) which suggests that MMP-3 in use was 
not ‘active’ or degraded form of the enzyme before it was subjected to trypsin 
digestion. Other signals corresponded to the N-terminus and C-terminus of 
the active sequence but no signal was observed from the mid section with 
active site reside E219 (Figure 4.6C). 
4.3.3.4 MMP-7 
From the trypsin digestion of rhMMP-7, 42 signals were observed (Figure 
4.7A) in the mass range of m/z 1065.46-2848.73 (Appendix 5). The 
theoretical m/z of peptides from human MMP-7 generated by 
SequenceEditor 3.2 is labeled T1-T27 (Appendix 4) and matched 
experimental m/z (Figure 4.7B) highlighted red in Figure 4.7C. A number of 
signals corresponded to tryptic peptides were generated for the theoretical 
sequence with a mass tolerance upto 0.37daltons. Of these peptide products, 
2 were partials (T3/4 and T10/11). Many peptides were detected within ‘pro’ 
region (18-94), with T10/11 starting within the cysteine switch (underlined in 
Figure 4.7C) which suggests that MMP-7 in use was not ‘active’ or degraded 
form of the enzyme before it was subjected to trypsin digestion. None of the 
signals including active site residue E215 (Figure 4.7C) or corresponded to 
the C-terminus of the active sequence were observed. 
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4.3.3.5 MMP-8 
From the trypsin digestion of rhMMP-8, 100 signals were observed (Figure 
4.8A) in the mass range of m/z 714.28-3320.20 (Appendix 5). The theoretical 
m/z of peptides from human MMP-8 generated by SequenceEditor 3.2 is 
labeled T1-T44 (Appendix 4) and matched experimental m/z (Figure 4.8B) 
highlighted red in Figure 4.8C. A number of signals corresponded to tryptic 
peptides were generated for the theoretical sequence with a mass tolerance 
upto 0.45daltons. Of these peptide products, 8 were with one partial and one 
tryptic peptide T41-43 was with 2 partials skipping arginine and lysine along 
the sequence. None of the peptide was detected in ‘pre’ (1-20) or ‘pro’ region 
(21-100) suggesting the enzyme was active or degraded form (Figure 4.8, C). 
Other signals corresponded to the hemopexin-like 1 (285-327), hemopexin-
like 3 (377-422) and hemopexin-like 4 (424-464) of the active sequence were 
observed. But no signal was observed from mid-section with active site 
reside E218 (Figure 4.8C). 
4.3.3.6 MMP-9 
From the trypsin digestion of rhMMP-9, 97 signals were observed (Figure 
4.9A) in the mass range of m/z 714.26-3674.97 (Appendix 5). The theoretical 
m/z of peptides from human MMP-9 generated by SequenceEditor 3.2 is 
labeled T1-T67 (Appendix 4) and matched experimental m/z (Figure 4.9B) 
highlighted red in Figure 4.10C. The accuracy of matched peptides was 
found to be upto 3.11daltons. Of these peptide products, 11 were with one 
partial and 5 were with 2 partials. Two peptide products T22 and T31/32 were 
found to be with carbamidomethylation of cysteine based on the difference of 
57.0340daltons between the detected peak m/z and that of the theoretical. 
The detection of peptides T3, T5, T6/7 and T10 within ‘pro’ region (20-93) 
suggested that enzyme in use was intact before the trypsin digestion (Figure 
4.9B and Figure 4.10C). Other signals corresponded to the fibronectin type-II 
1 (225-273), fibronectin type-II 2 (283-331) and fibronectin type-II 3 (342-390) 
were detected. Many tryptic peptides from the C-terminus of the protein were 
detected within the hemopexin-like 1 (521-565), hemopexin-like 2 (567-608), 
hemopexin-like 3 (613-659) and hemopexin-like 4 (661-704) of the active 
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sequence were observed. But no signal was observed from mid-section with 
active site reside E402 (Figure 4.10C). 
4.3.3.7 MMP-10 
From the trypsin digestion of rhMMP-10, 86 signals were observed (Figure 
4.11A) in the mass range of m/z 733.15-3759.14 (Appendix 5). The 
theoretical m/z of peptides from human MMP-10 generated by 
SequenceEditor 3.2 is labelled T1-T49 (Appendix 4) and matched 
experimental m/z (Figure 4.11B) highlighted red in Figure 4.12C. A number of 
signals corresponded to tryptic peptides were generated for the theoretical 
sequence with a mass tolerance upto 1.29daltons. Of these peptide products, 
10 were with one partial and 7 were with 2 partials. Since the rhMMP-10 in 
use was from Tyr18-Cys476 derived from Murine myeloma cell line so no 
peptide from ‘pre’ region (1-17) was detected. The detection of peptides T6-
8, T12/3 and T14/15 within ‘pro’ region (18-98) suggested that enzyme in use 
was intact before the trypsin digestion (Figure 4.11B and Figure 4.12C). 
Many tryptic peptides from the C-terminus of the protein were detected within 
the hemopexin-like 1 (295-337), hemopexin-like 2 (339-382), hemopexin-like 
3 (387-434) and hemopexin-like 4 (436-476) of the active sequence were 
observed. But no signal was observed with active site reside E218 (Figure 
4.12C). 
4.3.3.8 MMP-13 
From the trypsin digestion of rhMMP-13, 100 signals were observed (Figure 
4.13A) in the mass range of m/z 717.20-3131.86 (Appendix 5). Many of these 
signals were probably from the detergent which could not be removed by 
C18 desalting. The theoretical m/z of peptides from human MMP-13 
generated by SequenceEditor 3.2 is labeled T1-T48 (Appendix 4) and 
matched experimental m/z (Figure 4.13B) highlighted red in Figure 4.13C. A 
number of signals corresponded to tryptic peptides were generated for the 
theoretical sequence with a mass tolerance upto 1.42daltons. Of these 
peptide products, 5 were with one partial and 2 were with 2 partials. Since 
the rhMMP-13 in use was from Leu20-Cys471 derived from Murine myeloma 
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cell line so no peptide from ‘pre’ region (1-19) was detected. The detection of 
peptides within ‘pro’ region (20-103) suggested that enzyme in use was intact 
before the trypsin digestion (Figure 4.13B and C). Many tryptic peptides from 
the C-terminus of the protein were detected within the hemopexin-like 1 (290-
332), hemopexin-like 2 (334-377), hemopexin-like 3 (382-429) and 
hemopexin-like 4 (431-471) of the active sequence were observed. But no 
signal was observed from mid section with active site reside E223 (Green 
and enboxed in Figure 4.13C). 
4.3.3.9 MMP-14 
From the trypsin digestion of rhMMP-14, 48 signals were observed Figure 
4.14A) in the mass range of m/z 715.32-2996.93 (Appendix 5). The 
theoretical m/z of peptides from human MMP-14 generated by 
SequenceEditor 3.2 is labeled T1-T65 (Appendix 4) and matched 
experimental m/z (Figure 4.14B) highlighted red in Figure 4.14C. A number of 
signals corresponded to tryptic peptides were generated for the theoretical 
sequence with a mass tolerance upto 0.76daltons. Of these peptide products, 
7 were with one partial and 3 were with 2 partials. Only one peptide, T4, was 
detected within ‘pro’ region (21-111) suggested that enzyme in use was intact 
before the trypsin digestion (Figure 4.14B and C). Many tryptic peptides from 
the C-terminus of the protein were detected within the hemopexin-like 1 (323-
366), hemopexin-like 2 (368-412), hemopexin-like 3 (415-461), hemopexin-
like 4 (463-508) and cytoplasmic domain (563-582) of the active sequence 
were observed. But no signal was observed including active site reside E240 
(Figure 4.14C). 
4.3.4 MS/MS Ion Search for Peptide Fragment of rhMMPs 
MS/MS analysis of parent molecule rhMMP-3 with m/z 1143.42 (T17 in 
Figure 4.6A) generated fragments and submitted to mascot search engine 
(human, no modifications, 1 partial) giving a mascot score of 44 (threshold 
significance 30 at <0.05). 72 fragments corresponded to x,y,z ions of the 
peptide CGVPDVGHFR within a mass accuracy of 0.7dalton (Figure 4.15). 
When the m/z of all the fragments, parent and daughter ions (PFF) were sent 
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to Biotools, MMP-3 (human) identification was generated. The fragment ions 
and parent peptides (pointed with red arrows) for rhMMP-2, rhMM-7, rhMMP-
8, rhMMP-9, rhMMP-13 and rhMMP-14 are shown in Figure 4.15. The parent 
ions from each MMP were fragmented and data was sent to Biotools. The 
identification of corresponding MMP with a Mascot score greater than the 
threshold level (>30) proved the presence of the peptide molecule. 
94 
(A) 
(B) 
(C) 
Figure 4.4 A. MS PMF of rhMMP-1 annotated tryptic peptides, B. Mass 
data for peptides in daltons, C. Sequence coverage, ID peptides in red, 
active site green and arrow heads pointing start of various regions. 
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Theoretical Experimental Accuracy 
Mono MH+ m/z (Daltons)
T23 [209-214] 831.41 830.55 0.86 0 EYNLHR None
T22 [203-208] 837.40 836.53 0.87 0 WTNNFR None
T41/42 [400-405] 873.41 873.51 -0.10 1 YDEYKR None
T10 [ 66- 74] 1127.56 1127.51 0.04 0 QMQE...FGLK None
T16 [118-127] 1217.62 1216.46 1.15 0 IENYT...DLPR None
T40/41 [397-404] 1222.55 1220.70 1.86 1 YWRYDEYK None
T2/3 [ 37- 45] 1233.65 1232.41 1.24 1 YLEKYYNLK None
ModificationsTryptic Digests Range Partials Sequence
1 MHSFPPLLLL LFWGVVSHSF PATLETQEQD VDLVQKYLEK YYNLKNDGRQ
51 VEKRRNSGPV VEKLKQMQEF FGLKVTGKPD AETLKVMKQP RCGVPDVAQF
101 VLTEGNPRWE QTHLTYRIEN YTPDLPRADV DHAIEKAFQL WSNVTPLTFT
151 KVSEGQADIM ISFVRGDHRD NSPFDGPGGN LAHAFQPGPG IGGDAHFDED
201 ERWTNNFREY NLHRVAAHEL GHSLGLSHST DIGALMYPSY TFSGDVQLAQ
251 DDIDGIQAIY GRSQNPVQPI GPQTPKACDS KLTFDAITTI RGEVMFFKDR
301 FYMRTNPFYP EVELNFISVF WPQLPNGLEA AYEFADRDEV RFFKGNKYWA
351 VQGQNVLHGY PKDIYSSFGF PRTVKHIDAA LSEENTGKTY FFVANKYWRY
401 DEYKRSMDPG YPKMIAHDFP GIGHKVDAVF MKDGFFYFFH GTRQYKFDPK
451 TKRILTLQKA NSWFNCRKN 
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Figure 4.5 A. MS PMF of rhMMP-2 annotated tryptic peptides, B. Mass 
data for peptides in daltons, C. Sequence coverage, ID peptides in red, 
active site green and arrow heads pointing start of various regions. 
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Theoretical Experimental Accuracy 
Mono MH+ m/z (Daltons)
T46/47 [483-491] 1158.59 1158.47 0.12 1 GEIFFFKDR None
T15/16 [119-127] 1223.62 1223.48 0.13 1 WDKQ...ITYR None
T57/58 [580-590] 1403.71 1403.53 0.18 1 TYIF...KFWR None
T18 [147-158] 1418.74 1418.57 0.18 0 AFQV...TPLR None
T20 [162-175] 1587.76 1587.54 0.21 0 IHDG...NFGR None
T31 [297-310] 1608.67 1608.45 0.22 0 FQGT...TEGR Carbamidomethylation (C)
T13 [102-115] 1670.75 1670.51 0.24 0 CGNP...FFPR Carbamidomethylation (C)
T32/33 [311-325] 1837.75 1837.76 -0.01 1 TDGY...DYDR None
T17 [128-146] 2108.02 2107.71 0.31 0 IIGY...AFAR None
T11 [ 80- 98] 2183.04 2182.72 0.33 0 FFGL...ETMR None
T52 [532-550] 2224.07 2223.75 0.32 0 AVFF...TLER None
ModificationsTryptic Digests  Range Partials Sequence
1 MEALMARGAL  TGPLRALCLL GCLLSHAAAA PSPIIKFPGD VAPKTDKELA
51 VQYLNTFYGC  PKESCNLFVL KDTLKKMQKF FGLPQTGDLD QNTIETMRKP
101 RCGNPDVANY NFFPRKPKWD KNQITYRIIG YTPDLDPETV DDAFARAFQV
151 WSDVTPLRFS  RIHDGEADIM INFGRWEHGD GYPFDGKDGL LAHAFAPGTG
201 VGGDSHFDDD  ELWTLGEGQV VRVKYGNADG EYCKFPFLFN GKEYNSCTDT
251 GRSDGFLWCS  TTYNFEKDGK YGFCPHEALF TMGGNAEGQP CKFPFRFQGT
301 SYDSCTTEGR TDGYRWCGTT EDYDRDKKYG FCPETAMSTV GGNSEGAPCV
351 FPFTFLGNKY  ESCTSAGRSD GKMWCATTAN YDDDRKWGFC PDQGYSLFLV
401 AAHEFGHAMG  LEHSQDPGAL MAPIYTYTKN FRLSQDDIKG IQELYGASPD
451 IDLGTGPTPT  LGPVTPEICK QDIVFDGIAQ IRGEIFFFKD RFIWRTVTPR
501 DKPMGPLLVA  TFWPELPEKI DAVYEAPQEE KAVFFAGNEY WIYSASTLER
551 GYPKPLTSLG  LPPDVQRVDA AFNWSKNKKT YIFAGDKFWR YNEVKKKMDP
601 GFPKLIADAW  NAIPDNLDAV VDLQGGGHSY FFKGAYYLKL ENQSLKSVKF
651 GSIKSDWLGC 
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Figure 4.6 A. MS PMF of rhMMP-3 annotated tryptic peptides, B. Mass 
data for peptides in daltons, C. Sequence coverage, ID peptides in red, 
active site green and arrow heads pointing start of various regions. 
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Theoretical Experimental Accuracy
Mono MH+ m/z  (Daltons)
T43/44 [387-395] 960.54 961.40 -0.87 1 KIDAAISDK None
T39 [357-364] 991.51 991.41 0.10 0 GNQFWAIR None
T51 [416-424] 1006.47 1006.37 0.10 0 NSMEPGFPK None
T47 [400-407] 1048.50 1049.40 -0.90 0 TYFFVEDK None
T31/32 [304-312] 1090.63 1090.51 0.11 1 GEILIFKDR None
T18/19 [102-110] 1101.62 1101.50 0.13 1 TFPG...PKWR None
T15 [ 79- 88] 1178.57 1178.34 0.23 0 LDSD...EVMR None
T17 [ 92-101] 1143.55 1143.42 0.13 0 CGVP...GHFR Carbamidomethylation (C)
T42 [375-386] 1294.73 1294.58 0.15 0 GIHT...PTVR None
T25 [140-151] 1463.75 1463.59 0.17 0 VWEE...TFSR None
T47/48 [400-410] 1553.74 1553.56 0.18 1 TYFF...KYWR None
T4-6 [ 37- 49] 1690.87 1691.61 -0.74 2 YLEN...KDVK None
T26 [152-166] 1713.85 1713.64 0.21 0 LYEG...FAVR None
T24/25 [137-151] 1775.97 1775.75 0.22 1 ALKV...TFSR None
T41/42 [370-386] 1839.00 1838.67 0.34 1 AGYP...PTVR None
T22/23 [118-136] 2074.07 2073.81 0.27 1 IVNY...AVEK None
T14/15 [ 70- 88] 2123.11 2122.84 0.27 1 FLGL...EVMR None
ModificationsTryptic Digests Range Partials Sequence
1 MKSLPILLLL CVAVCSAYPL DGAARGEDTS MNLVQKYLEN YYDLKKDVKQ
51 FVRRKDSGPV VKKIREMQKF LGLEVTGKLD SDTLEVMRKP RCGVPDVGHF
101 RTFPGIPKWR KTHLTYRIVN YTPDLPKDAV DSAVEKALKV WEEVTPLTFS
151 RLYEGEADIM ISFAVREHGD FYPFDGPGNV LAHAYAPGPG INGDAHFDDD
201 EQWTKDTTGT NLFLVAAHEI GHSLGLFHSA NTEALMYPLY HSLTDLTRFR
251 LSQDDINGIQ SLYGPPPDSP ETPLVPTEPV PPEPGTPANC DPALSFDAVS
301 TLRGEILIFK DRHFWRKSLR KLEPELHLIS SFWPSLPSGV DAAYEVTSKD
351 LVFIFKGNQF WAIRGNEVRA GYPRGIHTLG FPPTVRKIDA AISDKEKNKT
401 YFFVEDKYWR FDEKRNSMEP GFPKQIAEDF PGIDSKIDAV FEEFGFFYFF
451 TGSSQLEFDP NAKKVTHTLK SNSWLNC
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Figure 4.7 A. MS PMF of rhMMP-7 annotated tryptic peptides, B. Mass 
data for peptides in daltons, C. Sequence coverage, ID peptides in red, 
active site green and arrow heads pointing start of various regions. 
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T14 [119-127] 1065.57 1065.46 0.11 0 DLPHITVDR None
T9 [ 78- 86] 1113.65 1113.47 0.17 0 VIEIMQKPR None
T4 [ 42- 50] 1165.54 1165.36 0.19 0 FYLYDSETK None
T3/4 [ 41- 50] 1321.64 1321.42 0.22 1 RFYLYDSETK None
T8 [ 65- 77] 1452.77 1452.51 0.26 0 FFGL...LNSR None
T10 [ 87-103] 1879.90 1879.53 0.37 0 CGVP...NSPK None
T10/11 [ 87-107] 2382.16 2383.50 -1.34 1 CGVP...WTSK Carbamidomethylation (C)
ModificationsTryptic Digests  Range Partials Sequence
1 MRLTVLCAVC LLPGSLALPL PQEAGGMSEL QWEQAQDYLK RFYLYDSETK
51 NANSLEAKLK EMQKFFGLPI TGMLNSRVIE IMQKPRCGVP DVAEYSLFPN
101 SPKWTSKVVT YRIVSYTRDL PHITVDRLVS KALNMWGKEI PLHFRKVVWG
151 TADIMIGFAR GAHGDSYPFD GPGNTLAHAF APGTGLGGDA HFDEDERWTD
201 GSSLGINFLY AATHELGHSL GMGHSSDPNA VMYPTYGNGD PQNFKLSQDD
251 IKGIQKLYGK RSNSRKK
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Figure 4.8 A. MS PMF of rhMMP-8 annotated tryptic peptides, B. Mass 
data for peptides in daltons, C. Sequence coverage, ID peptides in red, 
active site green and arrow heads pointing start of various regions. 
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T25/26 [300-305] 942.46 942.36 0.10 1 DRYFWR None
T42/T43 [458-465] 1047.53 1047.39 0.14 1 GNKWLNCR None
T36 [403-411] 1096.51 1096.38 0.13 0 QFMEPGYPK None
T24/25 [293-301] 1124.61 1124.47 0.14 1 GEILFFKDR None
T15/16 [108-116] 1238.63 1238.38 0.25 1 WERT...LTYR None
T41-43 [455-465] 1316.70 1316.42 0.28 2 VARG...LNCR None
T34 [387-397] 1522.71 1522.69 0.03 0 TYFF...QFWR None
T18 [119-131] 1535.73 1535.53 0.20 0 NYT...EVER None
T21 [151-165] 1724.86 1724.63 0.23 0 ISQG...FYQR None
T33/34 [385-397] 1737.84 1737.61 0.23 1 SKTY...QFWR None
T17/18 [117-131] 1804.92 1804.68 0.24 1 IRNY...EVER None
T38 [424-441] 2147.05 2146.76 0.29 0 VDAV...SGPR None
T36/37 [403-423] 2270.116 2270.591 -0.47 1 QFME...IESK None
T37/38 [412-441] 3320.65 3320.20 0.45 1 SISG...SGPR None
ModificationsTryptic Digests  Range Partials Sequence
1 MFSLKTLPFL LLLHVQISKA FPVSSKEKNT KTVQDYLEKF YQLPSNQYQS
51 TRKNGTNVIV EKLKEMQRFF GLNVTGKPNE ETLDMMKKPR CGVPDSGGFM
101 LTPGNPKWER TNLTYRIRNY TPQLSEAEVE RAIKDAFELW SVASPLIFTR
151 ISQGEADINI AFYQRDHGDN SPFDGPNGIL AHAFQPGQGI GGDAHFDAEE
201 TWTNTSANYN LFLVAAHEFG HSLGLAHSSD PGALMYPNYA FRETSNYSLP
251 QDDIDGIQAI YGLSSNPIQP TGPSTPKPCD PSLTFDAITT LRGEILFFKD
301 RYFWRRHPQL QRVEMNFISL FWPSLPTGIQ AAYEDFDRDL IFLFKGNQYW
351 ALSGYDILQG YPKDISNYGF PSSVQAIDAA VFYRSKTYFF VNDQFWRYDN
401 QRQFMEPGYP KSISGAFPGI ESKVDAVFQQ EHFFHVFSGP RYYAFDLIAQ
451 RVTRVARGNK WLNCRYG
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Figure 4.9 A. MS PMF of rhMMP-9 annotated tryptic peptides, B. Mass 
data of peptides. 
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T56 [624-630] 823.45 823.33 0.12 0 MLLFSGR None
T40/41 [536-541] 824.41 824.29 0.11 1 DGKYWR None
T44/45 [560-566] 867.52 867.30 0.22 1 WPALPRK None
T49 [579-585] 873.46 873.33 0.13 0 LFFFSGR None
T16 [135-143] 977.51 977.36 0.14 0 AVIDDAFAR None
T48/49 [578-585] 1001.56 1001.41 0.15 1 KLFFFSGR None
T23 [240-249] 1060.44 1061.19 -0.75 0 SYSA...TDGR None
T14 [107-115] 1084.53 1085.41 -0.88 0 FQTFEGDLK None
T32 [357-366] 1132.46 1133.54 -1.09 0 EYST...SEGR None
T5 [ 43- 51] 1184.60 1184.40 0.20 0 QLAEEYLYR None
T6/T7 [ 52- 61] 1245.60 1246.30 -0.70 1 YGYT...AEMR None
T59/60 [635-645] 1305.66 1305.53 0.13 1 FDVK...VDPR None
T54-56 [619-630] 1308.72 1309.61 -0.89 2 SGRG...FSGR None
T46/47 [567-577] 1322.70 1322.43 0.26 1 LDSV...RLSK None
T47-49 [575-585] 1329.77 1328.49 1.28 2 LSKK...FSGR None
T3 [ 25- 36] 1345.75 1345.51 0.23 0 QSTL...GDLR None
T53 [604-618] 1440.82 1440.58 0.23 0 LGLG...GALR None
T50 [586-599] 1532.82 1532.55 0.27 0 QVWV...LGPR None
T17 [144-158] 1680.91 1680.61 0.30 0 AFAL...TFTR None
T10 [ 77- 92] 1701.89 1701.60 0.29 0 QLSL...ATLK None
T37/38 [425-440] 1794.91 1794.59 0.33 1 FTEG...NGIR None
T52/53 [601-618] 1797.02 1798.62 -1.60 1 LDKL...GALR None
T62 [653-668] 1921.93 1921.57 0.35 0 MFPG...FQYR None
T51-53 [600-618] 1953.12 1952.77 0.36 2 RLDK...GALR None
T22 [222-239] 2012.92 2012.54 0.38 0 FGNA...FEGR Carbamidomethylation (C)
T64-66 [671-685] 1983.93 1983.47 0.46 2 AYFC...VSSR None
T43/44 [547-565] 2106.16 2105.78 0.38 1 GSRP...ALPR None
T41-43 [539-559] 2467.26 2464.16 3.11 2 YWRF...IADK None
T49-51 [579-600] 2543.37 2540.58 2.79 2 LFFF...GPRR None
T61/62 [646-668] 2666.27 2665.76 0.51 1 SASE...FQYR None
T61-63 [646-670] 2923.40 2920.81 2.59 2 SASE...YREK None
T20 [185-214] 3175.51 3174.93 0.58 0 DGLL...SLGK None
T31/32 [333-366] 3675.67 3674.97 0.70 1 ADST...SEGR Carbamidomethylation (C)
ModificationsTryptic Digests  Range Partials Sequence
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Figure 4.10 MMP-9 Sequence coverage, ID peptides in red, active site 
green and arrow heads pointing start of various regions. 
1 MSLWQPLVLV LLVLGCCFAA PRQRQSTLVL FPGDLRTNLT DRQLAEEYLY
51 RYGYTRVAEM RGESKSLGPA LLLLQKQLSL PETGELDSAT LKAMRTPRCG
101 VPDLGRFQTF EGDLKWHHHN ITYWIQNYSE DLPRAVIDDA FARAFALWSA
151 VTPLTFTRVY SRDADIVIQF GVAEHGDGYP FDGKDGLLAH AFPPGPGIQG
201 DAHFDDDELW SLGKGVVVPT RFGNADGAAC HFPFIFEGRS YSACTTDGRS
251 DGLPWCSTTA NYDTDDRFGF CPSERLYTQD GNADGKPCQF PFIFQGQSYS
301 ACTTDGRSDG YRWCATTANY DRDKLFGFCP TRADSTVMGG NSAGELCVFP
351 FTFLGKEYST CTSEGRGDGR LWCATTSNFD SDKKWGFCPD QGYSLFLVAA
401 HEFGHALGLD HSSVPEALMY PMYRFTEGPP LHKDDVNGIR HLYGPRPEPE
451 PRPPTTTTPQ PTAPPTVCPT GPPTVHPSER PTAGPTGPPS AGPTGPPTAG
501 PSTATTVPLS PVDDACNVNI FDAIAEIGNQ LYLFKDGKYW RFSEGRGSRP
551 QGPFLIADKW PALPRKLDSV FEERLSKKLF FFSGRQVWVY TGASVLGPRR
601 LDKLGLGADV AQVTGALRSG RGKMLLFSGR RLWRFDVKAQ MVDPRSASEV
651 DRMFPGVPLD THDVFQYREK AYFCQDRFYW RVSSRSELNQ VDQVGYVTYD
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Figure 4.11 A. MS PMF of rhMMP-10 annotated tryptic peptides, B. Mass 
data for peptides in Daltons. 
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Mono MH+ m/z (Daltons)
T6-8 [ 50- 54] 734.44 733.15 1.29 2 QFRRK None
T30/31 [310-315] 942.46 942.32 0.14 1 DRYFWR None
T35 [356-363] 992.50 992.34 0.16 0 GNEFWAIR None
T42/T43 [398-406] 1090.56 1090.36 0.20 1 KTYFFAADK None
T29/30 [303-311] 1174.59 1174.41 0.18 1 GEYLFFKDR None
T41-43 [397-406] 1218.65 1217.45 1.20 2 KKTYFFAADK None
T16-18 [108-116] 1260.70 1261.49 -0.79 2 WRKTHLTYR None
T37 [374-385] 1308.74 1308.51 0.23 0 GIHT...PTIR None
T37/38 [374-386] 1436.84 1437.55 -0.72 1 GIHT...TIRK None
T43/44 [399-409] 1467.71 1467.45 0.26 1 TYFF...KYWR None
T42/T44 [398-409] 1595.80 1595.51 0.30 2 KTYF...KYWR None
T45 [410-423] 1671.71 1671.41 0.29 0 FDEN...GFPR None
T34/35 [349-363] 1842.95 1842.62 0.33 1 DTVF...WAIR None
T35/36 [356-373] 2064.01 2063.64 0.37 1 GNEF...GYPR None
T12/13 [ 69- 87] 2137.12 2136.74 0.38 1 FLGL...EVMR None
T14/15 [ 88-107] 2143.06 2142.68 0.38 1 KPRC...GMPK None
T44/45 [407-423] 2176.95 2176.56 0.39 1 YWRF...GFPR None
T20-22 [127-150] 2704.42 2704.70 -0.28 2 DAVD...TFSR None
T34-36 [349-373] 2914.46 2913.94 0.52 2 DTVF...GYPR None
T47 [436-462] 3093.44 3092.88 0.56 0 VDAV...PNAR None
T43-45 [399-423] 3120.39 3119.84 0.55 2 TYFF...GFPR None
T33 [317-348] 3759.79 3759.14 0.65 0 SHWN...VNSR None
ModificationsTryptic Digests  Range Partials Sequence
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Figure 4.12 Sequence coverage for MMP-10, ID peptides in red, active 
site green and arrow heads pointing start of various regions. 
1 MMHLAFLVLL CLPVCSAYPL SGAAKEEDSN KDLAQQYLEK YYNLEKDVKQ
51 FRRKDSNLIV KKIQGMQKFL GLEVTGKLDT DTLEVMRKPR CGVPDVGHFS
101 SFPGMPKWRK THLTYRIVNY TPDLPRDAVD SAIEKALKVW EEVTPLTFSR
151 LYEGEADIMI SFAVKEHGDF YSFDGPGHSL AHAYPPGPGL YGDIHFDDDE
201 KWTEDASGTN LFLVAAHELG HSLGLFHSAN TEALMYPLYN SFTELAQFRL
251 SQDDVNGIQS LYGPPPASTE EPLVPTKSVP SGSEMPAKCD PALSFDAIST
301 LRGEYLFFKD RYFWRRSHWN PEPEFHLISA FWPSLPSYLD AAYEVNSRDT
351 VFIFKGNEFW AIRGNEVQAG YPRGIHTLGF PPTIRKIDAA VSDKEKKKTY
401 FFAADKYWRF DENSQSMEQG FPRLIADDFP GVEPKVDAVL QAFGFFYFFS
451 GSSQFEFDPN ARMVTHILKS NSWLHC
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Figure 4.13 A. MS PMF of rhMMP-13 annotated tryptic peptides, B. Mass 
data for peptides in daltons, C. Sequence coverage, ID peptides in red, 
active site green and arrow heads pointing start of various regions. 
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T12/13 [462-471] 1133.55 1133.56 -0.01 0 VMPA...ILWC None
T12-14 [325-333] 1145.57 1145.42 0.16 0 SFWPELPNR None
T16 [ 58- 69] 1364.66 1363.51 1.14 1 ENAA...ERLR None
T17/18 [ 45- 57] 1476.79 1476.57 0.22 0 SYYH...GILK None
T19 [ 96-109] 1608.76 1608.49 0.27 0 CGVP...VFPR Carbamidomethylation (C)
T20 [235-249] 1673.82 1672.41 1.42 0 DPGA...YTGK None
T20-22 [ 68- 82] 1741.89 1741.62 0.27 1 LREM...VTGK None
T25-27 [334-350] 2044.03 2043.69 0.34 0 IDAA...FIFR None
T27 [419-437] 2137.07 2136.72 0.35 1 LIEE...VYEK None
T31-33 [ 45- 67] 2553.24 2552.81 0.43 1 SYYH...MTER None
T32/33 [382-404] 2576.33 2575.89 0.44 1 ISAA...QVWR None
T35-37 [ 68- 92] 2886.44 2885.94 0.49 2 LREM...DVMK None
T37-39 [ 42- 67] 2985.49 2986.82 -1.33 2 YLRS...MTER None
ModificationsTryptic Digests Range Partials Sequence
1 MHPGVLAAFL FLSWTHCRAL PLPSGGDEDD LSEEDLQFAE RYLRSYYHPT
51 NLAGILKENA ASSMTERLRE MQSFFGLEVT GKLDDNTLDV MKKPRCGVPD
101 VGEYNVFPRT LKWSKMNLTY RIVNYTPDMT HSEVEKAFKK AFKVWSDVTP
151 LNFTRLHDGI ADIMISFGIK EHGDFYPFDG PSGLLAHAFP PGPNYGGDAH
201 FDDDETWTSS SKGYNLFLVA AHEFGHSLGL DHSKDPGALM FPIYTYTGKS
251 HFMLPDDDVQ GIQSLYGPGD EDPNPKHPKT PDKCDPSLSL DAITSLRGET
301 MIFKDRFFWR LHPQQVDAEL FLTKSFWPEL PNRIDAAYEH PSHDLIFIFR
351 GRKFWALNGY DILEGYPKKI SELGLPKEVK KISAAVHFED TGKTLLFSGN
401 QVWRYDDTNH IMDKDYPRLI EEDFPGIGDK VDAVYEKNGY IYFFNGPIQF
451 EYSIWSNRIV RVMPANSILW C
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Figure 4.14 A. MS PMF of rhMMP-14 annotated tryptic peptides, B. Mass 
data for peptides in daltons, C. Sequence coverage, ID peptides in red, 
active site green and arrow heads pointing start of various regions. 
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T61-63 [564-570] 879.50 878.91 0.59 2 RHGTPRR None
T56/57 [486-492] 891.51 890.87 0.64 1 FNNQKLK None
T22 [161-168] 1010.53 1010.37 0.16 0 EVPYAYIR None
T46/47 [427-434] 1032.53 1032.35 0.18 1 TYFFRGNK None
T20 [150-158] 1058.56 1058.39 0.17 0 VWESATPLR None
T10/11 [ 99-108] 1104.62 1103.85 0.76 1 FGAE...ANVR None
T17 [135-145] 1271.63 1271.42 0.21 0 VGEY...EAIR None
T38-40 [376-386] 1287.67 1287.50 0.17 2 DGKF...KGDK None
T21/22 [159-168] 1313.70 1313.49 0.21 1 FREV...AYIR None
T17/18 [135-146] 1399.72 1399.49 0.23 1 VGEY...AIRK None
T4 [ 57- 70] 1402.74 1402.51 0.23 0 SPQS...AMQK None
T36/37 [363-375] 1419.76 1419.55 0.21 1 GLPA...YERK None
T19/20 [147-158] 1432.77 1432.54 0.23 1 AFRV...TPLR None
T42-44 [402-414] 1463.83 1463.57 0.26 2 HIKE...PTDK None
ModificationsTryptic Digests Range Partials Sequence
1 MSPAPRPSRC LLLPLLTLGT ALASLGSAQS SSFSPEAWLQ QYGYLPPGDL
51 RTHTQRSPQS LSAAIAAMQK FYGLQVTGKA DADTMKAMRR PRCGVPDKFG
101 AEIKANVRRK RYAIQGLKWQ HNEITFCIQN YTPKVGEYAT YEAIRKAFRV
151 WESATPLRFR EVPYAYIREG HEKQADIMIF FAEGFHGDST PFDGEGGFLA
201 HAYFPGPNIG GDTHFDSAEP WTVRNEDLNG NDIFLVAVHE LGHALGLEHS
251 SDPSAIMAPF YQWMDTENFV LPDDDRRGIQ QLYGGESGFP TKMPPQPRTT
301 SRPSVPDKPK NPTYGPNICD GNFDTVAMLR GEMFVFKERW FWRVRNNQVM
351 DGYPMPIGQF WRGLPASINT AYERKDGKFV FFKGDKHWVF DEASLEPGYP
401 KHIKELGRGL PTDKIDAALF WMPNGKTYFF RGNKYYRFNE ELRAVDSEYP
451 KNIKVWEGIP ESPRGSFMGS DEVFTYFYKG NKYWKFNNQK LKVEPGYPKS
501 ALRDWMGCPS GGRPDEGTEE ETEVIIIEVD EEGGGAVSAA AVVLPVLLLL
551 LVLAVGLAVF FFRRHGTPRR LLYCQRSLLD KV
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Figure 4.15 Peptide fragments of rhMMP-1, rhMMP-2, rhMMP-3, rhMMP-
7, rhMMP-8, rhMMP-9, rhMMP-13 and rhMMP-14. 
Red arrows pointing parent peptide ions. 
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4.3.5 Elastase and Lysine-N for complete Digestion of rhMMPs 
To indicate a site of attachment of Olive H-7G in next set of experiments, it 
was important to achieve complete digestion of protein including active site 
residue. The digestion of rhMMP protein by trypsin might have been the 
reason why active site residue containing peptides could not be created as 
discussed in section 4.3.3. In order to achieve sufficient digestion of the 
protein, elastase and lysine-N were used. But efficiency of trypsin was found 
better than these two. Hence it was decided to keep trypsin as an enzyme for 
digestion. 
4.3.6 Interaction between rhMMP-2/rhMMP-14 and Olive H-7G 
The presence of detergent Brij-35 in rhMMP-2 did not allow noticeable shifts 
in specific mass peak of pure Olive H-7G (Mol. Wt. 869.1). The mass spectra 
of Olive H-7G solution (A) and Olive H-7G-MMP-2 complex (B) after the 
reaction is shown in Figure 4.16. The sample was analyzed after removal of 
detergent using C18 isolute columns and analyzed by MALDI mass 
spectrometry (Figure 4.16C) but it did not show enzyme signature peptides 
with an added mass of Olive H-7G indicating a site of attachment. It can be 
speculated that the significant signature peptides might have been lost during 
desalting process. Nevertheless the reaction of rhMMP-2 did change the 
specific profile of Olive H-7G (Figure 4.16A and C). Many m/z were present 
both in rhMMP-14 and Olive H-7G-MMP-14 complex, however, these were 
not matched with the theoretically digested peptide peak list created by using 
in-silico method. The 1/10th dilutions of rhMMP-14 and Olive H-7G-MMP-14 
complex were prepared in order to get a better resolution with diluted sample. 
A detailed comparison of m/z obtained from the trypsinization of rhMM-14, 
rhMMP-14-Olive H-7G complex showed only one peptide 1433.478 which is 
closest to the theoretically determined MMP-14 specific peak 1432.770 
(amino acid range 147-158 with a sequence of AFRVWESATPLUR). 
However, when MS/MS of the the daughter ion with m/z 1433.478 was 
performed and the daughter ion data was sent to Biotools, it did not generate 
MMP-14 identification. The Olive H-7G did not alter the m/z in control 
myoglobin + trypsin. 
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Figure 4.16 Mass Spectra of Olive H-7G and H-7G-MMP-2 complex. 
4.3.7 Interaction between Mixture of 11 rhMMPs and Olive H-7G 
The hypothesis that difference in the masses of peptides generated from 
trypsinization of MMP alone and attached to Olive H-7G will reveal site of 
attachment of later could not be proved because of complexity offered by 
detergent. Results for the reaction between Olive H-7G and MMP mixture 
obtained with (A) and without zip tipping (B) are shown in Figure 4.17. 
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Figure 4.17 Mass spectra of Olive H-7G-MMP complex.
4.4 Discussion 
The initial aim was to assess the integrity (intactness/ stability) of rhMMPs 
and optimize trypsin digestion assay as a part of sample preparation for 
mass spectrometric analysis before use in Olive H-7G chromatography. 
In the current study MALDI mass spectrometry was used to establish purity 
and integrity of rhMMPs by detecting m/z of ionized proteins. An attempt was 
made to determine accurate molecular mass of each MMP using MALDI-MS. 
Conventionally, molecular weight (MW) of pure proteins is determined by 
SDS-PAGE. The m/z of the proteins cannot be measured in these gel based 
characterization. One of the biggest challenges during the characterization of 
rhMMPs was the presence of detergent Brij-35 added to the commercial 
enzyme solution as a surfactant to impart stability and increase solubility. 
Brij-35 (Mol. Wt. 1225g, aggregation No. 40) is a non-ionic polyoxyethylene 
surfactant, which produces mass signals with a difference of 44daltons over 
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a mass range, masking the peaks related to the peptides. Attempts to 
remove the detergent using C4 zip tips were only partially successful (MMP-
3, MMP-7, MMP-10 and MMP-14) and could not be removed in the case of 
MMP-2, MMP-8, MMP-9, MMP-13 and MMP-16. It was anticipated that it 
might be the detergent (Brij-35) which is masking the specific peaks. 
Characterization of MMPs by identifying their signature peptides (PMF) after 
trypsin digestion was attempted in this study contrary to conventional 
methods of characterization of proteins such as western blotting, zymography 
etc. Trypsin is a pancreatic serine endoprotease that cleaves proteins or 
peptides on the carboxyl side of arginine (R) or lysine (K) residues. The rate 
of hydrolysis is slower when an acidic residue is located on either side of the 
cleavage site and cleavage may not occur if a proline residue is on the 
carboxyl side (Stone et al., 1998). To optimize the assay a highly purified and 
chemically stabilized trypsin offering excellent performance for use in in-
solution digestions was utilized. The peptide solutions were lyophilized to 
increase their concentration and improve digestion efficiency and denatured 
using 8M Urea followed by the reduction and alkylation of the cysteine 
present (see Figure 4.4-Figure 4.8C, Figure 4.10, Figure 4.12, Figure 4.13 
and Figure 4.14C for sequences or amino acid composition). Combined urea 
denaturation and alkylation results in unfolding of the secondary and tertiary 
structure for optimal digestion by trypsin. After incubation with the trypsin, 
proteolytic fragments were analyzed by mass spectrometry in positive ion 
mode. 
Mass spectrometry data can be used in three different ways for protein 
identification, PMF, sequence query and MS/MS ion search. PMF was the 
first method to be developed, and is in many ways the simplest approach. A 
manual comparison of experimental and theoretical peptide products was 
made to calculate the accuracy of acquired data and locate the sequence of 
amino acids in detected peptides (Figure 4.4-Figure 4.14). The selected 
derived m/z of rhMMP peptides from the list was submitted to a Mascot 
search engine in the present study. In this way MALDI mass spectra of 
rhMMPs peptides resulted in the identification of corresponding parent MMP. 
A Mascot search server was used because it provides option to select global 
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or variable modifications in protein and taxonomy filter on search form (Homo 
sapiens was selected) to limit the number of matches in results. Selecting 
variable modifications such as oxidation of methionine increase the search 
time because each site is tested with and without the modification. For 
example, if there are two methionines in a peptide, and MetOx is selected, 
then Mascot will try and get a match with 0 oxidised, 1 oxidised, and 2 
oxidised peptides. This also increases the chance of a random match and an 
unnecessary variable modification decreases the score. While analyzing data 
from MALDI-MS it is considered that the experimental protein may be shorter 
than the protein mass entry in the database. The reason why better PMF for 
some rhMMPs were not generated could be down to many reasons such as 
electronic noise, ion-to-ion variation in detector response, collection efficiency 
of peptide ions and m/z dependent efficiency of detector. A large fraction of 
spectra acquired do not identify any peptide and remain un-used. 
The MS/MS data (fragment ion masses) searching can be done either from a 
single peptide ion (parent ion) or from LC-MS/MS. In this study manual 
MS/MS from single peptide ions was done. A fragment mass tolerance of 
0.7Da was used. The peptide mass fingerprint data is sent to Mascot to 
detect all the ‘real’ peaks from the spectrum. It is very important to send 
optimum number of peaks (30-100) with right mass range with no 
contaminant peaks. For each peak that fails to match, the Mascot score will 
be reduced, so it is important not to submit profile data or lists full of noise 
peaks. Since peak intensity is relative so it is not sufficient to just pick the 
most intense peaks. Weak as well as strong mass signals may also 
correspond to peptides of the protein. Some peaks may be produced by 
trypsin digesting itself. Trypsin has the ability to digest itself to produce 
autolytic peptide peaks. These peaks may have identical masses to the 
peptides from protein of interest. Thus removing these peaks along with 
noise peaks may compromise the results. Although error tolerant matches 
are still an open issue and one spectrum is more likely to match more than 
one entry, the PFF generated for rhMMPs generated identifications with good 
Mascot scores. As it was known already that the mass spectra were from 
rhMMPs, nevertheless data was searched against database to help test 
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possible atypical conditions, e.g. non-trypsin cleavages, more partials than 
expected, unexpected modifications.  Such interpretation is best supported 
by MS/MS data. 
While interpreting the results, it was kept in mind that PMF and PFF both 
have certain limitations. PMF is relatively simple but can be complicated 
because of PTMs of proteins. Although generating a list of PMF of a protein 
is relatively less time-consuming than MS/MS, it still needs large amounts of 
protein samples to start with because data is generated after manual analysis 
and many laser shots are fired per spot. Mass spectrometry is relatively 
sensitive compared to other techniques and MS/MS data is more reliable 
since theoretically one peptide can generate a confident protein hit. PFF 
makes the data more authentic and specific as in case of PMF a sequence of 
amino acids in a peptide in reverse order is identified the same e.g; DEFG = 
GFED. However, MS/MS data can be low-throughput and de novo
sequencing is difficult to automate. 
Although ionization of proteins can be achieved both by ESI and MALDI, we 
chose MALDI for this study. The only common thing between the two is that 
both can ionize intact proteins without fragmentation. The chemistry and 
workflow of MALDI has been explained in introduction. In ESI a liquid sample 
flowing, often from HPLC system, into the ESI system is aerosolized and the 
droplets are ionized as they exit a charged nozzle. As the liquid in these 
drops evaporates, the droplets shrink, until the ionic charge repulsion is 
sufficiently intense to overcome the surface tension holding the droplet 
together, producing gas-phase ions. The advantage of this arrangement is 
that sample is injected at the top of the column and analyzed as it emerges. 
However, the disadvantage during ESI-based analysis is that a very short 
time window is available to achieve a significant chromatographic peak of 
one component. The problem magnifies if column flow rate of HPLC system 
increases. In addition, in ESI a sample cannot be reanalyzed. In contrast in 
MALDI an off-line option is available in which samples are spotted on a target 
plate prior to ionization and can be reanalyzed. Other differences between 
MALDI and ESI involve the charges they impart on ions. 
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MALDI mostly produces ions with charge +1 along with few +2 and +3 ions. 
On the other hand ESI produces a range of different charge states for each 
molecule rendering the mass spectra to be considerably complex. This brings 
to one of the advantages of ESI that by producing multiply charged ions, ESI 
makes larger proteins accessible to analysis than does MALDI. Hence, in ESI 
ions will carry a range of charges corresponding to a range of m/z. From 
larger molecules, smaller m/z available helps getting better resolving power. 
In general, MALDI is faster than ESI and enables higher throughput. But ESI 
is more sensitive, meaning it can detect lower amounts of a given substance. 
Though each has its pros and cons, both are equally important and in use 
because some proteins will only ionize with one technique or the other. Since 
recombinant human pro-MMPs have theoretical molecular weights from 50 to 
92kDa (active MMPs have lower molecular weights) so MALDI was selected 
for their characterization. MALDI is ideal for PMF study because individual 
MMPs can be spotted on target plate and analyzed repeatedly for longer 
time. Moreover, peptide molecules are very small and singly charged 
molecules in MALDI will generate smaller m/z giving better resolution. Also 
presence of multiple charges in ESI will create small peaks which might be 
masked by larger peaks from any possible contaminant or detergent. A 
salient feature of this study is that it was aimed to use very small quantities of 
MMPs (5pmoles) to emulate amounts in biological samples. 
The second goal of this chapter was to identify a shift in mass of Olive H-7G 
because of binding of MMP. It has been shown in many kinetic studies that 
triazinyl dyes interact with an enzyme in a non-covalent way involving the 
binding site for a natural biological ligand of the enzyme such as NADH, 
NADPH, NAD+, NADP+, GTP, IMP, ATP, HMG-CoA, folate, etc. (Denizli and 
Piskin, 2001). The reason why any peptide peaks could not be seen in Olive 
H-7G-MMP complex could be presence of Brij35 interfered with dye binding. 
Another possibility is that the complex did not get ionized so could not be 
detected in MALDI mass spectrometer. It was hoped that extensive 
sequence coverage from PMFs would identify proteolytic peptides specific for 
the ‘pro’ and ‘active’ regions of each MMP that might be suitable for 
discrimination of the latent and active forms of protease captured by dye 
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ligand chromatography. As there were large gaps in the sequence coverage 
which meant that ‘loss’ of signals due to presence of Olive H7-G during 
trypsin digestion would not necessarily be detected or subsequent clean up 
resulting in sample losses and poor MS sensitivity.
CHAPTER 5 
DYE LIGAND CHROMATOGRAPHY OF 
rhMMPs 
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5 Dye Ligand Chromatography of rhMMPs 
5.1 Introduction 
Affinity chromatography is a powerful tool for separation and enrichment of 
proteins. This method is based on the specific interaction between an 
immobilized ligand and the target protein to be separated. This study entails 
the use of a triazine dye Olive H-7G to purify MMPs with their subsequent 
identification by MALDI mass spectrometry. Pilot experiments were 
performed to improve chances of affinity chromatography outcome for 
enrichment of rhMMPs followed by identification with MALDI-MS. Mixtures 
comprising rhMMPs from various classes (basic, gelatinases, membrane 
bound and minimal domain) were used hence MALDI-MS/MS was combined 
with reverse phase nHPLC as a peptide separation strategy. This was 
attempted to provide qualitative proof that system has a potential to succeed 
on a full scale basis when cell line culture supernatants or biological samples 
are used. 
5.1.1 Aims 
The aims of experiments explained in this chapter were: 
• To apply mixtures of rhMMPs to Olive H-7G immobilized on 
chromatography beads to determine potential of Olive H-7G for 
enriching MMPs. It was anticipated that ligand supporting matrix 
(sepharose or magnetic beads) would not offer any evidence of MMP 
binding. LC-MALDI-MS/MS was employed to characterize MMPs if 
present in a sample. 
• Optimization of proteomics methods (LC-MS/MS) using smaller 
amounts of MMPs to address and overcome problems associated with 
the availability of small volumes of tumour biopsies in clinical set up. 
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• To recover rhMMPs off the chromatography beads (H-7G-Sepharose) 
once assured that the ligand binds the enzyme. This was achieved by 
employing an ELISA based assay which measured the activity of 
MMP-2 referred to as starting material (SM) before it was applied to H-
7G-Sepharose beads (B), in flow-throughs (FT) collected after 
washing B and in eluates (E) combined with what was left on the 
beads at the end. This also proved the reversible nature of binding 
between protein and the ligand dye under discussion. 
5.2 Materials and Methods 
5.2.1 Synthesis of H-7G-Sepharose Beads 
H-7G-Sepharose chromatography beads were prepared as described in 
Materials and Methods section 2.2. 
5.2.2 Synthesis of Olive H-7G-Magnetic Beads (H-7G-MB) 
Silica-coated iron oxide magnetic beads (Bioclone) with a diameter of 1μm 
and surface area of ~100m2/g were used. These beads are grafted with 
hydroxyl group on the surface and the functional group density is 
~200μmole/g of beads. Olive H-7G was immobilized on magnetic beads to 
synthesize H-7G-MB alongside control magnetic beads MB. To 10mg of 
magnetic beads 1mL of 34.6mM Olive H-7G solution (30mg/1mL of 4% 
NaOH) was added. Magnetic beads were then incubated at 80°C for 4 hour 
while constant stirring using a Fisher hotplate to create required temperature. 
The light brown colour of magnetic beads did not change suggesting the 
Olive H7-G had not bound to the beads. In order to ensure binding, the 
beads were transferred to glass flask and 20mL of 4% NaOH were added. 
The reactants were left on the shaker at 200rpm at 50°C for 45hours to allow 
binding of ligand on chromatography beads. The colour of the beads 
changed to greenish brown giving an indication that the Olive H-7G dye had 
bound to magnetic beads. H-7G-MB were then washed with 20mL water and 
centrifuged at 1200rpm for 1min at 18°C. The wash step was repeated twice 
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with 5mL distilled water. This was followed by another wash with 1mL 
distilled water. Finally 5 washes (1mL each) with methanol until non-bound 
dye was removed. The last wash with 1mL distilled water was given to 
remove any excess methanol. Beads were stored in 0.02% sodium azide 
solution (1:10 volume of suspension). Control beads MB (20mg) were 
prepared under identical conditions by adding 1mL of 4% NaOH in HPLC 
grade water, but absence of dye. 
5.2.3 H-7G-Sepharose Capture of rhMMP Mixture 
First set of experiments were performed with a mixture of 4 different rhMMPs 
namely MMP-1, MMP-2, MMP-3 and MMP-10. Once encouraging results 
indicating binding between H-7G-Sepharose were found, the number of 
MMPs was increased in mixture in the subsequent set of repeat experiments. 
Since identical temperature conditions, pH of buffers and incubations 
durations were tried to maintain in the repeat experiments, these will be 
explained simultaneously. Sepharose beads were used as a negative control 
and treated the same as probed beads (H-7G-Sepharose). 
5.2.3.1 H-7G-Sepharose Bead Equilibration 
Both beads suspension, H-7G-Sepharose and sepharose, were washed with 
1mL of TNC buffer {50mM Tris-HCl (pH 7.5); 0.15M NaCl; 5mM CaCl2 and 
0.02% (w/v) sodium azide}. The washing was repeated thrice followed by two 
large washes with 10mL each to remove all residual sodium azide in which 
the beads are stored. Once beads were prepared these were equilibrated in 
TNC buffer in 2:1 ratio. 
5.2.3.2 rhMMP Mixture Preparation 
Mixtures comprising of 4 different MMPs (rhMMP-1, rhMMP-2, rhMMP-3 and 
rhMMP-10) and 9 different MMPs (rhMMP-1, rhMMP-2, rhMMP-3, rhMMP-7, 
rhMMP-8, rhMMP-9, rhMMP-10, rhMMP-13 and rhMMP-14) were prepared 
separately. In view of limit of detection of MALDI-mass spec, at least 
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5pmoles of each of MMPs were added. Each MMP is at less than 1μM final 
concentration in mixture as shown in Table 5.1. 
Table 5.1 Final concentration of rhMMPs in mixtures. 
5.2.3.3 Reaction 
The mixture of rhMMPs (SM) containing 1μg protein (4 rhMMPs) or 2.5μg 
protein (9 rhMMPs) was added to 125μL and 250μL H-7G-Sepharose, 
respectively (Figure 5.1). The negative control sepharose beads were mixed 
in same amounts. A part of SM was kept aside for further analyses. After 
rotating the mixture for 1hr at 4°C, contents were centrifuged at 1200g and 
flow-throughs (H-7G-Sepharose FT and sepharose FT) were collected and 
kept on ice. The beads (H-7G-Sepharose and sepharose) were collected and 
washed with 1mL TNC buffer (5-times) with each spin at 1200g at 4°C. Since 
this experiment was performed to validate Olive H-7G as a potential ligand 
for MMPs, elution was skipped and MMPs were kept bound to the beads. 
MMP
MW 
(R&D)
(kDa)
Final Conc. in 
4 MMP Mixture
(μM)
Final Conc. in 
9 MMP Mixture
(μM)
MMP-1 53 0.35 0.35
MMP-2 72 0.35 0.35
MMP-3 52 0.35 0.35
MMP-7 28 - 0.7
MMP-8 51 - 0.35
MMP-9 77 - 0.28
MMP-10 52 0.35 0.35
MMP-13 52 - 0.35
MMP-14 31 - 0.63
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(A) 
(B) 
Figure 5.1 Reaction between H-7G-Sepharose beads and mixture of (A) 
4 rhMMPs, (B) 9 rhMMPs. 
5.2.4 H-7G-MB Capture of rhMMP Mixture 
Magnetic beads were used as an alternate matrix to sepharose to improve 
the specificity of Olive H-7G once immobilized on their surface. A mixture of 
11 rhMMPs was applied to probed and control magnetic beads synthesized 
as explained in section 5.2.2. The experimental design for the experiment is 
shown in Figure 5.2. Control magnetic beads (will be referred to as MB) were 
treated with TNC buffer to find their signature peaks when analyzed by 
MALDI mass spectrometry. Another lot of magnetic beads was treated with 
mixture of rhMMPs (will be referred to as MB-MMPs) to observe if these offer 
Sepharose
(125μL beads)
4 MMP Mixture
(1μg protein) 
H-7G-Sepharose
(125μLbeads)
4 MMP Mixture
(1μg protein)
+
1hr at 4C
1hr at 4C
+ Collect FT
Collect FT
k
k
Sepharose
(250μL beads)
9 MMP Mixture
(2.5μg protein) 
H-7G-Sepharose
(250μLbeads)
9 MMP Mixture
(2.5μg protein)
+
1hr at 4C
1hr at 4C
+ Collect FT
Collect FT
k
k
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any affinity to the proteins. The magnetic beads probed with Olive H-7G were 
mixed with rhMMP mixture (will be referred to as H-7G-MB-MMPs). 
Figure 5.2 Experimental design for magnetic beads. 
5.2.4.1 Magnetic Bead Equilibration 
Magnetic beads were prepared by collecting with magnet and adding 1mL 
TNC buffer and left for 10minutes to equilibrate. After spinning at 1200g for 
5minutes, supernatant was discarded and 2 further washes were followed. 
The magnetic beads were left in 200μL suspension. 
5.2.4.2 rhMMP Mixture Preparation 
Each MMP is at less than 1μM final concentration in mixture as shown in 
Table 5.2. 
MMPs in buffer Chromatography Beads
H-7G
Flow-through
Magnetic Beads
MMPs in buffer Magnetic Beads
Flow-through
Magnetic Beads
Magnetic Beads
Flow-through
Magnetic Beads
Buffer
k
k
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Table 5.2 Final concentration in mixture of 11 rhMMPs. 
5.2.4.3 Reaction 
A mixture of 11 rhMMPs (SM) containing 3μg protein was added to 10mg of 
each of H-7G-MB and control beads MB (H-7G-MB-MMP and MB-MMP). 
Another control MB to which TNC buffer (pH7.5) was added instead of MMP 
were also prepared. The H-7G-MB-MMP beads, control beads MB-MMP and 
MB were rotated for 1 hour at 4°C at a rotator at 30rpm. The beads were 
attracted to bottom of polystyrene eppendorf by using a strong magnetic field 
and corresponding flow-throughs H-7G-MB-MMP FT, MB-MMP FT and MB 
FT were collected and kept in ice bucket until further analysis. All three 
different magnetic beads (H-7G-MB-MMP, MB-MMP and MB), were washed 
5-times with 1mL TNC buffer. After the last wash, beads were not kept in any 
suspension. Moreover, no elution was performed because the idea of this 
experiment was to analyze whether MMPs bind to Olive H-7G or not. 
MMP MW (R&D)(kDa)
Final Conc. In Mixture
(μM)
MMP-1 53 0.35
MMP-2 71 0.35
MMP-3 52 0.35
MMP-7 28 0.7
MMP-8 51 0.35
MMP-9 77 0.28
MMP-10 52 0.35
MMP-12 52 0.35
MMP-13 52 0.35
MMP-14 31 0.63
MMP-16 31 0.63
121 
Figure 5.3 Reaction between magnetic beads and mixture of 11 
rhMMPs. 
5.2.5 Preparation of rhMMPs Peptides (In-solution) 
To prepare samples for trypsin digestion only FT was desalted using NAP-5 
(Materials and Methods section 2.5) and lyophilized at 37°C/aqueous in 
GenVac evaporator. In-solution trypsin digestion was performed as described 
in Materials and Methods section 2.9.1 with the following variations in 
volumes for magnetic beads SM and FT: 13μL of 8M urea, 1μL of 50mM 
DTT, 1μL of 100mM IAC, 36μL of HPLC grade water and 7.65μL of 20μg/mL 
of trypsin solution. 
5.2.6 Preparation of rhMMPs Peptides (On-bead) 
To the beads (H-7G-Sepharose and sepharose), 1mL of 25mM ambic was 
added, mixed gently, centrifuged and buffer was discarded. It was repeated 
to wash the beads properly. To these beads, urea was added to give an 8M 
concentration (48.048mg for 100μL of suspension) and vortexed. Then 25μL 
of 50mM DTT were added, mixed and heated to 50oC for 15minutes. After 
bringing it to room temperature 25μL of 100mM IAC were added, vortexed, 
MB-MMP
(10mg beads)
11 MMP Mixture
(3μg protein) 
H-7G-MB-MMP
(10mg beads)
11 MMP Mixture
(3μg protein) 
MB
(10mg beads)
TNC Buffer
(No protein)
+
+
1hr at 4C
1hr at 4C
+
1hr at 4C
Collect FT
Collect FT
Collect FT
k
k
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centrifuged and incubated for 15-20minutes at room temperature in dark. To 
dilute the urea concentration, 250μL of HPLC grade water were added. This 
was followed by the addition of 6.13μL of trypsin solution (20μg/mL) and 
incubated at 28oC for 18hours followed by addition of 50μL of trypsin solution 
(20μg/mL) for another 20hours at 37oC for complete digestion of proteins. 
The reaction was stopped by freezing at -20°C. For magnetic beads (neither 
desalted nor lyophilized) all the steps were performed as described above 
with following changes in amounts of reagents: 13μL of 8M urea, 1μL of 
50mM DTT, 1μL of 100mM IAC, 36μL of HPLC grade water and 7.65μL of 
20μg/mL of trypsin solution were used with an overnight digestion at 28ºC. 
5.2.7 Removal of Detergent from Peptide Solution 
For manual MALDI mass spectrometry, peptide solutions were spotted on 
MALDI target plate using C18 zip tips (Materials and Methods section 
2.10.2). Before nHPLC fractionation of individual peptide solutions of SM, FT 
and B, C18 isolute columns were used to remove detergents or salts 
(Materials and Methods section 2.10.1). 
5.2.8 Reverse phase nHPLC coupled to MALDI-MS/MS 
The peptides were successfully separated using in-house nHPLC. 
Separation was confirmed through the generation of unique MS spectra 
following manual analysis of random fractions. The overall intensities 
(ranging from 103 to 105 a.u) suggested sufficient peptide concentrations for 
duplicate automated MS/MS analysis on each single fraction. The collected 
fractions were analyzed as described in Materials and Methods section 2.12. 
5.2.9 Enrichment of rhMMP-2 
Sample (rhMMP-2) was added to the H-7G-Sepharose chromatography bead 
suspension and mixed with rotation for 1 hour at 4°C to affinity bind to the H-
7G-Sepharose chromatography beads (Materials and Methods section 2.4) 
and elution of the enzyme was performed using a salt gradient of 0.3-2M 
NaCl buffers as described in Materials and Methods section 2.4.1. 
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5.2.10 Quantification of rhMMP-2 in Chromatographic Fractions 
Once chromatographic fractions (FT and E) were collected, the rhMMP-2 
amounts were detected (Materials and Methods section 2.7). The beads (B) 
collected at the end of the chromatography were also analyzed for any bound 
rhMMP-2. 
5.3 Results 
5.3.1 MALDI-MS of Mixture of 4 rhMMPs (H-7G-Sepharose Captured) 
Horse myoglobin was digested into expected peptides, T1, T3, T4, etc 
(Appendix 3) for theoretical peptides) indicating that trypsin was working 
effectively. The trypsin control (in the absence of any target proteins) 
indicated some autolytic degradation, generating known products of the 
bovine enzyme {MH+ = 1045.613, 2212.15 and 2300.215 (Mooney, 2007)}. 
The myoglobin control (incubated in the absence of protease) was intact, 
exhibiting no storage related degradation products. A complex series of 
signals between m/z 700 and 4000 was observed for SM comprising the 
mixture of 4 rhMMPs, H-7G-Sepharose and sepharose (Figure 5.4) indicative 
of proteolytic digestion. The SM exhibited peptides from MMP-1, MMP-2, 
MMP-3 and MMP-10 (Table 5.3). On-bead digestion of H-7G-Sepharose 
incubated with MMPs exhibited peptides from MMP-1, MMP-2 and MMP-3, 
whereas the equivalent sample from the sepharose control showed none of 
the MMP related peaks. Only autolytic product of trypsin 843.475 in H-7G-
Sepharose and 843.391 in SM was observed. Since MMPs also degrade and 
undergo autolysis so some signals could be from rhMMPs. 
A number of signals did not correlate with expected trypsin products, 
especially in the sepharose control. These could be from traces of detergent 
Brij-35 already present in the rhMMPs. A 0.05% solution of Brij-35 was 
analyzed with MALDI and m/z are given in Appendix 6. Many of signals were 
matched with the peaks determined in samples. A possible contamination of 
keratins in the sample due to handling may have contributed towards some 
of the signals. The common peaks from keratin can be 1179.60, 1208.6, 
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1210.5, 1277.78, 1307.67, 1383.69, 1475.75, 1707.77, 1713.82, 1716.85, 
1765.73, 1794.84, 1993.98, 2383.95, 2705.15 and 2872.34. Few of these 
were observed in SM e.g. 1713.61 and 2705.01. Some of these m/z can be 
common between the protein of interest such as MS/MS analysis of peptide 
with m/z 1713.61 identified MMP-3 in SM (Table 5.3). MS/MS analysis of m/z
1418.552 and 1713.945 in sample H-7G-Sepharose confirmed the signals 
corresponded to peptides in MMP-2 and MMP-3 respectively. 
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Figure 5.4 MALDI mass spectra for H-7G-Sepharose, H-7G-Sepharose 
FT and mixture of 4 rhMMPs. 
Table 5.3 Theoretical and experimental digest peaks for 4 rhMMP 
mixture, H-7G-Sepharose and sepharose. 
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5.3.2 MALDI-MS of Mixture of 9 rhMMPs (H-7G-Sepharose Captured) 
The number of rhMMPs was increased in the mixture against which Olive H-
7G was to screen its potential as a broad-spectrum ligand. As described in 
section 5.2.3, after 1 hour incubation of a mixture of 9 rhMMPs with H-7G-
Sepharose chromatography beads and negative control sepharose, on-bead 
trypsin digestion was performed. Trypsinization created peptides fragments, 
larger and smaller, these were ionized in MALDI mass spectrometer to 
demonstrate a mass peak profile. Manual MS analyses showed similar peak 
profile as depicted in 4 rhMMP mixture and beads. Some of these signals 
might be autolytic products of trypsin or rhMMPs. The detergent specific 
peaks were identified but lesser, both in number and intensity, than found in 
4 rhMMP mixture. The peaks from keratin 1307.67, 1475.75, and 2705.15 
were detected. 
Figure 5.5 MALDI mass spectra for H-7G-Sepharose, H-7G-Sepharose 
FT and mixture of 9 rhMMPs (n=3). 
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5.3.3 MALDI-MS of Mixture of 11 rhMMPs (H-7G-MB Captured) 
The negative control beads MB to which TNC buffer was added is shown in 
Figure 5.6. The close analysis of MB FT indicates either the solvent A used 
for washing zip tips or solvent B used for elution of peptides were 
contaminated. After MB treated with rhMMP mixture (MB-MMP in Figure 5.6) 
seems to bind Brij-35 specific peaks suggesting that zip tipping did not 
remove the detergent. The washing of the beads MB-MMPs did not remove 
the detergent peaks indicating stronger interaction between magnetic beads 
and Brij-35 micelle. A similar pattern was observed for H-7G-MB-MMP and 
its corresponding flow-through. Some MMP specific peaks were detected in 
the beads. A clear cut conclusion could not be made by observing the 
magnetic beads with bound Olive H-7G treated with rhMMP mixture. In an 
LC-MS/MS run the fraction H-7G-MB-MMPs showed 3 proteins of which 
MMP-8 (Mascot score 38) and MMP-12 (Mascot score 16) were identified 
with a sequence coverage of 2% and 1% respectively.
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Figure 5.6 MALDI mass spectra of MB, MB-MMP, H-7G-MB-MMP and 
mixture of 11 rhMMPs. 
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5.3.4 LC-MS/MS of rhMMP Peptides 
The successful separation of peptides by nHPLC was confirmed through the 
generation of unique MS spectra following manual analyses. The overall 
intensities (ranging from 103 to 105 a.u) suggested sufficient peptide 
concentrations for duplicate automated MS/MS analysis. The nHPLC UV 
profiles measured at 280nm and 215nm obtained for SM (mixture of 9 
rhMMP), Beads (probed and control) and their corresponding FT are shown 
in Figure 5.7. The LC-MS/MS runs for each sample identified MMPs with at 
least 1 peptide above the Mascot significance threshold of 30 (p<0.05) (Table 
5.4). The nHPLC profile for SM showed discrete peaks for MMP specific 
peptides, however, these were much weaker in the chromatographic 
fractions due to the presence of non-peptide contaminating peaks of 
unknown character. Some of these peaks were identified to be from the 
detergent. The comparison of probed beads H7G-Sepharose and sepharose 
control beads shows that it is Olive H-7G which binds MMPs since only 
MMP-9 was identified in later and most of the MMPs (MMP-3, MMP-8, MMP-
9 and MMP-10) were leaching into sepharose FT suggesting that sepharose 
does not permanently trap the MMPs. A possible reason why all MMPs 
added to the mixture were not identified in sepharose FT could be the 
identification of less MMPs from same peptides generated from variable 
regions of different MMPs. The identification of MMP-3, MMP-7, MMP-9 and 
MMP-10 in H-7G-Sepharose confirms the previous findings that Olive H-7G 
has an affinity for MMPs and it can be used to purify these endopeptidases. 
In an attempt to exploit the achieved results in this experiment to discriminate 
‘pro’ and ‘active’ forms of MMPs, a comparison of sequence coverage 
obtained was made for the MMPs identified in H-7G-Sepharose beads and 
SM applied onto it. The sequence coverage as depicted by Mascot search 
results is shown in Table 5.5. The sequence of amino acids in red font is the 
peptides identified in each sample with a reliable Mascot score (30) 
confirming their identity as true signature peptides for the MMPs. For further 
elaboration of the results obtained, the sequence of MMPs has been 
enlarged to show the amino acid sequence in ‘pro’ region and the active site 
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‘E’ is highlighted green and enboxed. No peptide was detected with active 
site amino acid as part of its sequence. This implies that enzymes present in 
the SM were ‘pro’ form. A higher Mascot score results for an individual 
peptide if it is present in sufficient quantity. The lesser sequence coverage in 
MMPs in H-7G-Sepharose as compared to SM identified in could be for many 
reasons such as less affinity for Olive H-7G, degradation during trypsin 
digestion or lesser MS/MS fragmentation. 
Figure 5.7 nHPLC profiles for mixture of 9 rhMMPs, H-7G-Sepharose, 
sepharose and corresponding FT. 
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Table 5.4 LC-MS/MS results. 
* *Not Detected 
Sample MMP Mascot Score Peptides #
(n=2) (n=2)
SM
(Mixture of 9 
MMPs)
2 115.5 8
3 306 13
7 166 5.5
8 419 12
9 478 16.5
10 501.5 16.5
13 480.5 12
14 161 4.5
H-7G-
Sepharose 
Beads
3 63.5 5
7 16.5 1
8 45 2.5
9 60 6
10 178 9
13 92.5 3.5
14 30.5 1.5
H-7G-
Sepharose FT
3 21.5 1
8 25.5 2
9 57 4.5
10 91 5
14 29 1
Sepharose 9 15.5 0.5
Sepharose FT
3
8
9
10
132 
Table 5.5 Sequence coverage of MMPs to discriminate ‘Pro’ and ‘Active’ forms. 
Starting Material    H-7G-Sepharose Beads  
MMP-2 
Score: 100
Peptides Matching: 7
Seq. Coverage: 12% 
MMP-3 
Score: 612
Peptides Matching: 26
Seq. Coverage: 42%
MMP-7 
Score: 332
Peptides Matching: 11
Seq. Coverage: 37% 
MMP-2  
MMP-3 
Score: 127
Peptides Matching: 10
Seq. Coverage: 16%
MMP-7 
Score: 33
Peptides Matching: 2
Seq. Coverage: 5% 
NOT DETECTED 
1 MKSLPILLLL CVAVCSAYPL DGAARGEDTS MNLVQKYLEN YYDLKKDVKQ 
51 FVRRKDSGPV VKKIREMQKF LGLEVTGKLD SDTLEVMRKP RCGVPDVGHF
101 RTFPGIPKWR KTHLTYRIVN YTPDLPKDAV DSAVEKALKV WEEVTPLTFS 
151 RLYEGEADIM ISFAVREHGD FYPFDGPGNV LAHAYAPGPG INGDAHFDDD 
201 EQWTKDTTGT NLFLVAAHEI GHSLGLFHSA NTEALMYPLY HSLTDLTRFR 
251 LSQDDINGIQ SLYGPPPDSP ETPLVPTEPV PPEPGTPANC DPALSFDAVS 
301 TLRGEILIFK DRHFWRKSLR KLEPELHLIS SFWPSLPSGV DAAYEVTSKD 
351 LVFIFKGNQF WAIRGNEVRA GYPRGIHTLG FPPTVRKIDA AISDKEKNKT 
401 YFFVEDKYWR FDEKRNSMEP GFPKQIAEDF PGIDSKIDAV FEEFGFFYFF 
451 TGSSQLEFDP NAKKVTHTLK SNSWLNC
1 MRLTVLCAVC LLPGSLALPL PQEAGGMSEL QWEQAQDYLK RFYLYDSETK 
51 NANSLEAKLK EMQKFFGLPI TGMLNSRVIE IMQKPRCGVP DVAEYSLFPN 
101 SPKWTSKVVT YRIVSYTRDL PHITVDRLVS KALNMWGKEI PLHFRKVVWG 
151 TADIMIGFAR GAHGDSYPFD GPGNTLAHAF APGTGLGGDA HFDEDERWTD 
201 GSSLGINFLY AATHELGHSL GMGHSSDPNA VMYPTYGNGD PQNFKLSQDD 
251 IKGIQKLYGK RSNSRKK
1 MEALMARGAL  TGPLRALCLL GCLLSHAAAA PSPIIKFPGD VAPKTDKELA 
51 VQYLNTFYGC  PKESCNLFVL KDTLKKMQKF FGLPQTGDLD QNTIETMRKP 
101 RCGNPDVANY NFFPRKPKWD KNQITYRIIG YTPDLDPETV DDAFARAFQV 
151 WSDVTPLRFS  RIHDGEADIM INFGRWEHGD GYPFDGKDGL LAHAFAPGTG 
201 VGGDSHFDDD  ELWTLGEGQV VRVKYGNADG EYCKFPFLFN GKEYNSCTDT 
251 GRSDGFLWCS  TTYNFEKDGK YGFCPHEALF TMGGNAEGQP CKFPFRFQGT 
301 SYDSCTTEGR  TDGYRWCGTT EDYDRDKKYG FCPETAMSTV GGNSEGAPCV 
351 FPFTFLGNKY  ESCTSAGRSD GKMWCATTAN YDDDRKWGFC PDQGYSLFLV 
401 AAHEFGHAMG  LEHSQDPGAL MAPIYTYTKN FRLSQDDIKG IQELYGASPD 
451 IDLGTGPTPT  LGPVTPEICK QDIVFDGIAQ IRGEIFFFKD RFIWRTVTPR 
501 DKPMGPLLVA  TFWPELPEKI DAVYEAPQEE KAVFFAGNEY WIYSASTLER 
551 GYPKPLTSLG  LPPDVQRVDA AFNWSKNKKT YIFAGDKFWR YNEVKKKMDP 
601 GFPKLIADAW  NAIPDNLDAV VDLQGGGHSY FFKGAYYLKL ENQSLKSVKF 
651 GSIKSDWLGC 
1 MKSLPILLLL CVAVCSAYPL DGAARGEDTS MNLVQKYLEN YYDLKKDVKQ 
51 FVRRKDSGPV VKKIREMQKF LGLEVTGKLD SDTLEVMRKP RCGVPDVGHF
101 RTFPGIPKWR KTHLTYRIVN YTPDLPKDAV DSAVEKALKV WEEVTPLTFS 
151 RLYEGEADIM ISFAVREHGD FYPFDGPGNV LAHAYAPGPG INGDAHFDDD 
201 EQWTKDTTGT NLFLVAAHEI GHSLGLFHSA NTEALMYPLY HSLTDLTRFR 
251 LSQDDINGIQ SLYGPPPDSP ETPLVPTEPV PPEPGTPANC DPALSFDAVS 
301 TLRGEILIFK DRHFWRKSLR KLEPELHLIS SFWPSLPSGV DAAYEVTSKD 
351 LVFIFKGNQF WAIRGNEVRA GYPRGIHTLG FPPTVRKIDA AISDKEKNKT 
401 YFFVEDKYWR FDEKRNSMEP GFPKQIAEDF PGIDSKIDAV FEEFGFFYFF 
451 TGSSQLEFDP NAKKVTHTLK SNSWLNC
1 MRLTVLCAVC LLPGSLALPL PQEAGGMSEL QWEQAQDYLK RFYLYDSETK 
51 NANSLEAKLK EMQKFFGLPI TGMLNSRVIE IMQKPRCGVP DVAEYSLFPN 
101 SPKWTSKVVT YRIVSYTRDL PHITVDRLVS KALNMWGKEI PLHFRKVVWG 
151 TADIMIGFAR GAHGDSYPFD GPGNTLAHAF APGTGLGGDA HFDEDERWTD 
201 GSSLGINFLY AATHELGHSL GMGHSSDPNA VMYPTYGNGD PQNFKLSQDD 
251 IKGIQKLYGK RSNSRKK
MMP-8 
Score: 795 
Peptides Matching: 19
Seq. Coverage: 35%
MMP-8 
Score: 90
Peptides Matching: 5
Seq. Coverage: 10%
1 MFSLKTLPFL LLLHVQISKA FPVSSKEKNT KTVQDYLEKF YQLPSNQYQS 
51 TRKNGTNVIV EKLKEMQRFF GLNVTGKPNE ETLDMMKKPR CGVPDSGGFM 
101 LTPGNPKWER TNLTYRIRNY TPQLSEAEVE RAIKDAFELW SVASPLIFTR 
151 ISQGEADINI AFYQRDHGDN SPFDGPNGIL AHAFQPGQGI GGDAHFDAEE 
201 TWTNTSANYN LFLVAAHEFG HSLGLAHSSD PGALMYPNYA FRETSNYSLP 
251 QDDIDGIQAI YGLSSNPIQP TGPSTPKPCD PSLTFDAITT LRGEILFFKD 
301 RYFWRRHPQL QRVEMNFISL FWPSLPTGIQ AAYEDFDRDL IFLFKGNQYW 
351 ALSGYDILQG YPKDISNYGF PSSVQAIDAA VFYRSKTYFF VNDQFWRYDN 
401 QRQFMEPGYP KSISGAFPGI ESKVDAVFQQ EHFFHVFSGP RYYAFDLIAQ
451 RVTRVARGNK WLNCRYG
1 MFSLKTLPFL LLLHVQISKA FPVSSKEKNT KTVQDYLEKF YQLPSNQYQS 
51 TRKNGTNVIV EKLKEMQRFF GLNVTGKPNE ETLDMMKKPR CGVPDSGGFM 
101 LTPGNPKWER TNLTYRIRNY TPQLSEAEVE RAIKDAFELW SVASPLIFTR 
151 ISQGEADINI AFYQRDHGDN SPFDGPNGIL AHAFQPGQGI GGDAHFDAEE 
201 TWTNTSANYN LFLVAAHEFG HSLGLAHSSD PGALMYPNYA FRETSNYSLP 
251 QDDIDGIQAI YGLSSNPIQP TGPSTPKPCD PSLTFDAITT LRGEILFFKD 
301 RYFWRRHPQL QRVEMNFISL FWPSLPTGIQ AAYEDFDRDL IFLFKGNQYW 
351 ALSGYDILQG YPKDISNYGF PSSVQAIDAA VFYRSKTYFF VNDQFWRYDN 
401 QRQFMEPGYP KSISGAFPGI ESKVDAVFQQ EHFFHVFSGP RYYAFDLIAQ 
451 RVTRVARGNK WLNCRYG
Propeptide (30-109)
Propeptide (18-99)
Propeptide (18-94)
Propeptide (21-100)
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Starting Material    H-7G-Sepharose Beads  
MMP-9 
Score: 884
Peptides Matching: 28
Seq. Coverage: 39%
MMP-10
Score: 1003
Peptides Matching: 33
Seq. Coverage: 48%
MMP-9 
Score: 120 
Peptides Matching: 12
Seq. Coverage: 14%
MMP-10
Score: 356
Peptides Matching:18
Seq. Coverage: 27%
1 MSLWQPLVLV LLVLGCCFAA PRQRQSTLVL FPGDLRTNLT DRQLAEEYLY 
51 RYGYTRVAEM RGESKSLGPA LLLLQKQLSL PETGELDSAT LKAMRTPRCG 
101 VPDLGRFQTF EGDLKWHHHN ITYWIQNYSE DLPRAVIDDA FARAFALWSA 
151 VTPLTFTRVY SRDADIVIQF GVAEHGDGYP FDGKDGLLAH AFPPGPGIQG 
201 DAHFDDDELW SLGKGVVVPT RFGNADGAAC HFPFIFEGRS YSACTTDGRS 
251 DGLPWCSTTA NYDTDDRFGF CPSERLYTQD GNADGKPCQF PFIFQGQSYS 
301 ACTTDGRSDG YRWCATTANY DRDKLFGFCP TRADSTVMGG NSAGELCVFP 
351 FTFLGKEYST CTSEGRGDGR LWCATTSNFD SDKKWGFCPD QGYSLFLVAA 
401 HEFGHALGLD HSSVPEALMY PMYRFTEGPP LHKDDVNGIR HLYGPRPEPE 
451 PRPPTTTTPQ PTAPPTVCPT GPPTVHPSER PTAGPTGPPS AGPTGPPTAG 
501 PSTATTVPLS PVDDACNVNI FDAIAEIGNQ LYLFKDGKYW RFSEGRGSRP 
551 QGPFLIADKW PALPRKLDSV FEERLSKKLF FFSGRQVWVY TGASVLGPRR 
601 LDKLGLGADV AQVTGALRSG RGKMLLFSGR RLWRFDVKAQ MVDPRSASEV 
651 DRMFPGVPLD THDVFQYREK AYFCQDRFYW RVSSRSELNQ VDQVGYVTYD 
701 ILQCPED
1 MMHLAFLVLL CLPVCSAYPL SGAAKEEDSN KDLAQQYLEK YYNLEKDVKQ 
51 FRRKDSNLIV KKIQGMQKFL GLEVTGKLDT DTLEVMRKPR CGVPDVGHFS 
101 SFPGMPKWRK THLTYRIVNY TPDLPRDAVD SAIEKALKVW EEVTPLTFSR 
151 LYEGEADIMI SFAVKEHGDF YSFDGPGHSL AHAYPPGPGL YGDIHFDDDE 
201 KWTEDASGTN LFLVAAHELG HSLGLFHSAN TEALMYPLYN SFTELAQFRL 
251 SQDDVNGIQS LYGPPPASTE EPLVPTKSVP SGSEMPAKCD PALSFDAIST 
301 LRGEYLFFKD RYFWRRSHWN PEPEFHLISA FWPSLPSYLD AAYEVNSRDT 
351 VFIFKGNEFW AIRGNEVQAG YPRGIHTLGF PPTIRKIDAA VSDKEKKKTY 
401 FFAADKYWRF DENSQSMEQG FPRLIADDFP GVEPKVDAVL QAFGFFYFFS 
451 GSSQFEFDPN ARMVTHILKS NSWLHC
1 MSLWQPLVLV LLVLGCCFAA PRQRQSTLVL FPGDLRTNLT DRQLAEEYLY 
51 RYGYTRVAEM RGESKSLGPA LLLLQKQLSL PETGELDSAT LKAMRTPRCG 
101 VPDLGRFQTF EGDLKWHHHN ITYWIQNYSE DLPRAVIDDA FARAFALWSA 
151 VTPLTFTRVY SRDADIVIQF GVAEHGDGYP FDGKDGLLAH AFPPGPGIQG 
201 DAHFDDDELW SLGKGVVVPT RFGNADGAAC HFPFIFEGRS YSACTTDGRS 
251 DGLPWCSTTA NYDTDDRFGF CPSERLYTQD GNADGKPCQF PFIFQGQSYS 
301 ACTTDGRSDG YRWCATTANY DRDKLFGFCP TRADSTVMGG NSAGELCVFP 
351 FTFLGKEYST CTSEGRGDGR LWCATTSNFD SDKKWGFCPD QGYSLFLVAA 
401 HEFGHALGLD HSSVPEALMY PMYRFTEGPP LHKDDVNGIR HLYGPRPEPE 
451 PRPPTTTTPQ PTAPPTVCPT GPPTVHPSER PTAGPTGPPS AGPTGPPTAG 
501 PSTATTVPLS PVDDACNVNI FDAIAEIGNQ LYLFKDGKYW RFSEGRGSRP 
551 QGPFLIADKW PALPRKLDSV FEERLSKKLF FFSGRQVWVY TGASVLGPRR 
601 LDKLGLGADV AQVTGALRSG RGKMLLFSGR RLWRFDVKAQ MVDPRSASEV 
651 DRMFPGVPLD THDVFQYREK AYFCQDRFYW RVSSRSELNQ VDQVGYVTYD 
701 ILQCPED
1 MMHLAFLVLL CLPVCSAYPL SGAAKEEDSN KDLAQQYLEK YYNLEKDVKQ 
51 FRRKDSNLIV KKIQGMQKFL GLEVTGKLDT DTLEVMRKPR CGVPDVGHFS 
101 SFPGMPKWRK THLTYRIVNY TPDLPRDAVD SAIEKALKVW EEVTPLTFSR 
151 LYEGEADIMI SFAVKEHGDF YSFDGPGHSL AHAYPPGPGL YGDIHFDDDE 
201 KWTEDASGTN LFLVAAHELG HSLGLFHSAN TEALMYPLYN SFTELAQFRL 
251 SQDDVNGIQS LYGPPPASTE EPLVPTKSVP SGSEMPAKCD PALSFDAIST 
301 LRGEYLFFKD RYFWRRSHWN PEPEFHLISA FWPSLPSYLD AAYEVNSRDT 
351 VFIFKGNEFW AIRGNEVQAG YPRGIHTLGF PPTIRKIDAA VSDKEKKKTY 
401 FFAADKYWRF DENSQSMEQG FPRLIADDFP GVEPKVDAVL QAFGFFYFFS 
451 GSSQFEFDPN ARMVTHILKS NSWLHC
MMP-13 
Score: 825 
Peptides Matching: 19
Seq. Coverage: 43%
MMP-13 
Score: 185
Peptides Matching: 7
Seq. Coverage: 10% 
MMP-14
Score: 322
Peptides Matching: 9
Seq. Coverage: 12%
MMP-14
Score: 61
Peptides Matching: 3
Seq. Coverage: 6%
1 MHPGVLAAFL FLSWTHCRAL PLPSGGDEDD LSEEDLQFAE RYLRSYYHPT 
51 NLAGILKENA ASSMTERLRE MQSFFGLEVT GKLDDNTLDV MKKPRCGVPD 
101 VGEYNVFPRT LKWSKMNLTY RIVNYTPDMT HSEVEKAFKK AFKVWSDVTP 
151 LNFTRLHDGI ADIMISFGIK EHGDFYPFDG PSGLLAHAFP PGPNYGGDAH 
201 FDDDETWTSS SKGYNLFLVA AHEFGHSLGL DHSKDPGALM FPIYTYTGKS 
251 HFMLPDDDVQ GIQSLYGPGD EDPNPKHPKT PDKCDPSLSL DAITSLRGET 
301 MIFKDRFFWR LHPQQVDAEL FLTKSFWPEL PNRIDAAYEH PSHDLIFIFR 
351 GRKFWALNGY DILEGYPKKI SELGLPKEVK KISAAVHFED TGKTLLFSGN 
401 QVWRYDDTNH IMDKDYPRLI EEDFPGIGDK VDAVYEKNGY IYFFNGPIQF 
451 EYSIWSNRIV RVMPANSILW C
1 MSPAPRPSRC LLLPLLTLGT ALASLGSAQS SSFSPEAWLQ QYGYLPPGDL 
51 RTHTQRSPQS LSAAIAAMQK FYGLQVTGKA DADTMKAMRR PRCGVPDKFG 
101 AEIKANVRRK RYAIQGLKWQ HNEITFCIQN YTPKVGEYAT YEAIRKAFRV 
151 WESATPLRFR EVPYAYIREG HEKQADIMIF FAEGFHGDST PFDGEGGFLA 
201 HAYFPGPNIG GDTHFDSAEP WTVRNEDLNG NDIFLVAVHE LGHALGLEHS 
251 SDPSAIMAPF YQWMDTENFV LPDDDRRGIQ QLYGGESGFP TKMPPQPRTT 
301 SRPSVPDKPK NPTYGPNICD GNFDTVAMLR GEMFVFKERW FWRVRNNQVM 
351 DGYPMPIGQF WRGLPASINT AYERKDGKFV FFKGDKHWVF DEASLEPGYP 
401 KHIKELGRGL PTDKIDAALF WMPNGKTYFF RGNKYYRFNE ELRAVDSEYP 
451 KNIKVWEGIP ESPRGSFMGS DEVFTYFYKG NKYWKFNNQK LKVEPGYPKS 
501 ALRDWMGCPS GGRPDEGTEE ETEVIIIEVD EEGGGAVSAA AVVLPVLLLL 
551 LVLAVGLAVF FFRRHGTPRR LLYCQRSLLD KV
1 MHPGVLAAFL FLSWTHCRAL PLPSGGDEDD LSEEDLQFAE RYLRSYYHPT 
51 NLAGILKENA ASSMTERLRE MQSFFGLEVT GKLDDNTLDV MKKPRCGVPD 
101 VGEYNVFPRT LKWSKMNLTY RIVNYTPDMT HSEVEKAFKK AFKVWSDVTP 
151 LNFTRLHDGI ADIMISFGIK EHGDFYPFDG PSGLLAHAFP PGPNYGGDAH 
201 FDDDETWTSS SKGYNLFLVA AHEFGHSLGL DHSKDPGALM FPIYTYTGKS 
251 HFMLPDDDVQ GIQSLYGPGD EDPNPKHPKT PDKCDPSLSL DAITSLRGET 
301 MIFKDRFFWR LHPQQVDAEL FLTKSFWPEL PNRIDAAYEH PSHDLIFIFR 
351 GRKFWALNGY DILEGYPKKI SELGLPKEVK KISAAVHFED TGKTLLFSGN 
401 QVWRYDDTNH IMDKDYPRLI EEDFPGIGDK VDAVYEKNGY IYFFNGPIQF 
451 EYSIWSNRIV RVMPANSILW C
1 MSPAPRPSRC LLLPLLTLGT ALASLGSAQS SSFSPEAWLQ QYGYLPPGDL 
51 RTHTQRSPQS LSAAIAAMQK FYGLQVTGKA DADTMKAMRR PRCGVPDKFG 
101 AEIKANVRRK RYAIQGLKWQ HNEITFCIQN YTPKVGEYAT YEAIRKAFRV 
151 WESATPLRFR EVPYAYIREG HEKQADIMIF FAEGFHGDST PFDGEGGFLA 
201 HAYFPGPNIG GDTHFDSAEP WTVRNEDLNG NDIFLVAVHE LGHALGLEHS 
251 SDPSAIMAPF YQWMDTENFV LPDDDRRGIQ QLYGGESGFP TKMPPQPRTT 
301 SRPSVPDKPK NPTYGPNICD GNFDTVAMLR GEMFVFKERW FWRVRNNQVM 
351 DGYPMPIGQF WRGLPASINT AYERKDGKFV FFKGDKHWVF DEASLEPGYP 
401 KHIKELGRGL PTDKIDAALF WMPNGKTYFF RGNKYYRFNE ELRAVDSEYP 
451 KNIKVWEGIP ESPRGSFMGS DEVFTYFYKG NKYWKFNNQK LKVEPGYPKS 
501 ALRDWMGCPS GGRPDEGTEE ETEVIIIEVD EEGGGAVSAA AVVLPVLLLL 
551 LVLAVGLAVF FFRRHGTPRR LLYCQRSLLD KV
Propeptid (20-93)
Propeptide (18-98)
Propeptide (20-103)
Propeptide (21-211)
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5.3.5 rhMMP Recovery from H-7G-Sepharose 
MMP-2 is a well characterized, representative member of the matrix 
metalloproteinase family, with established assays and antibodies for its 
detection. Materials and Methods section 2.7 describes the validation of 
ELISA assay using commercially available recombinant human pro-MMP-2 
(rhMMP-2). The concentration of the rhMMP-2 in SM and in H-7G-Sepharose 
chromatography fractions (FT, E and beads) were determined using an 
ELISA based quantification kit. The standard curve showing linear correlation 
between amounts of standards and absorbance in the range 0.78-50ng/mL is 
shown in Figure 2.4. To measure the MMP-2 activity within the calibration 
range samples were concentrated and desalted using NAP-5 columns. The 
eluates from NAP-5 columns were lyophilized and then resuspended in 50μL 
of RD5-32 ELISA buffer, performed rest of the steps as instructed by the 
ELISA kit and absorbance of product was measured at 450nm to calculate 
MMP-2 amounts (Table 5.6). The amount of rhMMP-2 in SM was 370ng 
based on information specified by supplier but it was detected to be 93.00ng. 
The results indicate that the yield of rhMMP-2 was 95.01% with 30.62% in 
the flow through, 43.91% eluted and 20.48% retained on the beads after 
elution. Therefore, within the measurement of ELISA assay, a good yield was 
achieved. However, the calculated amount of rhMMP-2 in starting material 
was 370ng hence, 24.05% of rhMMP-2 was retrieved. 
Table 5.6 MMP recovery from H-7G-Sepharose based on ELISA. 
Mean (n=2) SD Mean (n=2) SD
rhMMP-2 SM 93.00 0.16
rhMMP-2 FT 28.48 1.64
rhMMP-2 E1 23.52 0.09
rhMMP-2 E2 17.32 0.79
rhMMP-2 B 19.05 0.47
(ng)
rhMMP-2
Samples %age Retrieval
ϵϱ͘Ϭϭ Ϯ͘Ϭϰ
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The presence of MMP-2 in FT could be because of the super saturation of 
beads i.e. the MMP-2 amounts were more than the capacity of beads 
volume. It could also be because of reversible nature of binding of MMP-2 to 
the dye ligand. Since the affinity between the two is not of covalent nature so 
MMP-2 might come off the beads during vortexing or centrifugation for 
washing the beads. The results obtained by ELISA of eluents (from 0.3M and 
2M salt buffers) validate the findings of sections 5.3.1, 5.3.2 and 5.3.4 that 
Olive H-7G binds MMPs. The affinity chromatography of rh-MMP-2 
comprising of binding of the enzyme to the dye and subsequent elution was 
performed to achieve the retrieval of the enzyme. The results obtained by 
ELISA quantification proved that the Olive H-7G not only bound the rhMMP-2 
but also, recovery of the enzyme was possible using elution buffers 
containing the right salt concentrations (0.3M and 2M). 
5.4 Discussion 
The successful capture of MMPs with H-7G-Sepharose (section 5.3.1 and 
5.3.2) as well as the successful identification of these proteins using LC-
MS/MS (section 5.3.4) and the elution of these proteins based on dye ligand 
chromatography (section 5.3.5) paved the way for proteomic analysis of 
complex proteome (This will be reported in Chapter 6 and 7). Sufficient MMP 
amounts (in ng) very close to the sensitivity range of LC-MALDI based 
proteomic analysis was added to the mixture in small volumes (in μL) which 
allowed successful identification of the MMPs. The successful identification of 
MMPs after LC-MS within a small time-window was an important 
achievement since recombinant proteins are more prone to degradation 
without the stabilizing proteins found in complex proteomes. Previous studies 
based upon samples from cell lines have used much higher protein amounts 
(in μg or mg) in larger volumes (in mL or L) of cell line culture supernatants. 
For instance, within their study, Imai and co-workers used a four-step 
purification of MMPs starting from 250mL of rheumatoid synovial fibroblast 
culture supernantant concentrating it down to 37mL. From this, they purified 
different MMPs in various steps which is time-consuming (Imai and Okada, 
2008). 
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This chapter serves to demonstrate the development of proteomics mass 
spectrometric method for the detection, identification and characterization of 
MMPs in one robust step. As described in Introduction of this chapter, the 
need for new and effective profiling methods for MMPs is especially pressing 
with respect to their role in metastasis and as a target for MMP-activated 
drug development. This model study attempt with rhMMPs was made in need 
of developing a technique using smaller amounts of MMPs in smaller 
volumes of biological samples for gauging the expression of ‘pro’ and ‘active’ 
forms of MMPs. The combination of dye ligand chromatography for MMP 
enrichment, nHPLC for peptide separation and MALDI tandem mass 
spectrometry for identification has proved to be successful system in 
characterizing MMPs. This will help achieve the ultimate goal of this project 
which is to utilize this methodology for identifying MMPs in clinical tissues 
and working with limited supply of tumour samples is a well-recognized 
challenge due to their complex proteome. 
For the study of complex peptide mixtures, LC-MALDI provides an 
opportunity to concentrate and separate the peptides prior to analysis 
thereby extending time available for MS/MS interrogation resulting in 
increased sequence coverage. This in turn results in higher sensitivity and 
means that more MS/MS spectra can be generated from the sample. Rather 
than acquiring all the MS/MS spectra from the same spot, with the sample 
being depleted with each spectrum acquired, signals are collected from 
different positions on the MALDI target and sample depletion is less of an 
issue. All the samples were analyzed manually before carrying forward for 
LC-MALDI-MS/MS TOF/TOF. A high level of stringency was adopted to avoid 
false discovery. For MMP captured on beads, H-7G-Sepharose, (Table 5.5) 
where a better sequence coverage was not achieved from a peptide sample, 
this may have been due to poor peptide ionization or low sample 
concentration. While interpreting data and assigning protein identification, the 
MS/MS tolerance threshold (0.07) which states the likelihood that the peptide 
has been matched by chance, was considered. A lower value indicates a 
more confident match. It is a way of determining the quality of a match. The 
number of peptides matched was also considered as higher number of 
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matched peptides indicates more confidence in the protein. Two or more 
peptides were desirable for confident MMP identification. Other factors such 
as number of missed cleavages (2) and the variable modifications of peptides 
(carbamidomethylation of cysteine and oxidation of methionine in this study) 
were also considered. 
One of the noteworthy finding of this study is that the ligand under discussion 
has affinity for MMP-8, MMP-13 and MMP-14 in addition to previously 
reported MMPs (MMP-3, MMP-7, MMP-9 and MMP-10). This finding 
highlights the broad applicability of Olive H-7G. The identification of these 
three new MMPs could be attributed to the LC-MS/MS complimentary protein 
identification. Ideally, there should not be any MMPs being detected in flow-
through however, the identification of MMP-3, MMP-7, MMP-8, MMP-9, 
MMP-13 and MMP-14 in H-7G-Sepharose FT (Table 5.4) could be because 
of the fact that beads were saturated and excess MMPs were washed. These 
results are very encouraging and not only confirm the previously reported 
potential of the Olive H-7G affinity for MMP-3, MMP-7, MMP-9 and MMP-10 
but also for MMP-8, MMP-13 and MMP-14 reported in this study. 
The analysis was extended to use magnetic beads, a matrix of choice for 
immobilizing ligands. Recently, there has been increased interest in the use 
of magnetic carriers in biomolecule coupling, nucleic acid and protein 
purification. The magnetic character implies that they respond to a magnet, 
making sampling and collection easier and faster. In a study conducted by 
Nilgun, 2007 a triazine dye, Cibacron Blue F3GA-attached mPHEMA (2-
hydroxyethylmethacrylate) beads provided an efficient method to separate 
lysozyme, showing high binding capacity, assuring a purity of about 87.4% 
with recovery about 79.6%. It was hoped that the smaller diameter of 
magnetic beads (1micron) as compared to sepharose (45microns) would 
allow minimum protein binding hence allowing immobilized ligand to enrich 
the MMPs. The results obtained were not clear. Possible reasons for this 
could be (i) Olive H-7G did not react to the hydroxyl groups on the surface of 
beads (ii) the pH, temperature or salt concentrations were not optimal during 
the capture of MMPs (iii) autolytic degradation of MMPs causing changes in 3 
dimensional structure. This is in agreement with the finding of study by 
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Trinkle-Mulcahy that no single matrix among sepharose, agarose and 
magnetic beads gives required results under all conditions . Since, H-7G-
Sepharose showed better results than magnetic beads so it was decided to 
omit the use of magnetic beads in the following experiments. Functionalized 
magnetic beads allow for relatively rapid and easy purification from crude 
biological samples, thereby eliminating the need for most of the pre-treatment 
steps such as centrifugation, filtration and membrane separation (Corchero 
and Villaverde, 2009)  
The elution buffer (0.3M and 2M NaCl) were used to elute off the 
endopeptidases after confirming the affinity of Olive H-7G for MMPs (section 
5.3.1 and 5.3.4) to gain a very fundamental information that whether bound 
MMPs to Olive H-7G could be retrieved or not. The ELISA assay was used to 
measure the MMP concentration in collected chromatography fractions and 
compared to the starting material (Table 5.6). The assay was optimized using 
recombinant form of MMP-2 to interrogate cancer cell lines selected for the 
study (explained in next chapters). The data offered persuasive evidence as 
a consequence of the observed 95.01% recovery of MMPs from Olive H-7G 
immobilized on sepharose. This finding appeared to be very plausible and 
suggested that it is worth viewing Olive H-7G as a potential probe for 
purification of MMPs in keeping with the previous studies. Nevertheless, it 
still remains vital to clarify whether it discriminates ‘pro’ form of MMPs from 
‘active’. The ELISA used for determining MMP-2 levels in samples did not 
differentiate ‘pro’ and active forms. This draws attention to the limitations of 
the assay. Yet within the measurements of the assay, a good yield was 
achieved. The discrepancy between expected level (370ng) in the SM and 
actual measured (93ng) by ELISA could be for many reasons such as the 
potential presence of uncleaved substrate whose absorbance is measured, 
presence of some component (preservatives and surfactants in kit supplied 
reagents) interfering to the efficiency of the assay or lyophilized samples 
were not completely dissolved in diluent buffer could be some of the factors. 
The detection of rhMMP-2 on chromatography beads (19.05ng) collected at 
the end means that the entire bound enzyme was not eluted using salt 
containing buffers. Both ELISA and MALDI mass spectrometry have their 
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merits and limitations. For a sandwich based ELISA assay, an enzyme label 
such as HRP is conjugated to antibody raised against the antigen of the 
target protein. The assay involves washing steps which remove unbound 
material and leaves behind the specific protein bound to the capture antibody 
coated to the polystyrene micro-titre pate. In MALDI, there is no need to 
adjust the wavelength to match absorption frequency of each analyte 
because matrix is used. Also, matrix does not allow the formation of cluster of 
molecules which helps increase accuracy and resolution. The sensitivity of 
MALDI MS is down to the attomole concentrations as opposed to ELISA 
where micromolar concentrations are vital. ELISA is restricted to the proteins 
for which antibodies have been raised to a smaller part of the protein 
structure. In case of MALDI, many proteins can be identified simultaneously 
because databases have theoretical profiles for all the known proteins. 
Taken together these data add weight to the validity of Olive H-7G as a 
potential affinity tool for the separation of MMPs from complex proteome. 
This compelling data was viewed as a further justification of the choice of 
Olive H-7G as a potentially useful purifying tool for MMPs. This pilot study 
with rhMMPs helped to scale up the amount of MMPs in samples of low total 
protein content for later analyses with MALDI-MS since most of the proteins 
are lost during preparation for final analysis. Moreover, there is no published 
data of using a mixture of recombinant human MMPs (basic, gelatinases, 
membrane bound and minimal domain) shown to bind to one dye ligand 
(Olive H-7G) and identified by LC-MS/MS presented in this study. To the best 
of my knowledge, the binding of MMP-8, MMP13 and MMP-14 to Olive H-7G 
is reported for the first time in this study. 
CHAPTER 6 
PURIFICATION OF SECRETED AND 
CELLULAR MMPs FROM PRE-CLINICAL 
CANCER MODEL AND PROTEOMIC MASS 
SPECTROMETRY 
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6 Purification of Secreted and Cellular MMPs from Pre-clinical Cancer 
Model and Proteomic Mass Spectrometry 
6.1 Introduction 
The expression of MMPs is related to the progression of various cancers 
such as the breast and colorectal cancer (Garbett et al., 1999), human 
gastric carcinoma (Nomura et al., 1996) and oral squamous cell carcinomas 
(Patel et al., 2007) and the metastases of endometrial and gastrointestinal 
carcinomas (Shiomi and Okada, 2003). The role of MMPs in cancer has been 
covered in detail in Introduction (Introduction section 1.5). 
Compartmentalization, that is where and how in the pericellular environment 
an MMP is released and held is important (Ra and Parks, 2007). The 
architectural complexity of natural site of action of MMPs, the ECM into which 
MMPs are secreted, is maintained by a large portfolio of matrix proteins, 
signaling molecules, proteases, and cell types that play a fundamental role in 
the remodeling process. Membrane bound MMPs can serve as a localized, 
pericellular site of ECM proteolytic activity. 
In vitro cell lines have been in use to facilitate the characterization of new 
molecular targets (Bibby, 1999). The fibrosarcoma cell line HT1080 has been 
used for the purification of pro-MMP-9 and its mechanism of activation 
(Okada et al., 1992). The characterization of MMPs and more specifically 
expression of active MMPs in tumour cell lines have been used as a means 
of elucidating disease state. In a study, the expression pattern of the 23 
human MMPs was investigated in different gynecological cancer cell lines 
from three endometrium carcinomas (Ishikawa, HEC-1-A, AN-3 CA), three 
cervical carcinomas (HeLa, Caski, SiHa), three chorioncarcinomas (JEG, 
JAR, BeWo), two ovarian cancers (BG-1, OAW-42) and one eratocarcinoma 
(PA-1). The expression of MMPs was analyzed by RT-PCR, western blot and 
gelatin zymography. The major findings of the study were that Ishikawa, 
Caski, OAW-42 and BeWo cell lines could be the best choice for experiments 
on MMP regulation and their role in endometrial, cervical, ovarian or 
choriocarcinoma development, whereas the teratocarcinoma cell line PA-1 in 
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which a broad range of 16 MMPs could be found  and could be used as a 
positive control for general MMP experiments  (Schropfer et al., 2010). 
Despite this a dearth of data exists with respect to pro/active/TIMP 
complexed MMP expression in various pathological conditions at a given 
time point. The ruling out of one gene-one protein dogma due to the 
presence of post-translational modifications (PTMs) has rendered the 
proteome analysis difficult using standardized methodologies such as 
western blotting and activity assays. Examples of more than 100 PTMs have 
been reported for a single protein (O'Donovan et al., 2001). Protein structural 
diversity is one of the major analytical challenges in detecting low abundance 
proteins (Gross and Lapiere, 1962). The fact that biological samples contain 
mixture of proteins, most of which are high abundance proteins (HAP), offers 
a great deal of obstacle in characterizing target proteins.  
Back in 80’s, triazine based reactive dye were more frequently used for 
protein purification as explained in Introduction section 1.8.4.1. Affinity 
chromatography is based on highly specific biological interactions between 
two molecules and provide significant time savings and several hundred-fold 
or higher purification (Urh et al., 2009). With the growing popularity of affinity 
purification, many of the commonly used ligands attached to affinity matrices 
are now commercially available and are ready to use. However, in some 
cases new affinity chromatographic material may need to be developed by 
pairing the ligand onto the matrix such that the ligand retains specific binding 
affinity for the protein of interest. Thus, it is important to optimize the 
purification protocol to achieve efficient capture and maximum recovery of 
the target protein. The recent development of mass spectrometry and use of 
proteomic approaches has allowed the rapid, high-throughput identification of 
proteins including those secreted in culture supernatant and cell extracts. 
Successful application of proteome analysis is accomplished by tandem 
mass spectrometry (MS/MS) because of its tremendous power of protein 
identification and sequencing by analyzing signature peptides. Identification 
of MMPs with mass spectrometry based methods is challenging because of 
their membership of low abundance proteins (LAP). 
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For LAP, chromatography enrichment helps bring their concentration high 
enough for detection and quantification. For example, a 1000-fold Immuno-
affinity enrichment of proteins can achieve 1ng/mL limit of MS quantification 
(Berna and Ackermann, 2009). The problems with the identification of LAP 
such as MMPs can be overcome if appropriate enrichment and separation 
techniques both at protein and peptide level are combined with tandem mass 
spectrometry. This is achieved by devising affinity based chromatography 
systems which segregate and enrich proteins of interest followed by 
controlled digestion of proteins and separating the corresponding peptides by 
liquid chromatography. In the present study an attempt was made to make 
these various techniques compatible with each other starting with lowest 
possible amounts of biological samples and optimize tandem mass 
spectrometry to detect MMPs. For enrichment, H-7G-Sepharose 
chromatography beads were synthesized. Following demonstration of 
signature peptides of MMPs (Chapter 4), H-7G-Sepharose chromatography 
beads showed evidence of capture of rhMMPs and were successfully 
identified by LC-MS/MS (Chapter 5). This gave confidence to proceed for the 
purification of these endopeptidases from a mixture of proteins. Hence, 
culture supernatants and cell lysates from HT1080 and HT29, fibrosarcoma 
and colon carcinoma cell lines, respectively, known to express MMP-2, MMP-
9, MMP-7 and MMP-14 etc, were used as a source of MMPs. The affinity 
chromatography was performed following standard protocol using 0.3M and 
2M NaCl buffers (Okada et al., 1990; Okada et al., 1986) and with the 
variation in the composition of elution buffers. Once chromatography 
fractions were generated, a series of experiments were performed which will 
be explained in detail in this chapter. Briefly, presence of purified proteins 
was confirmed by performing SDS-PAGE and staining either with Coomassie 
blue or silver stain to get a better visual. The recovery of MMP-2, as a 
representative of MMPs, from H-7G-Sepharose chromatography beads was 
measured by ELISA. The results were validated by western blotting as well. 
Finally tandem mass spectrometry was performed on selected 
chromatography fractions to identify MMPs. 
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6.1.1 Aims 
The specific goals could be summarized as: 
• The first aim of this chapter was maintaining a continuous source of 
MMPs so selected immortalized HT1080 and HT29 cell lines were 
cultured to create culture supernatants and cell extracts for 
chromatography method development and additional material for 
supplementary tests such as MMP-2 ELISA assays and western 
blotting to corroborate results. It was aimed to avoid the known 
problems caused by proteins present in the foetal calf serum (FCS) 
added to the growing cells, it was decided to replace serum-containing 
culture supernatant (S+CS) with serum-free RPMI-1640 media and 
allowed the cells to grow for 48hours so that enough MMPs could be 
secreted into the culture supernatant. This serum-free culture 
supernatant (SFCS) was used for subsequent experiments. Cell 
lysates were prepared extracting MMPs in three sequential steps 
using salt (NaCl) containing buffers, dimethyl sulphoxide (DMSO) 
containing buffers and urea containing buffers as described by (Davis 
et al., 1998). Salt and DMSO remove matrix bound MMPs and urea 
removes soluble MMPs. 
• FCS was trypsinized and subjected to LC-MS/MS for identifying 
proteins present in it. 
• A major issue that tumour biopsies are available in small amounts was 
kept in mind while optimizing various methods. Hence, SFCS in small 
volumes such as 50mL in comparison to larger volumes (250-500mL) 
in previous studies (Okada et al., 1992; Okada et al., 1990) and cell 
lysates from 7x106 cells, which possibly expressed MMPs in 
nanogram amounts, were applied to H-7G-Sepharose 
chromatography beads. The idea was to use affinity chromatography 
(H-7G-Sepharose beads) as enrichment means as well as specifically 
elute MMPs in sufficient amounts that beside potential losses at 
144 
subsequent sample preparations, nHPLC fractionation should still 
enable detection and identification of each MMP in amounts close to 
the limit of detection of MALDI mass spectrometer. Chromatography 
optimization included variation in salt concentration (0.3-5M NaCl) and 
addition or exclusion of inhibitors such as EDTA. Additional 
optimization included handling of chromatographic fractions to enable 
compatibility with MALDI-MS analyses, such as concentrating, 
desalting (NAP-5 GPC columns, Isolute RP C18 columns and 
proteolysis (trypsin, lysine and elastase) methods.
• HT1080 cell lysate analyses using all above methods to compare their 
MMP profile with that of culture supernatant. 
In conclusion this chapter aims to demonstrate the application of H-7G-
Sepharose chromatography with biological samples in amounts that will 
emulate the limited amounts of materials expected from tumour biopsy 
collection. Consequently tumour cell lines previously reported to express high 
levels of MMPs were examined. 
6.2 Materials and Methods 
6.2.1 Preparation of Foetal Calf Serum (FCS) for LC-MS/MS 
Heat inactivated FCS (4mg/μL) was desalted through NAP-5 column and 
lyophilized at 37°C in evaporator. To lyophilized protein, 20μL of 8M urea 
was added, vortexed and spun for 1minute. 5μL of 50mM DTT was added 
and heated for 20minutes at 80°C. After bringing it to room temperature, 5μL 
of 100mM IAC was added, centrifuged at 14000g for 1minute and left in dark 
for the reaction completion. A 1mg/μL trypsin solution was added after 
diluting the contents with HPLC grade water to bring down the urea 
concentration to 2M. An overnight incubation in water bath at 37°C was set 
up to complete the digestion. The peptide solution was desalted with C18 
columns and lyophilized 37°C. The lyophilized peptides were resuspended in 
10% CH3CN and a 25μg equivalent of protein digest was run through nHPLC 
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as described in Materials and Methods section 2.12.1. An automated MALDI-
MS/MS (Materials and Methods section 2.12) was followed to detect the 
proteins present in serum. 
6.2.2 Preparation of Culture Supernatants (Serum+ and Serum-free) 
The collected HT1080 and HT29 culture supernatants S+CS and SFCS 
(Materials and Methods section 2.3.3) were desalted using NAP-5 columns at 
4°C to ensure minimal protein degradation and lyophilized at 37ºC. Work 
following this was carried out as quickly as possible in sterile conditions to 
avoid keratin contamination. 
6.2.3 Specific variations in Olive H-7G Chromatography applied for 
Culture Supernatants 
The standard protocol using salt containing buffers (0.3M and 2M NaCl) was 
followed for the isolation of MMPs from HT1080 and HT29 culture 
supernatants as described in Material and Methods section 2.4. However, 
following modifications in elution buffers were applied to achieve specific 
elution of MMPs. 
6.2.3.1 EDTA Elution 
After washing the equilibrated beads {50mM Tris-HCl (pH 7.5); 0.15M NaCl; 
5mM CaCl2 and 0.02% (w/v) sodium azide} elution was performed mixing the 
beads in 1mL of 10mM EDTA solution {50mM Tris-HCl (pH 7.5); 0.15M NaCl; 
10mM EDTA; 5mM CaCl2 and 0.02% (w/v) sodium azide} for 1-2minutes and 
centrifuged at 4°C for 5minutes and collected supernatant termed E1a. This 
was repeated to collect E1b and E1c followed by washing (2-times) the 
beads with 10mL of same elution buffer and discarded the supernatant. A 
further elution was performed using 100mM EDTA {50mM Tris-HCl (pH 7.5); 
0.15M NaCl; 100mM EDTA; 5mM CaCl2 and 0.02% (w/v) sodium azide} and 
eluates E2a-c collected. The beads were stored in 0.02% sodium azide 
solution after washing in elution buffer and discarded the supernatants. The 
fractions were desalted and concentrated using NAP-5 columns and 10mM 
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NH4HCO3 + 20μM EDTA was used to avoid autolytic degradation of MMPs 
during the process. After concentration each of the fractions were lyophilized 
at 37°C in evaporator. The trypsin-digested samples prepared (Materials and 
Methods section 2.9.1) using amounts shown in Table 6.1 were pooled 
during the process so as that E2c was kept separate because of high salt 
and to assure the protein resuspension. The peptide solution was then 
desalted using C18 columns and lyophilized at 37ºC in evaporator.  
Table 6.1 Trypsin digestion for EDTA eluates. 
6.2.3.2 Salt + EDTA Elution 
Following washing the equilibrated beads, elution was performed incubating 
them in elution buffer containing 50mM Tris-HCl (pH 7.5); 0.15M NaCl; 5mM 
EDTA; 5mM EGTA; 1μM ZnCl2; 0.5mM CaCl2 and 0.02% (w/v) sodium azide. 
The supernatant E1a was collected after centrifugation at 4°C for 5minutes. 
This was repeated twice to collect E1b and E1c. A further elution was 
performed in elution buffer containing high salt concentration (0.3M, 2M or 
5M as opposed to 0.15M). This was repeated three times and the flow-
throughs termed E2a-c, E3a-c, and E4a-c. The beads were then washed 
twice with a further 10mL of elution buffer and the resultant flow-through 
discarded. The fractions E1a-c, E2a-c, E3a-c and E4a-c were pooled and 
labeled as E1, E2, E3 and E4, respectively. While desalting the fractions 
using NAP-5 columns, 10mM NH4HCO3 + 20μM EDTA was used to avoid 
Samples 
        8M Urea        50mM DTT 100mM IAC    HPLC H2O       Trypsin 
SM             (Lyophilized) 20 μL             2 μL      2μL           112μL         5μL 
FT             (Lyophilized) 30 μL             3 μL      3μL             84μL         5μL 
SFCS E1a+b+c (Lyophilized) 30 μL             3 μL      3 μL             84μL         5μL 
SFCS E2a+b (Lyophilized) 40 μL             4 μL      4 μL            112μL         5μL 
SFCS E2c  (Lyophilized) 20 μL             2 μL      2μL            112μL         5μL
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autolytic degradation of MMPs during the process. After lyophlization at 37ºC 
each fraction was resuspended in 20μL of HPLC grade water for further 
analyses. 
6.2.4 Protein Extraction from Cells 
6.2.4.1 Method I 
The resulting cell pellet (HT1080 grown in serum-free medium) prepared as 
described in Materials and Methods section 2.3 was incubated in lysis buffer 
containing 50mM Tris-HCl (pH 7.5); 150mM NaCl; 10mM CaCl2; 0.02% (w/v) 
NaN3; 0.05% (v/v) Brij-35; 2mM PMSF for 10minutes at room temperature 
with vortexing to homogenize the sample. The cell homogenate was 
centrifuged at 12000g for 10minutes and the resultant supernatant containing 
the soluble MMPs collected (termed extract SE). The cell pellet was then 
incubated in lysis buffer containing 2% (v/v) DMSO for 10minutes, 
centrifuged at 12000g and the supernatant containing matrix- and 
membrane-bound MMPs (termed extract DE). The cell pellet was then further 
incubated in lysis buffer containing 10M urea for 10minutes, centrifuged at 
12000g, and the supernatant containing the remaining MMPs collected 
(termed extract UE). The subsequent cell pellet was then stored at -20°C 
until further analyses. 
6.2.4.2 Method II 
The HT1080 cell pellet (grown in serum-free medium) prepared as described 
in Materials and Methods section 2.3 was incubated in lysis buffer containing 
50mM Tris-HCl (pH 7.5); 150mM NaCl; 2% (v/v) DMSO; 10M urea; 10mM 
CaCl2; 0.02% (w/v) NaN3; 0.05% (v/v) Brij-35; 2mM PMSF for 10minutes at 
room temperature with vortexing to homogenize the sample. The cell 
homogenate was centrifuged at 12000g for 10minutes and the resultant 
supernatant collected. The cell pellet was then incubated in above lysis buffer 
for 10minutes, centrifuged at 12000g and the supernatant. The step was 
repeated one more time to ensure extraction of soluble and matrix MMPs and 
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collected supernatants pooled. The subsequent cell pellet was then stored at 
-20°C until further analyses. 
6.2.5 Olive H-7G Chromatography of Cell Extracts 
The proteins were purified from HT1080 cell extracts using 0.3M and 2M 
NaCl buffers without Brij-5 as described in Materials and Methods section 2.4 
and 2.4.1. 
6.3 Results 
6.3.1 In vitro Models 
In order to ensure that cells were harvested during their exponential growth 
phase, growth patterns were studied. Growth curves and a summary of 
growth characteristics of the HT1080 fibrosarcoma cell line and colon cancer 
cell line HT29 used in this study is presented in Figure 6.1. The HT1080 cells 
entered log phase of growth at day 2 with a lag phase of 1 day. The doubling 
time for the cells in log phase growth was calculated as 8.6hours. Following 4 
days of growth, cells entered a plateau phase of growth. Growth rates varied 
between two cell lines as demonstrated by their doubling times. Although 
HT29 entered log phase at day 2 the number of cells was lower than that of 
HT1080 suggesting HT29 has a slower growth rate. From these data the 
optimum time of harvesting for both cell lines was identified. 
6.3.2 LC-MS/MS of Foetal Calf Serum (FCS) 
FCS generated 36 proteins (n=2) from automated LC-MALDI with search 
parameters (Taxonomy: Mammals, Partials: 2, MS/MS tolerance: 100ppm). 
The protein list from one of the repeats is shown in Appendix 7. These 
proteins will be deducted from the results obtained from various fraction 
produced from cell line culture supernatants assuming that trace amounts of 
serum left in the culture supernatant might have contributed towards the 
identification of the bovine proteins. Serum albumin (Accession No.: 
ALBU_BOVIN; Mass: 69.25) was observed with a Mascot score of 1654 
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(n=2). The number of peptides contributed towards the identification was 34 
(n=2). The sequence of the peptides collectively identifying bovine serum 
albumin is shown in Appendix 8. These sequences will be 
matched/compared with peptides of MMPs identified in later experiments to 
find the sequence of competing parts of the two proteins to bind to Olive H-
7G. The peptides highlighted in yellow were different in two separate LC-
MALDI runs. The peptide RHPEYAVSVLLR in FCS (Repeat 1) appearing 3-
times is because of the reason that it is detected on 3 different positions on 
target plate (J16, F1 and F8). The MH+ of the peptide is the same (1439.81) 
but individual ion scores (38.55, 79.2 and 74.5) are different. 
6.3.3 HT1080 and HT29- S+CS vs. SFCS 
6.3.3.1 Protein Quantification 
Prior to isolating MMPs using H-7G-Sepharose chromatography beads and 
detecting with mass spectrometry, it was necessary to confirm the suitability 
of HT1080 and HT29 cell lines for the production of MMPs. Accurate and 
reproducible determination of protein concentration is a central requirement 
for proteomic analysis. HT1080 and HT29 cell lines were cultured and S+CS, 
SFCS (from HT1080 and HT29) and cell lysates (from HT1080 in serum-free 
media) were obtained as described in Materials and Methods sections 2.3 
and 6.2.4, respectively. In order to determine the protein concentrations of 
test samples it was necessary to standardize sample dilution at 20-fold, to 
remove inaccuracies of the assay caused by high salt concentrations or 
detergents. Initially, protein concentrations were below the level of detection 
of the assay (62.5μg/mL), therefore it was necessary to concentrate the 
samples after desalting using NAP-5 columns. Following NAP-5 column 
enrichment, samples were then within the accurate range of the assay and 
concentrations could be calculated by interpolation of the standard curves. 
The gene expression studies on HT1080 and HT29 cell lines and their 
xenografts were determined using RT-PCR (by a colleague, Jennifer 
Atkinson at ICT) and they exhibited expression of a number of MMPs at 
different levels from low to very high (Figure 6.2). To confirm this data the 
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amounts of proteins in HT1080 and HT29 culture supernatants (50mL for 
each) and lysates (from 6million HT1080 cells) were determined by Bradford 
assay (Materials and Methods section 2.6; standard curve Figure 2.3) and 
results are shown in Table 6.2 and Table 6.3. Serum-containing culture 
supernatants contained a total of 64.43mg (±0.51mg) in a total volume of 
50mL (n=3), whereas serum-free supernatants contained a total of 41.29mg 
(±1.64mg) in a total volume of 50mL (n=9). The amount of protein was much 
higher than expected which may be due to serum carry over. A strong 
albumin band (66kDa) in Coomassie blue-stained SDS-PAGE gels confirms 
this (Figure 6.6). 
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(A) 
(B) 
Figure 6.1 Tumour cell line growth curves. 
HT1080 (A) and HT29 (B) cells growth curves. Cells were plated on day 0 at 
1x103 cells per flask. At daily intervals, a flask of cells was trypsinized and 
the total number of cells calculated. 
Data representative of the mean ±SD of 3 independent experiments. 
0.10
1.00
10.00
100.00
0 2 4 6
Ce
ll N
um
be
r (
10
4 )
Time (Days)
0.10
1.00
10.00
100.00
0 2 4 6
Ce
ll N
um
be
r (
10
4 )
Time (Days)
152 
6.3.3.2 MMP-2 Production by HT1080 and HT29 Cell Lines 
To confirm gene expression data the secreted and extracted MMP-2 
amounts in the culture supernatants (S+CS, SFCS) and lysates (SE, DE and 
UE) were determined by ELISA assay (Materials and Methods section 2.7). 
The presence of MMP-2 in these samples was used as an indicator of the 
presence of a wide range of MMPs in HT1080 and HT29 cell lines. The 
standard curves for the assay were highly reproducible (n=25) showing linear 
correlation between amounts of standards and absorbance in the range 0.78-
50ng/mL (Standard curve Figure 2.4). Preliminary analyses of culture 
supernatants indicated that the MMP-2 amounts were below the level of 
detection. Using NAP-5 columns to desalt and concentrate the samples, it 
was possible to measure the MMP-2 activity within the calibration range. The 
eluates from NAP-5 columns were lyophilized and then resuspended in 
minimum possible diluent (50μL of RD5-32 diluent). Another desalting 
device, Slide-A-Lyzer Dialysis Cassettes, was used to see if it is a better 
approach to enrich proteins. But it diluted the samples instead since it 
involves an overnight immersion of dialysis cassettes in dialysis buffer 
(Appendix 1). So, it was decided to desalt chromatography fractions using 
NAP-5 columns. Results for secreted and extracted MMP-2 are shown in 
Table 6.2 and Table 6.3, respectively. Interestingly, cell lysates (SE, DE and 
UE) showed MMP-2 activity which reflects the successful extraction of 
cellular MMPs. This is encouraging for profiling cellular MMPs. As predicted 
by gene expression data (Figure 6.2), MMP-2 was not detected in HT29 
culture supernatants because the cell line is negative for the expression of 
the enzyme. 
6.3.3.3 Protein Separation (SDS-PAGE)  
Using Coomassie detection and silver staining, proteins were detectable in all 
serum-containing and serum-free culture supernatants of HT1080 (Figure 
6.6) and HT29. No bands corresponding to pro-MMP-2 were detectable 
because possibly presence of albumin band corresponding to 66kDa hides 
the expression of closely resolved proteins. Although, NAP-5 concentrated 
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samples were loaded still MMPs amounts could be less than the detection 
limits for the stains in use. 
6.3.3.4 Western Blotting of MMP-2 
Analysis of gels in parallel to staining, using immuno-blotting were 
undertaken to determine the presence of MMP-2 in starting material (S+CS 
and SFCS). In order to determine whether MMP-2 was absent from these 
media, 30μg of protein was loaded on gels after being concentrated by NAP-
5 columns. Immuno-blotting of these samples (SM) resulted in no 
identification of a band corresponding to molecular weight of 72kDa both in 
serum-containing and serum-free culture supernatants (Figure 6.8). MMP-2 
could be present in amounts less than the detection limit of anti-MMP-2 
antibody which was determined to be 0.3μg/mL. Immuno-blotting of HT29 
culture supernatants using anti-MMP-2 antibody was not performed since it 
does not express MMP-2. 
6.3.3.5 MALDI-MS 
Based on the presence of proteins as shown by SDS-PAGE gels (some 
shown) and concentration found in ELISA (Table 6.2 and Table 6.3), S+CS, 
SFCS, SE, DE, UE (used as starting materials to apply on the H-7G-
Sepharose chromatography beads) were analyzed manually by MALDI-MS. 
The S+CS showed very high expression of peptides as shown in Figure 6.3 
which could be explained by the contribution of proteins from the FCS added 
to the media for cell culturing. Since the mass spectra were complicated with 
the serum present hence for the following experiments serum-free culture 
supernatants were used as a starting material hoping that the peptides, even 
though with lower intensity as compared to S+CS, are from the proteins 
secreted by the HT1080 cells into the media. Many of these mass peaks 
were found to be specific to proteins such as TIMPs, MMPs, kellikerin-6 etc. 
This was confirmed when these proteins were identified in SFCS subjected to 
automated analyses. A similar mass peak profile for the manual MALDI-MS 
of HT29 SFCS showed two signals (m/z 1156.29 and 1639.59) specific to 
MMP-7 as identified in rhMMP-7 (Appendix 5) with mass error of 0.17 and -
154 
0.1, respectively. Mass spectra of cell extracts, SE, DE and UE, were gained 
from manual MALDI-MS analyses (Materials and Methods section.2.11) but 
specific peaks to MMPs could not be found.  However, amounts of protein 
and MMP-2 in SE, DE and UE (Table 6.3) suggest that cell lysate extraction 
(method I) was successful but MALDI-MS methods need to be optimized to 
gain a better mass peak profile. 
6.3.3.6 LC-MS/MS 
To avoid proteins from FCS, HT1080 SFCS were selected as a starting 
material to apply on the H-7G-Sepharose chromatography beads. A sample 
was selected for LC-MS/MS in which 431ng/50mL of MMP-2 was detected by 
ELISA. However, among 69 proteins identified, only TIMP-1 (Mascot: score 
112, No. of peptides: 5) and TIMP-2 (Mascot score: 86, No. of peptides: 1) 
were detected. In the following experiments, TIMP-1 and TIMP-2 were 
identified in HT1080 SFCS with significant Mascot scores. It was anticipated 
that enrichment through chromatography (reported later in this chapter) will 
bring the concentration of MMPs up to be compatible with LC-MS/MS. Since 
HT29 expresses MMP-7 in very high amounts, the MMP-7 (Mascot score: 
126, No. of peptides: 8) was identified in HT29 SFCS by LC-MS/MS. Among 
124 proteins, TIMP-1 was detected Mascot score 30 (No. of peptide: 2) which 
is border line significant. Although other proteins were also being identified, 
the detection of TIMP-2 and MMP-7 gave a confidence that as low volume as 
50mL of the culture supernatant from the selected cell lines could be used 
and LC-MALDI methods could be optimized for screening the MMP 
enrichment capability of H-7G-Sepharose chromatography beads. 
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Table 6.2 MMP-2 production by HT1080 and HT29 culture 
supernatants. 
S+CS: Serum-containing culture supernatant; SFCS: Serum-free 
culture supernatant; ND: Not detected. 
Table 6.3 MMP-2 production by HT1080 cell lysates. 
SE: Salt extract; DE: DMSO extract; UE: Urea extract. 
(50mL) Mean SD  Mean SD
S+CS 64.43 (n=3) 0.51 3447.33 (n=3) 1339.73
SFCS 41.29 (n=9) 1.64 196.38   (n=9) 165.89
HT29 SFCS 43.35 (n=2) 1.05 ND ND
Cell Line
HT1080 
MMP-2 Amount (ELISA )
(ng)
Protein Amount (Bradford Assay)
(mg)
Sample
6x106 Mean (n=3) SD  Mean (n=3) SD
SE 1.95 1.16 21.31 16.81
DE 0.56 0.97 3.80 0.72
UE 2.73 2.4 16.19 15.32
Sample
HT1080 
Cell Line
Protein Amount (Bradford Assay) MMP-2 Amount (ELISA )
(mg) (ng)
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Figure 6.3 MALDI mass spectra of HT1080 S+CS and SFCS. 
Figure 6.4 MALDI mass spectra of HT1080 cell lysates (SFCS).
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6.3.4 Olive H-7G Chromatography- HT1080 S+CS vs. SFCS (Salt 
Elution) 
6.3.4.1 Protein Quantification 
In case of SFCS, due to the selective nature of binding by dye 
chromatography, most of the protein was in the flow-through. Proteins were 
detected in fractions eluted with various Brij-35 free elution buffers (0.3M and 
2M NaCl). In each case most protein was eluted with the initial addition of 
salt (E1a and E2a), decreasing with each elution. Therefore, three volumes 
of eluate were sufficient to remove proteins at each salt concentration. The 
results of a representative H-7G-Sepharose chromatography are shown in 
Table 6.4. Some serum proteins were still present even after replacing 
serum-containing media and allowing cells to grow in serum-free conditions. 
Despite the selectivity of the Olive H-7G, the complex nature of serum means 
that some serum proteins may also compete with MMPs for binding sites and 
therefore limit the effectiveness of the chromatography. Protein yields could 
not be calculated in H-7G-Sepharose chromatography fractions since starting 
material SFCS has lower amount of protein (40.11mg) than determined in 
combined H-7G-Sepharose chromatography fractions. This could be 
because of handling error or starting material was too diluted. 
6.3.4.2 MMP-2 Quantification (%age yield by H-7G-Sepharose Beads)  
The concentration of the secreted MMP-2 in SM (HT1080 SFCS) and in H-
7G-Sepharose chromatography fractions were determined using an ELISA 
based quantification kit to assure the reproducibility of chromatography. The 
standard curves for four chromatography experiments to confirm the 
reproducibility (n=4) showed linear correlation between amounts of standards 
and absorbance in the range 0.78-50ng/mL. The recovery of MMP-2 
determined by ELISA in SFCS eluates by H-7G-Sepharose chromatography 
beads is 14.47% (Table 6.5). The data shown was generated by performing 
four independent experiments with fresh stock of HT1080 SFCS. As shown, 
most of the MMP-2 activity is being lost in wash flow-throughs and eluates 
159 
(E1a-c and E2a-c) but some is still bound to the H-7G-Sepharose 
chromatography beads. The yield is 14.47% if calculated by combining all the 
lost MMP-2 in wash flow-throughs and beads. This very low yield could 
possibly be because of the over-loading of ligand Olive H-7G with MMP-2 as 
there will be specific number of sites available for binding. Another reason 
might be that MMP-2 was degrading during extensive steps of washings. 
Table 6.4 Protein amounts in HT1080 SFCS and H-7G-Sepharose 
chromatography fractions (Detergent-free elution buffers). 
6.3.4.3 Protein Separation (SDS-PAGE) 
SDS-PAGE and immuno-blotting was performed as a second approach to 
detect proteins if present. The capture of proteins by H-7G-Sepharose 
chromatography beads was confirmed by Coomassie and silver staining 
(Figure 6.5). Although these beads had been treated with elution buffers 
(0.3M and 2M NaCl), many proteins were still bound to the beads. In 
Coomassie detection of proteins in HT1080 cell culture media (in the 
presence and absence of serum) and in all fractions of chromatography 
performed using detergent-free elution buffers, many protein bands were 
detectable (Figure 6.6). It is clear that silver staining is more sensitive than 
Coomassie staining and better band visibility is attained. The presence of 
66kDa albumin in S+CS and its corresponding chromatography fraction 
Volume Protein Amount (Bradford Assay)
(mL) (mg) (n=1)
SM 50 40.11
FT 50 124.86
tϭĂ ϭ ϰ͘Ϭϭ
ϭĂ ϭ ϮϬ͘ϮϮ
ϭď ϭ Ϯ͘ϲϮ
ϭĐ ϭ E
ϮĂ ϭ ϯ͘Ϭϯ
Ϯď ϭ Ϯ͘ϯϳ
ϮĐ ϭ E
ĞĂĚƐ ϭ ϭ͘ϬϮ
HT1080 SFCS
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masks the presence of other proteins in the similar mass range. Hence the 
use of serum was omitted in the following experiments and SFCS eluates did 
not show any sign of albumin as shown. This is not clear whether albumin 
binds to the Olive H-7G or leeching off the beads. No bands corresponding to 
MMP-2 were detectable in HT1080 cell culture media and in all fractions of 
chromatography performed using detergent-free elution buffers. 
Table 6.5 MMP-2 amounts in HT1080 SFCS to show yield in H-7G-
Sepharose chromatography. 
6.3.4.4 Western blotting of MMP-2 
Immuno-blotting was performed to determine the presence of MMP-2 in 
starting material (S+CS and SFCS) and the fractions in which this protein is 
eluted. Protein (30μg) was loaded on gels after being concentrated by NAP-5 
columns. Immuno-blotting of these samples resulted in the identification of a 
band corresponding to an approximate molecular weight of 72kDa in H-7G-
Sepharose chromatography beads treated with S+CS after the 0.3M and 2M 
salt elution (Figure 6.7). The H-7G-Sepharose beads treated with SFCS did 
not show MMP-2 either due to elution of all the MMP-2 off the beads or very 
small amounts in SFCS to begin with. The success of H-7G-Sepharose 
chromatography is revealed by the immuno-blotting of MMP-2 that although 
levels in SFCS are below detection in the starting material or on beads, 
 Mean (n=4) SD Mean (n=4) SD Mean (n=4) SD
SM 8377.70 711.70
FT 234.88 1.84 2.80 0.26
W1a 44.80 5.61 0.53 0.79
W1b 33.84 4.18 0.40 0.59
E1a 26.60 53.19 0.32 7.47
E1b 229.32 2.04 2.74 0.29
E1c 209.09 11.77 2.50 1.65
E2a 252.37 25.61 3.01 3.60
E2b 131.93 14.23 1.57 2.00
E2c 34.30 18.97 0.41 2.67
Beads 15.27 9.40 0.18 1.32
0.26
MMP-2 Amounts (ELISA )
(ng)HT1080 SFCS Individual Fractions
%age Yield %age Yield
Total
14.47
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elution with salt (0.3M) concentrated MMP-2 and demonstrated a band of the 
correct mass in eluates E1a and E1b (Figure 6.8). The SM however did not 
show any band. This suggests that chromatography concentrated the eluates 
while SM was too dilute hence not enough MMP-2 to be detected by the anti-
MMP-2 antibody which requires at least 0.3μg/mL MMP-2. 
6.3.4.5 MALDI-MS 
As mentioned earlier, based on the peak pattern in mass spectrum from 
S+CS and presence of more albumin shown by gels, it was decided to 
analyze SFCS only for LC-MS/MS analyses. Initial experiments were 
performed using Brij-35 in elution buffers because it helps break the affinity 
between the proteins and the dye as reported in literature (Imai and Okada, 
2008). But the mass peaks from the detergent were interfering with the data 
analysis (Figure 6.9). For removing detergent, samples were diluted 10-fold 
before desalting still there was detergent left to interfere with the specific 
pattern of peaks in spectra. The detergent could not be removed even after 
desalting sample dilutions twice, first using 1mL C18 columns and then using 
C18 zip tips to desalt when spotting sample on target plate for manual 
MALDI-MS analysis. Since presence of Brij-35 in elution buffers was causing 
problems in acquisition of specific mass spectra, it was decided to omit its 
use. Although literature supports the use of this detergent for the elution of 
MMPs off the ligand (Imai and Okada, 2008) yet we performed 
chromatography successfully using elution buffers without any detergent. To 
avoid any traces of detergents from distilled water, all buffers were prepared 
in HPLC grade water. The H-7G-Sepharose chromatography fractions and 
beads obtained were trypsinized as described in Materials and Methods 
section 2.9 and analyzed by manual MALDI-MS after desalting using C18 
columns to see if there are any peaks showing presence of peptides. Based 
on the detection of peak pattern specific to peptides, the fractions were 
selected for LC-MS/MS analyses. 
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Figure 6.5 SDS-PAGE to show capture of proteins by H-7G-
Sepharose chromatography beads. 
Figure 6.6 Staining of S+CS and SFCS H-7G-Sepharose 
chromatography fractions to show recovery of proteins. 
Control: Concentrated HT1080 serum-containing culture supernatant.
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Figure 6.7 Immuno-blotting to show MMP-2 capture by H-7G-Sepharose 
chromatography beads (after elution) from HT1080 S+CS and SFCS. 
rhMMP-2 (12.5ng/μL) was used as positive control. 
Figure 6.8 Immuno-blotting of HT1080 culture cupernatants and Olive H-
7G chromatography fractions. 
SM: Starting material, FT: Equilibration flow-through, W1a: Wash flow-
through, E1a: Eluate1a, E1b: Eluate1b, E2a: Eluate 2a, E2b: Eluate2b, B: 
Beads, MMP-2: Recombinant human MMP-2 (12.5ng/μL) used as positive 
control. 
72kDa
(pro-MMP-2)
HT1080 S+CS / Detergent-free HT1080 SFCS / Detergent-free
72kDa
(pro-MMP-2)
HT1080 S+CS / Detergent-free
72kDa
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0.3M NaCl 2M NaCl 0.3M NaCl 2M NaCl
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Figure 6.9 MALDI mass spectra of HT1080 eluate showing detergent 
peaks. 
6.3.4.6 LC-MS/MS 
The H-7G-Sepharose chromatography fraction from 2M NaCl (HT1080 SFCS 
E2a) was selected for LC-MS/MS because Coomassie stained gel and 
Bradford assay (1.25μg/mL) showed presence of proteins in the fraction. 
After the completion of MS/MS analysis, although a tissue inhibitor of 
metalloproteinases 1 (TIMP-1) was found; there was no MMP among 13 
proteins in the sample. The Mascot score for TIMP-1 was 41 and was 
identified with two signature peptides (Table 6.6). Malate dehydrogenase 
which has been reported to bind to triazine dyes was considered as an in-
house protein control assuming Olive H-7G bound to the protein and elution 
buffers reversed the affinity. The mitochondrial precursor of Malate 
dehydrogenase (MDHM) was identified with Mascot score 40 from 5 peptides 
in the same fraction. LC-MS/MS of the 2M NaCl eluate (HT1080 SFCS E2c) 
identified 57 proteins including tissue inhibitor of metalloproteinases 2 (TIMP-
2) with a Mascot score = 146 (No. of peptides: 7) and MMP-14, Mascot score 
= 50 (No. of peptides: 3). The MDHM was detected with Mascot score 287 
(No. of peptides: 13). Once subjected to LC-MS/MS analysis, 0.3M NaCl 
eluate (HT1080 SFCS E1a-c) identified 121 proteins including TIMP-1, TIMP-
2 and matrix metalloproteinase-14 precursor (MMP-14 or MT-1-MMP). The 
1397.7851116.589
1529.853
896.479
1573.881
852.456
1661.938
808.426
1749.976
0
500
1000
1500
2000
In
te
ns
. [
a.
u.
]
1000 1500 2000
2M Salt Eluate (1/10 dilution)
165 
sequence and amino acid range of the peptides identifying these proteins is 
shown in Table 6.6. The peptides for MMPs are from hemopexin-like 
domains within the protein structure which is a part of the active enzyme. 
MMP-2 was identified in 0.3M NaCl eluate with a Mascot score of 145 with 3 
peptides greater than threshold. 
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6.3.5 H-7G Chromatography of HT1080 SFCS (EDTA Elution) 
6.3.5.1 LC-MS/MS 
When EDTA was used, as an alternative to NaCl, to elute proteins bound to 
H-7G-Sepharose, TIMP-1 and TIMP-2 were detected in tandem mass 
spectrometry of the chromatography fractions (Table 6.7). Although ELISA 
indicated an MMP-2 concentration of 9.94ng/mL in the SM (HT1080 SFCS), 
proteomics analysis did not detect the enzyme (Table 6.7). The smaller 
number of proteins in SM and FT than in eluates shows that affinity 
chromatography is an enrichment method. Neither method detected MMP-2 
in the FT, 10mM (E1a-c) or 100mM EDTA eluates (E2a+b and E2c) as 
shown in Table 6.7. TIMP-1 and TIMP-2 were detected by proteomics 
analysis in the SM and eluted in E2, but not in the FT and E1. However, 17 
and 38 proteins were also detected along with TIMPs in 100mM EDTA 
sequential fractions E2a+b and E2c respectively, indicating elution was not 
specific. Moreover, the protein Malate dehydrogenase is eluting off in 100mM 
EDTA buffer. The list of the proteins (human) in all the eluate fractions from 
10mM and 100mM EDTA elution buffers is shown in Table 6.8. As 
anticipated, albumin was detected in all the eluates (highlighted blue in Table 
6.8). The green highlighted proteins are only coming off the chromatography 
beads with 100mM EDTA. Of these proteins, kellikerin-6 is a potential serum 
cancer biomarker. Galectin-3 is used in studies where tumours are resistant 
to chemotherapy. The un-highlighted proteins are specific to the EDTA 
concentration in which these are being identified. 
Table 6.7 Protein (BA) and MMP-2 amounts (ELISA) in EDTA eluates 
(10mM, 100mM) and LC-MS/MS results. 
ND: Note detected 
HT1080
SFCS
BA ELISA LC-MS/MS TIMP-1 TIMP-2
Protein
(mg/50mL)
MMP-2
(ng/50mL)
No. of Proteins Mascot Score Peptide # Mascot Score Peptide #
SM 41.3 497 17 112 5 86 1
FT ND ND 4 - - - -
10mM  E1a-c ND ND 15 - - - -
100mM  E2a+b ND ND 17 44 2 48 2
100mM  E2c ND ND 38 82 7 71 2
169 
Table 6.8 Proteins eluted in 10mM and 100mM EDTA. 
SM FT E1-c (10mM EDTA elution) E2a+b (100mM EDTA elution) E2c (100mM EDTA elution)
60S ribosomal protein L30 Non-histone chromosomal protein HMG-17 Serum albumin Keratin, type II cytoskeletal 1 Cystatin-C 
C-X-C motif chemokine 5 Serum albumin OS=Homo sapiens High mobility group protein B1 Serum albumin Kallikrein-6 
Cystatin-C High mobility group nucleosome-binding domain-containing protein 3 Keratin, type II cytoskeletal 1 Cystatin-C Serum albumin
Fibronectin Protein MON2 homolog OS=Homo sapiens Non-histone chromosomal protein HMG-17 Alpha-enolase Alpha-enolase 
Growth/differentiation factor 15 Keratin, type II cytoskeletal 2 epidermal Lactotransferrin 10 kDa heat shock protein, mitochondrial 
Histone H1.5 Angiogenin Kallikrein-6 Peptidyl-prolyl cis-trans isomerase A 
Histone H2A type 1-A High mobility group nucleosome-binding domain-containing protein 4 Metalloproteinase inhibitor 2 Stathmin 
Kallikrein-10 Insulin-like growth factor-binding protein 7 10 kDa heat shock protein, mitochondrial Metalloproteinase inhibitor 1
Keratin, type I cuticular Ha1 Keratin, type I cytoskeletal 9 Metalloproteinase inhibitor 1 Malate dehydrogenase, cytoplasmic 
Keratin, type I cuticular Ha3-II Cadherin-23 Protein disulfide-isomerase A3 Non-histone chromosomal protein HMG-17 
Proteasome subunit beta type-1 Amyloid beta A4 protein Methyl-CpG-binding protein 2 Metalloproteinase inhibitor 2
Pyruvate kinase isozymes M1/M2 Myotubularin-related protein 9 Phosphoglycerate kinase 1 Insulin-like growth factor-binding protein 2 
Serum albumin Roquin Galectin-3 Eukaryotic translation initiation factor 5A-1
Signal recognition particle 9 kDa protein Keratin, type I cytoskeletal 10 Fructose-bisphosphate aldolase A Lactotransferrin 
Small nuclear ribonucleoprotein Sm D3 Mesencephalic astrocyte-derived neurotrophic factor Cadherin-23 Polypyrimidine tract-binding protein 1 
Splicing factor, proline- and glutamine-rich Kininogen-1 Galectin-3 
Uncharacterized protein C10orf68 Peroxiredoxin-1 Keratin, type II cytoskeletal 1 
Protein disulfide-isomerase A3 
Inter-alpha-trypsin inhibitor heavy chain H2 
Malate dehydrogenase, mitochondrial 
Common between E1a-c and E2a+b Abhydrolase domain-containing protein 8 
Common between E2a+b and E2c Nucleosome-remodeling factor subunit BPTF 
Common among E1a-c, E2a+b and E2c Protein piccolo 
Filamin-A 
Alpha-fetoprotein 
Antithrombin-III 
Tetraspanin-14 
Transcription termination factor 2 
Fructose-bisphosphate aldolase A 
Sperm-associated antigen 1 
Methyl-CpG-binding protein 2
Vinculin
Kininogen-1 
Cadherin-23 
Glutathione S-transferase P 
Peroxiredoxin-1 
Heterogeneous nuclear ribonucleoprotein A1 
High mobility group nucleosome-binding domain-containing protein 3
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6.3.6 H-7G Chromatography of HT1080 SFCS (Salt + EDTA Elution) 
6.3.6.1 LC-MS/MS  
The higher number of proteins in eluate E1 (75) and E4 (82) suggest that 
neither a lower salt concentration of 0.15M nor a very high concentration of 
5M NaCl is optimum for binding of proteins to Olive H-7G (Table 6.9). On the 
other hand, 0.3M and 2M salt concentration elute proteins specifically as 16 
proteins were common in all the four eluates. The proteins shown in Table 
6.10 were identified in eluates E1, E2, E3 and E4 from 0.15M, 0.3M, 2M and 
5M NaCl buffers containing EDTA, respectively. These salt concentrations 
seem to help proteins to disengage from beads and go into solution. 
Although no MMPs were identified however, with increasing salt 
concentration in elution buffers, TIMPs were being identified with better 
Mascot scores (Table 6.9). 
Table 6.9 TIMP-1 and TIMP-2 Mascot scores in Salt + EDTA eluates. 
ND: Not detected 
HT1080
SFCS
BA ELISA LC-MS/MS TIMP-1 TIMP-2
Protein
(mg/50mL)
MMP-2
(ng/50mL) No. of Proteins Mascot Score Peptide # Mascot Score Peptide #
SM 39.14 164.04 19 - - 34 2
FT ND ND 12 - - - -
0.15 M NaCl E1 ND ND 75 - - 53 3
0.3 M NaCl E2 ND ND 47 56 4 95 2
2M NaCl E3 ND ND 41 58 3 106 5
5M NaCl E4 ND ND 82 185 4 193 6
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Table 6.10 Proteins eluted in Salt + EDTA elution buffers. 
SM FT E1 (0.15M NaCl elution) E2 (0.3M NaCl elution) E3 (2M NaCl elution) E4 (5M NaCl elution)
14-3-3 protein sigma Alpha-2-antiplasmin 10 kDa heat shock protein, mitochondrial 10 kDa heat shock protein, mitochondrial 10 kDa heat shock protein, mitochondrial
14-3-3 protein zeta/delta Alpha-2-HS-glycoprotein 5'-nucleotidase domain-containing protein 3 60S ribosomal protein L30 
Calsyntenin-1 Amyloid beta A4 protein 78 kDa glucose-regulated protein 78 kDa glucose-regulated protein 78 kDa glucose-regulated protein 78 kDa glucose-regulated protein 
DNA replication licensing factor MCM4 CASP8-associated protein 2 Actin, cytoplasmic 1 Actin, cytoplasmic 1 Actin, cytoplasmic 1 Actin, cytoplasmic 1 
Fibronectin CD44 antigen Agrin Alpha-enolase Amyloid beta A4 protein Activated RNA polymerase II transcriptional coactivator p15 
Galectin-3-binding protein Clusterin Alpha-enolase Amyloid beta A4 protein Annexin A2 Adenylate kinase 2, mitochondrial 
Heat shock 70 kDa protein 6 Cystatin-C Amyloid beta A4 protein Annexin A2 Antileukoproteinase Agrin 
Heat shock cognate 71 kDa protein Fibulin-1 Annexin A2 Anterior gradient protein 2 homolog Cadherin-1 Amyloid beta A4 protein 
Heat shock protein 75 kDa, mitochondrial Galectin-3-binding protein Antileukoproteinase Beta-2-syntrophin DNA-(apurinic or apyrimidinic site) lyase Angiogenin 
Heat shock protein HSP 90-alpha Heat shock cognate 71 kDa protein ATP synthase subunit alpha, mitochondrial Calreticulin Endoplasmic reticulum resident protein 29 Annexin A1 
Heat shock protein HSP 90-beta Hemoglobin subunit alpha Beta-enolase Chitinase-3-like protein 1 Ezrin Annexin A2 
Histone H4 Hemoglobin subunit beta Blood vessel epicardial substance Collagen alpha-2(IV) chain Fibroblast growth factor-binding protein 1 Antileukoproteinase
Metalloproteinase inhibitor 2 Histone H2A type 1-A Calmodulin DNA-(apurinic or apyrimidinic site) lyase Fibronectin Cadherin-1 
Neuralized-like protein 4 Inter-alpha-trypsin inhibitor heavy chain H2 Calreticulin EGF-containing fibulin-like extracellular matrix P1 Fructose-bisphosphate aldolase A Calreticulin
POTE ankyrin domain family member E Inter-alpha-trypsin inhibitor heavy chain H3 Calsyntenin-1 Elongation factor 1-alpha 1 Heat shock protein HSP 90-alpha Citrate synthase, mitochondrial 
Serum albumin Keratin, type II cytoskeletal 1 Chloride intracellular channel protein 1 Endoplasmin Heterogeneous nuclear ribonucleoprotein D0 Coproporphyrinogen-III oxidase, mitochondrial
SPARC Kininogen-1 Clusterin Ezrin Heterogeneous nuclear ribonucleoprotein G DNA-(apurinic or apyrimidinic site) lyase 
Tetraspanin-14 Lactotransferrin Coiled-coil domain-containing protein 157 Fibronectin Heterogeneous nuclear ribonucleoproteins A2/B1 Dystrophin-related protein 2 
Triosephosphate isomerase Liprin-alpha-3 Collagen alpha-2(IV) chain Galectin-3 Histone H2A type 1-A Endoplasmic reticulum resident protein 29 
Metalloproteinase inhibitor 1 Complement component 1 Q subcomponent-binding protein Glutaminyl-peptide cyclotransferase Histone H4 Extracellular matrix protein 1
Midasin DNA-(apurinic or apyrimidinic site) lyase Glutathione reductase, mitochondrial Insulin-like growth factor-binding protein 7 Ezrin 
Peroxiredoxin-1 EGF-containing fibulin-like extracellular matrix protein 1 Heat shock cognate 71 kDa protein Kallikrein-10 Fibroblast growth factor-binding protein 1 
POTE ankyrin domain family member E Elongation factor 1-alpha 1 Heat shock protein 75 kDa, mitochondrial L-lactate dehydrogenase A chain Fibronectin 
Common between E1 & E2 Probable 3-hydroxymethyl-3-methylglutaryl-CoA lyase 2 Elongation factor 1-alpha 2 Heat shock protein HSP 90-alpha L-lactate dehydrogenase B chain Filamin-A 
Common between E1 & E3 Protein MON2 homolog Elongation factor 2 Heterogeneous nuclear ribonucleoprotein A1 Malate dehydrogenase, cytoplasmic Fructose-bisphosphate aldolase A 
Common between E1 & E4 Protein piccolo Endoplasmin Histone H2A type 1-A Malate dehydrogenase, mitochondrial Galectin-3 
Common between E2 & E3 Protein TANC1 Fibronectin Histone H4 Metalloproteinase inhibitor 1 Gelsolin 
Common between E2 & E4 Putative beta-actin-like protein 3 Filamin-A Lamin-A/C Metalloproteinase inhibitor 2 Glucose-6-phosphate 1-dehydrogenase
Common between E3 & E4 Serum albumin Filamin-B L-lactate dehydrogenase A chain Nucleoside diphosphate kinase B GMP reductase 2 
Common among    E1, E2 & E3 SPARC Galectin-3 L-lactate dehydrogenase B chain Peptidyl-prolyl cis-trans isomerase B Growth/differentiation factor 15 
Common among    E1, E2 & E4 Sulfhydryl oxidase 1 Galectin-3-binding protein Malate dehydrogenase, cytoplasmic Peroxiredoxin-1 Heat shock cognate 71 kDa protein 
Common among    E1, E3 & E4 Thrombospondin-1 Gamma-glutamyl hydrolase Malate dehydrogenase, mitochondrial POTE ankyrin domain family member E Heat shock protein HSP 90-alpha
Common among    E2, E3 & E4 Triosephosphate isomerase Glucosidase 2 subunit beta Metalloproteinase inhibitor 1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 Heat shock protein HSP 90-beta 
Common among    E1, E2, E3, E4 Ubiquitin Glutaminyl-peptide cyclotransferase Metalloproteinase inhibitor 2 Protein disulfide-isomerase A3 Heterogeneous nuclear ribonucleoproteins A2/B1 
Vitamin D-binding protein Glutathione reductase, mitochondrial Neuropilin-1 Protein disulfide-isomerase A6 High mobility group protein B1 
Glyceraldehyde-3-phosphate dehydrogenase Nucleolin Putative heterogeneous nuclear ribonucleoprotein A1-like 3 Histone H2A
Glypican-1 Peptidyl-prolyl cis-trans isomerase B Quinone oxidoreductase Histone H4 
Heat shock 70 kDa protein 1A/1B Peroxiredoxin-1 Small nuclear ribonucleoprotein Sm D1 Insulin-like growth factor-binding protein 7
Heat shock cognate 71 kDa protein Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 Small nuclear ribonucleoprotein Sm D3 Kallikrein-10 
Heat shock protein 75 kDa, mitochondrial Protein disulfide-isomerase A3 Sulfhydryl oxidase 1 Kunitz-type protease inhibitor 1 
Heat shock protein HSP 90-alpha Protein disulfide-isomerase A4 Thioredoxin domain-containing protein 5 Lamin-A/C 
Heat shock protein HSP 90-beta Serum albumin Thrombospondin-1 L-lactate dehydrogenase A chain 
Histone H2A type 1-A Small nuclear ribonucleoprotein Sm D3 Voltage-dependent L-type calcium channel subunit b-2 L-lactate dehydrogenase B chain 
Histone H3-like Sulfhydryl oxidase 1 Malate dehydrogenase, cytoplasmic 
Histone H4 Suppressor of tumorigenicity 14 protein Malate dehydrogenase, mitochondrial 
Kallikrein-6 Suprabasin Mesencephalic astrocyte-derived neurotrophic factor 
Keratin, type II cytoskeletal 8 Thioredoxin-dependent peroxide reductase Metalloproteinase inhibitor 1
L-lactate dehydrogenase A chain Thrombospondin-1 Metalloproteinase inhibitor 2 
L-lactate dehydrogenase B chain Moesin 
Lysosome-associated membrane glycoprotein 2 Neutral alpha-glucosidase AB 
Malate dehydrogenase, cytoplasmic Non-histone chromosomal protein HMG-17 
Malate dehydrogenase, mitochondrial Nucleoside diphosphate kinase A 
Metalloproteinase inhibitor 2 Nucleoside diphosphate kinase B 
Moesin Nucleosome assembly protein 1-like 1 
Neutrophil gelatinase-associated lipocalin Peptidyl-prolyl cis-trans isomerase B 
Olfactory receptor 8J2 Peroxiredoxin-1 
Peptidyl-prolyl cis-trans isomerase A POTE ankyrin domain family member E 
Peptidyl-prolyl cis-trans isomerase B Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 
Proteasome subunit alpha type-1 Protein disulfide-isomerase A3 
Proteasome subunit alpha type-6 Protein disulfide-isomerase A4 
Protein disulfide-isomerase Protein disulfide-isomerase A6 
Protein disulfide-isomerase A3 Putative heterogeneous nuclear ribonucleoprotein A1-like 3 
Receptor-type tyrosine-protein phosphatase kappa Quinone oxidoreductase 
S-adenosylmethionine synthetase isoform type-2 Radixin 
Serine/threonine-protein kinase TAO3 Ras-GEF domain-containing family member 1A 
Serum albumin Rho GTPase-activating protein 30 
Stress-70 protein, mitochondrial Ribonuclease 4
Sulfhydryl oxidase 1 RNA-binding protein EWS 
Syndecan-1 Small nuclear ribonucleoprotein G-like protein 
Thioredoxin reductase 1, cytoplasmic Small nuclear ribonucleoprotein Sm D1 
Thrombospondin-1 Small nuclear ribonucleoprotein Sm D2 
Transforming growth factor-beta-induced protein ig-h3 Small nuclear ribonucleoprotein Sm D3 
Tubulin alpha-1A chai Small nuclear ribonucleoprotein-associated proteins B and B
Tyrosine-protein phosphatase non-receptor type 21 Splicing factor, arginine/serine-rich 1 
Ubiquitin Splicing factor, arginine/serine-rich 3 
Sulfhydryl oxidase 1 
Thioredoxin domain-containing protein 5 
Thrombospondin-1 
Transferrin receptor protein 1 
Transforming growth factor-beta-induced protein ig-h3 
Voltage-dependent L-type calcium channel subunit alpha-1F 
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6.3.7 H-7G Chromatography of HT1080 SF Cell Extract
6.3.7.1 Protein Quantification 
The HT1080 cell lysates (salt extract, DMSO extract and urea extract) 
prepared by method I as described in section 6.2.4.1 showed a significant 
protein yield. Lower protein amount in SE (1.95mg/mL) than in flow-through 
(2.6mg/mL) (Table 6.11) could be explained by the fact that binding of 
Bradford reagent and proteins is occurring only in chromatography fractions 
because chromatography beads might remove interfering components in 
original lysate. Urea extract showed maximum amount (2.73mg/mL) of 
proteins measured by Bradford assay (Table 6.13) and an 84.24% yield was 
achieved from combined fractions. 
6.3.7.2 MMP-2 Quantification 
The results for salt extract (prepared as Method I; section 6.2.4.1) and its 
corresponding chromatography fractions (Table 6.11) showed that most of 
the proteins were not binding to the beads and leaching off in equilibration 
flow-through and washes (4.43ng + 5.35ng respectively out of 21.31ng in salt 
extract). MMP-2 amounts were measured in salt extract fractions showing a 
59.17% yield when calculated by combining all the activities including flow-
through (or column washes). MMP-2 activities measured in DMSO extract 
(prepared as Method I; section 6.2.4.1) and H-7G-Sepharose 
chromatography beads (Table 6.12) showed same response as there was 
more enzyme in flow-through fractions (3.40ng + 4.18ng) than in the SM 
(3.80ng) as seen for SE (Table 6.11). MMP-2 amounts in urea extract 
(prepared as Method I; section 6.2.4.1) measured by ELISA (50.60% yield 
from combined fractions) are in accordance with the expected profile for 
chromatography where some proteins are lost in the washes (4.60ng + 
1.58ng), then eluted in elution buffers (0.85ng + 1.05ng) with no proteins left 
bound to the beads (0.12ng). 
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Table 6.11 Protein (BA) and MMP-2 (ELISA) amounts in HT1080 cells 
Salt Extract and H-7G-Sepharose chromatography fractions. 
Table 6.12 Protein (BA) and MMP-2 (ELISA) amounts in HT1080 cells 
DMSO Extract and H-7G-Sepharose chromatography fractions. 
Table 6.13 Protein (BA) and MMP-2 (ELISA) amounts in HT1080 cells 
Urea Extract and H-7G-Sepharose chromatography fractions. 
            MMP-2 Amount (ELISA)
Mean (n=3) SD Mean (n=3) SD
 SE 1.95 1.16 21.31 16.81
 SE Beads 0.00 0.00 1.28 1.34
 SE FT 2.60 2.25 4.43 4.68
 SE W 0.10 0.17 5.35 4.28
 SE 0.3M NaCl E 0.00 0.00 0.98 0.98
 SE 2M NaCl E 0.01 0.02 0.57 0.35
Sample (ng)
Protein Amount (Bradford Assay)
(mg)
           MMP-2 Amount (ELISA)
Mean (n=3) SD Mean (n=3) SD
 DE 0.56 0.97 3.80 0.72
 DE Beads 0.08 0.14 0.23 0.29
 DE FT 1.48 2.43 3.40 2.97
 DE W 1.57 1.36 4.18 0.83
 DE 0.3M NaCl E 0.26 0.45 0.94 0.62
 DE 2M NaCl E 0.23 0.39 0.94 0.73
Sample
Protein Amount (Bradford Assay)
(mg) (ng)
           MMP-2 Amount (ELISA)
Mean (n=3) SD Mean (n=3) SD
 UE 2.73 2.40 16.19 15.32
 UE Beads 0.00 0.00 0.12 0.20
 UE FT 0.00 0.00 4.60 4.68
 UE W 1.50 2.60 1.58 1.25
 UE 0.3M NaCl E 0.80 1.39 0.85 0.70
 UE 2M NaCl E 0.00 0.00 1.05 0.66
Sample
Protein Amount (Bradford Assay)
(mg) (ng)
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6.3.7.3 Protein Separation (SDS-PAGE) 
To isolate membrane bound MMPs, HT1080 cell lysis was performed and 
cell extracts were subjected to affinity chromatography. All the H-7G-
Sepharose chromatography fractions were analyzed by silver staining to 
identify presence of proteins and western blotting for MMP-2. As evident from 
silver stained gel (Figure 6.10A-F), beads (SE B and DE B) lost bound 
proteins after NAP-5 desalting (SE B NAP-5 and DE B NAP-5). This loss of 
proteins is also evident in case of urea extract (UE B vs. UE B NAP-5). 
These stained gels showed that cell lysis occurred since there are many 
proteins in starting cell extracts (SE panel A, DE panel B and UE panel C) 
but most of proteins did not bind to the beads and went into the flow-through 
fractions (SE/DE/UE FT). 
6.3.7.4 Western Blotting of MMP-2 
Once bands were developed and identified in western blotting for culture 
supernatants, MMP-2 expression in HT1080 cell lysates (prepared as 
Method I; section 6.2.4.1) and corresponding chromatography fractions were 
analyzed (Figure 6.10G-I). The results obtained in this case showed that 
MMP-2 expression in supernatants is more than observed in cell lysates. The 
western blots showed interesting results as DMSO starting material and 
chromatography fractions showed a band near 72kDa molecular weight 
showing the presence of MMP-2. A distinct band visible in blots where 
standard rh-MMP-2 (12.5ng/μL) was loaded, indicates that antibody to MMP-
2 was specific and conditions for western blotting allowed proper binding of 
antibody to proteins. Salt extracts and urea extract however only showed 
bands of 35kDa in starting material and flow-through (Figure 6.10G and I). 
Immuno-bloting of cell lysates prepared by Method II (section 6.2.4.2) did not 
show MMP-2 specific bands (results not shown). 
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6.3.7.5 MALDI-MS 
Mass spectra of salt extract, DMSO or urea extracts or H-7G-Sepharose 
chromatography fractions with or without C18 (zip tip or Isolute columns) 
clean-up, no peptide were detected following trypsin digestion. However, the 
cell lysates prepared by Method II (section 6.2.4.2) showed mass signals in 
the MALDI mass spectra with some peaks specific to proteins. Based on 
these mass spectra, fractions were selected for LC-MS/MS. 
6.3.7.6 LC-MS/MS 
The number of proteins identified by LC-MS/MS of cell extracts and 
corresponding chromatography fractions was from 155-294 but none of the 
MMPs or TIMPs was detected suggesting the method of preparation of these 
fractions need to be optimized. There were some MMP related peaks in the 
MS/MS data but the Mascot score for the peptides were not high enough to 
identify any MMPs. 
Table 6.14 Protein (BA) and MMP-2 (ELISA) amounts in cell lysates 
(Method II) and Olive H-7G chromatography fractions and LC-MS/MS 
results. 
6.3.8 Olive H-7G Chromatography of HT29 SFCS (Salt Elution) 
The serum-free culture supernatants (50mL) from HT29 cell line were treated 
with H-7G-Sepharose chromatography beads to isolate MMP-7 and MMP-14 
which have been reported to be expressed by the cell line. For elution of 
HT1080
Cell Lysate
(Method II)
Protein Amount (Bradford Assay) MMP-2 Amount (ELISA) LC-MALDI-MS/MS
(mg) (ng)
Mean (n=2) SD Mean (n=2) SD No. of Proteins
SM 1.15 0.01 0.24 0.00 172
FT 0.59 0.00 0.31 0.00 -
0.3M NaCl E1 0.55 0.01 0.03 0.00 155
2M NaCl E2 0.57 0.00 0.03 0.00 164
Beads 0.57 0.01 ND - 294
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proteins, 0.3M and 2M NaCl buffers were used as described in Materials and 
Methods section 2.4. 
6.3.8.1 MMP-2 Quantification 
Since MMP-2 is not expressed by the cell line, hence ELISA for MMP-2 did 
not detect show any absorbance for the chromatography fractions. 
6.3.8.2 MALDI-MS 
The mass spectra of experiments performed using HT29 SFCS as a SM 
confirming successful trypsinization. The SFCS was also treated with 
sepharose as a negative control. The mass spectra for SM, 0.3M NaCl eluate 
(E1) and 2M NaCl eluate (E2) showed that eluates have more peaks 
common to SM when compared to the eluates from sepharose control. This 
quick manual MALDI-MS analysis gave evidence that ligand Olive H-7G 
bound to the sepharose was responsible for the concentration of peptides. 
Many of these peaks were showing m/z as found for rhMMP-7 and rhMMP-
14 (Chapter 4). None of the MMPs were identified by LC-MS/MS of 
chromatography fractions indicating lower amounts of MMPs. 
6.4 Discussion 
The aim of this chapter was to use H-7G-Sepharose chromatography beads 
to purify MMPs and detect their expression in cell line culture supernatants 
that have previously been shown to express MMPs. The ELISA assay 
employed to examine MMP activity in HT1080 the lung fibrosarcoma cell line 
utilized antibody coated to the surface of wells. A yield of MMP-2 (14.4% 
±0.26) was found and this low yield could possibly be because of the over-
loading of ligand Olive H-7G with MMP-2 as there will be specific number of 
sites available for binding. Another reason might be that MMP-2 was 
degrading during extensive steps of washings. The MMP-2 amounts detected 
by ELISA showed high standard deviation (SD) in some of the 
chromatography fractions. The high SD indicates that the data points are 
spread out over a large range of values. 
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Coomassie brilliant blue binds to proteins stoichiometrically and is therefore, 
a quantitative method for determination of differential protein expression. This 
method is quick, quantitative and convenient. Separated proteins being 
detected as blue bands on a clear background, can be simultaneously fixed 
and stained in the same solution. Although convenient, the major 
disadvantage of this method is less sensitivity as it needs 3μg of protein to be 
detected. A more sensitive method than Coomassie staining for protein 
detection is silver staining. This process relies on differential reduction of 
silver ions that are bound to the side chains of amino acids (Oakley et al., 
1980; Switzer et al., 1979). This method is 100-fold more sensitive to 
Coomassie staining (Merril et al., 1981). Although, this method can detect 
trace amounts of proteins from 0.1-1ng, it employs solutions which are light 
sensitive and do not work if left for a long time thus increasing the cost. 
Another disadvantage of this method is that some proteins cannot be stained 
with silver salts well stained with Coomassie brilliant blue (Merril et al., 1981). 
Examination of western blot data for HT1080 revealed varying expression 
levels in serum-containing and serum-free fractions as measured by primary 
anti-MMP-2 antibodies. The immune-blots of eluate fractions from 0.3M and 
2M NaCl buffers from both (S+CS and SFCS) showed 72kDa bands specific 
to MMP-2 (Figure 6.8). However, no bands could be detected in starting 
material and corresponding chromatography flow-through fractions 
suggesting that level of MMP-2 were close to the lower limits of detection or 
samples were too diluted. In initial experiments when Brij-35 detergent was 
used to elute MMPs, primary anti-MMP-2 antibody did not show specific 
bands to MMP-2. However when Brij-35 was omitted from elution buffers, 
antibody worked. The chromatography beads treated S+CS showed MMP-2 
specific bands but not with SFCS probably for the reason that when cells 
were well nourished in the presence of serum, these secreted more MMP-2 
while during 48hours of depletion of serum, MMP-2 productivity of cells 
decreased as shown in the MMP-2 ELISA data in Table 6.2. 
Cursory and detailed examination of chromatography fractions with highly 
sophisticated technique MALDI-MS served to reveal the nature of samples to 
be containing enormous number of non-specific proteins. Despite the 
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evidence presented in Chapter 5 that rhMMPs were binding to H7-G dye 
ligand, the tumour cell line SFCS demonstrated least binding primarily 
because of complex nature of sample. Moreover, with respect to MMPs, the 
samples most commonly exhibited low to undetectable levels. The data 
shown in Appendix 9, Table 6.8 and Table 6.10 indicates that the ligand Olive 
H-7G is not specific to MMPs and has affinity towards other proteins 
including heterogeneous nuclear ribonucleoproteins and histones. These 
data questioned the effective use of Olive H-7G as a specific probe for 
MMPs. This highlights the importance of introducing structural changes in 
Procion Olive H-7G dye so as to enhance its selectivity towards MMPs. 
Since many proteins were binding to Olive H-7G beads, specific elution of 
MMPs off the beads was pursued leaving other proteins on the beads. For 
this purpose EDTA which is a potent inhibitor of MMPs was used as it has 
been reported to act as a competitor to bind to MMPs (Alberto Passo, 1999). 
The proteins eluting in 100mM EDTA solution shown in Table 6.8 include 
TIMPs which are natural inhibitors of MMPs. Although the main goal of this 
project was isolating MMPs yet the identification of TIMP-1 and TIMP-2 with 
high Mascot scores suggests the possibility of using EDTA elution to purify 
TIMPs using Olive H-7G to concentrate them from the biological sources. 
The identification of some other biologically significant proteins such as 
kellikerin-6, galactin-3 and 10kDa heat shock protein that eluted with EDTA 
qualifies Olive H-7G as a ligand of choice if these proteins need to be 
isolated. The internal control of Olive H-7G, MDHM, was also detected 
confirming the activity of the ligand under discussion. These results were 
further confirmed when EDTA was used in buffers with increasing NaCl 
concentration from 0.15-5M to enhance the reversibility of bound proteins. 
Although EDTA was added to reduce the autolytic degradation of MMPs, it 
might have helped in elution off the Olive H-7G ligand immobilized on the 
chromatography beads. The identification of TIMP-1 and TIMP-2 in eluates 
from 0.15-5M (Table 6.10) with high Mascot scores approves the use of the 
dye for their isolation. Moreover, galactin-3, MDHM, thrombospondin-1, heat 
shock proteins (10kDa and 70kDa) and many other proteins of biological 
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importance were identified proving the potential of Olive H-7G as a purifying 
tool for these proteins. 
Cell lysates of HT1080 human fibrosarcoma cells were utilized to optimize 
the MALDI-MS protocol. In order to eliminate the possibility of competition 
from enormous number of proteins other than MMPs for finding room on 
chromatography beads, cell lysates were washed with 1X PBS to remove cell 
debris, centrifuged several times and filtered using 0.45micron syringe filters. 
Although cell pellets yielded poor definition, it did however demonstrate that 
MMP expression could be illustrated by MALDI-MS means. In cell lysates it 
was expected that there would be high enough levels of membrane bound 
MMPs which would be sufficient for the capacity of Olive H-7G immobilized 
chromatography beads. The unaccountable expression pattern of other 
cellular proteins (172 proteins in cell extract identified by LC-MS/MS in this 
study) may have been made it unlikely for MMPs to bind to their ligand. 
Further evidence of the specificity of the primary antibody for MMP-2 was 
provided by the western blotting of the cellular fractions. Significantly, in the 
present study western blot analysis using MMP-2 antibody exhibited bands 
representative of high MMP-2 expression (Figure 6.10). These western blot 
and ELISA data (Table 6.11, Table 6.12 and Table 6.13) did not concur with 
the data acquired from both manual MALDI-MS and automated LC-MS/MS 
(Table 6.14). This could be for the reason that in contrast to western blotting, 
MALDI-MS involves strong denaturation conditions (8M Urea) and an 
overnight trypsin digestion. As a consequence, it can be hypothesized that 
signature peptides for MMPs could be degraded/lysed in a way that does not 
allow the protein identification after being fragmented by laser within MALDI 
mass spectrometer. Furthermore, ionization process within source of the 
instrument holds a complex chemistry. To the best of my knowledge, 
currently there is no published data referring to the purification of cellular 
MMPs from human cell lines and consequent analysis by MALDI-MS. 
Research has highlighted the potential shortcomings of MALDI-MS and has 
emphasized on the need for caution in the interpretation of resulting data. 
Variables such as level of expression of protein under investigation, quality of 
matrix in use, ionization potential of peptides and calibration of instrument 
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have all been implicated in jeopardizing the quality of data. Moreover, the 
exhaustive optimization of procedure and performance of replicate 
experiments should have limited the probable errors implicit within the 
investigation. 
MMPs (MMP-2 and MMP-14) were identified among many of the attempts of 
LC-MS/MS of SFCS eluates hence the HT1080 cell line showed low levels of 
MMPs quite frequently. The reason is unclear but a possible explanation 
could be that MMPs were lower than sensitivity limit of detection of MALDI 
mass spectrometer; this requires further elucidation of other cell lines. The 
cell line HT29 was used in the present study but significant results could not 
be generated. Another reason could be that a small volume (50mL) of 
starting material was used and the potential loss of the protein during various 
steps along the preparation of samples for final analysis might have failed the 
techniques used. It is possible that presence of other proteins which have 
affinity towards the Olive H-7G may have interfered with the true outcome of 
the methodology under discussion. The issue of non-specific binding found in 
this study is in keeping with the published data by other groups (Trinkle-
Mulcahy et al., 2008). The data presented here strongly resemble to the 
findings of Trinkle-Mulcahy study that both qualitative and quantitative mass 
spectrometry results were affected by most commonly used affinity matrices 
because of non-specific binding of proteins. Many of the proteins enlisted by 
Trinkle-Mulcahy study binding non-specifically to sepharose matrix were 
similar to those found in present study. Although promising results were 
found for Olive H-7G dye ligand when mixture of rhMMPs were used 
(Chapter 5), due to the issues of non-specific binding and limit of detection of 
MALDI mass spectrometer it was not possible to make clear-cut conclusion 
when cell culture supernatants were used. Currently there is no published 
data since previous studies have not addressed this issue. 
Alternative approaches were considered and it was decided to synthesize 
more MMP specific ligands. Of great importance to this project was the 
synthesis of economical compounds using in-house resources within ICT. 
Unfortunately the synthesis of MMP inhibitor illomastat-based 
chromatography beads attempted encountered many problems so it was not 
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used within the time-frame of this project. In view of understanding the site of 
attachment of Olive H-7G ligand and the part of the MMPs (and TIMPs) 
where it binds, NMR analysis of the ligand was conducted, but did not yield 
any interpretable results (results not shown). 
In short, the findings of the study indicate that the triazine dye-based ligand 
(Olive H-7G, Reactive Green-8) immobilized on chromatography beads can 
be utilized to purify latent MMPs and TIMPs (possibly complexed with 
MMPs). Results suggest the ligand interacts with a site common to both 
latent and active forms of MMPs, the later being preferential, allowing their 
isolation using gradient salt buffers. Using this methodology, the MS/MS 
spectral peaks specific to MMPs (MMP-2, MMP-14), and two endogenous 
inhibitors (TIMP-1 and TIMP-2) were found in cell culture supernatants. 
Although detergent-free elution buffers improved MALDI analysis, recovery of 
MMPs from biological samples was sub-optimal. Taken together these 
observations suggest that MMPs can be identified using a smaller volume 
(50mL) of cell line culture supernatant as starting material. In terms of the 
development of MMP targeted purifying tools, the data presented in this 
chapter suggests that this would not be an easily achievable goal. The 
detection of MMP-2 activity (ELISA) and identification of MMPs in highly 
sensitive tandem mass spectrometry reinforces the potential of this strategy 
but lack of ability of specifically identifying MMPs in complex protein mixture 
remains an issue. These findings though promising, the diagnostic use of this 
methodology needs further optimization to remove non-specific binding of 
proteins. Although, none of the MMPs could be identified nevertheless, EDTA 
containing buffers could be of use if target proteins are TIMPs. These data 
are fundamental to this study. However, next chapter will entail the attempts 
to remove non-specific binding of proteins. 
CHAPTER 7 
STRATEGIES TO REMOVE NON-SPECIFIC 
BINDING AND ENHANCE MMP ENRICHMENT
183 
7 Strategies to remove Non-specific binding and Enhance MMP 
Enrichment 
7.1 Introduction 
This chapter describes the attempts made to reduce biological sample 
complexity and selective isolation of target protein family (MMPs). The 
proteome is a highly complex mixture of diverse proteins and peptides 
varying in concentration and states. To understand the time-dependant 
interplay of the different pathways, and the structure and function of all 
involved proteins is a challenging task. Post-translational modifications such 
as glycosylation, phosphorylation etc. add an extra layer of complexity and 
are important in development of certain diseases. The challenges posed by a 
large range (Abrahams et al., 1996) of proteins binding non-specifically to 
affinity matrices has been described previously (Sutton, 2011). Such 
components binding non-specifically to affinity matrices, can affect the 
experimental outcome by reducing the possibility of low abundance target 
proteins bound specifically being suppressed in proteomics analysis. 
Research, to date, has not provided a single simple solution to preventing or 
interpreting non-specific binding. Methods that have been tried often relate to 
the specific affinity interaction between the target protein and the immobilized 
capture compound (e.g. an analogue of the compound that is known not to 
recognize the target proteins) or adapting the stringency conditions for 
binding. 
The mesenchyme-derived dermal papilla plays a major regulatory role in the 
complex cell biology of the hair follicle. The ability to culture dermal papilla 
cells from a range of species and particularly a range of normal and 
disordered human hair follicles has enabled the development of a powerful 
new model system for investigating hair follicle biology (Randall, 1996). The 
dermal papilla is a cluster of specialized mesenchymal cells at the bottom of 
the mammalian hair follicle, embedded in a loose extracellular matrix. These 
cells have the capability to induce and support hair growth via close 
epithelial-mesenchymal interactions with the keratinocytes surrounding the 
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hair matrix. The extracellular matrix of the dermal papilla differs markedly 
from the interfollicular matrix. In a study the expression pattern and activity of 
MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1, TIMP-2 and MT1-MMP in in vitro
cultures of cells derived from scalp dermal papilla and fibrous sheath were 
reported (de Almeida et al., 2005). Zymographic analysis showed activation 
of MMP-2 in all cells grown in three-dimensional collagen lattices whereas 
MMP-9 was activated only in three-dimensional collagen cultures of dermal 
fibroblasts and weakly in follicular cells. Expression of MMP-1, TIMP-1, 
TIMP-2 and MT1-MMP was similar in all cells, in both culture conditions, 
whereas expression of MMP-3 was absent in dermal papilla cells (de 
Almeida et al., 2005). Many studies have been conducted to understand 
dermal abnormalities and many MMPs have been reported to play important 
roles. Neutrophil elastase has been reported to be associated with solar 
elastosis. Photo aging of skin or solar elastosis (which is probably an end 
product of elastic fiber degradation) results from an influx of neutrophils on 
exposure of human skin to a certain threshold of UV, infrared radiation (IR), 
and heat. In this study the neutrophils, packed with potent proteolytic 
enzymes capable of degrading collagen and, particularly, elastic fibers 
responsible for ECM damage  were observed in several non-dermatological 
conditions. Taken together with their data this group proposed that MMPs 
generated by sub-erythemogenic doses of UV and low doses of IR/heat are 
involved in cellular processes other than ECM degradation (Rijken and 
Bruijnzeel, 2009). 
7.1.1 Aims 
In the present study various strategies were explored to remove proteins, 
other than MMPs, binding non-specifically to sepharose (results from Chapter 
6). The strategies followed were: 
• To sweep abundant proteins in culture supernatant using sepharose 
followed by use of H-7G-Sepharose beads to bind MMPs. 
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• To add ADP/GDP in culture supernatant so that proteins having 
affinity for these nucleotides could be engaged giving opportunity to 
MMPs for binding to Olive H-7G supported on matrix.
• To use sephadex as a matrix as opposed to conventional sepharose 
to reduce the chances of getting MMPs trapped in porous soft gel 
hence enhancing likelihood of binding to Olive H-7G. 
7.2 Materials and Methods 
7.2.1 Pre-clearing Dermal Papilla Culture Supernatant using Sepahrose 
(Non-Cancer source of MMPs) 
Dermal papilla culture supernatant (henceforth referred to as CS) was kindly 
provided by one of the colleagues Heero Rehman at the University of 
Bradford. The ‘CS’ was divided into two 15mL tubes (5mL each). To one 
labeled ‘CS-1 H-7G-Sepharose’ 1mL of ‘H-7G-Sepharose’ beads (washed 
and equilibrated Materials and Methods section 2.4) were added and to other 
tube labeled ‘CS-2 Sepharose’ 1mL of ‘Sepharose’ control beads were 
added. The workflow for the experiment is depicted in Figure 7.1. The 
contents of both tubes were rotated on a rotator at 30rpm for 2hours at 4°C. 
The corresponding flow-throughs were collected and frozen at -20°C. The 
flow-through ‘CS-2 FT 2’ was presumably cleared by ‘Sepharose’ since this is 
the trapping net for proteins. To this cleared flow-through, ‘H-7G-Sepharose’ 
beads were added and left on a rotator at 30rpm for 2hours at 4°C for binding 
any proteins which were not swept by Sepharose or were in excess. The 
beads were collected in the end and divided into two 1.5mL eppendorfs. To 
one part elution was performed using 0.3M and 2M NaCl buffers as 
described in Materials and Methods section 2.4.1. On-bead trypsin digestion 
was performed keeping in view the amount of proteins, 50μL of trypsin 
solution (10μg/mL) was added and incubated at 28oC for 18hours followed by 
desalting peptide solution (Materials and Methods section 2.10.1). 
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7.2.2 ADP/GDP use in HT1080 SFCS 
ADP and GDP bind to most of the proteins. HT1080 SFCS was mixed with 
1mM ADP and 1mM GDP to remove non-specific binding. The affinity 
chromatography was performed as described in Materials and Methods 
section 2.4. All fractions were NAP-5 desalted and lyophilized at 37°C. 
Figure 7.1 Affinity chromatography of dermal papilla culture 
supernatant before and after sepharose pre-clearing. 
7.2.3 Low Porosity Beads (Sephadex) 
H-7G-Sephadex chromatography beads were synthesized (Materials and 
Methods section 2.2) and treated with HT1080 SFCS for affinity 
chromatography (Materials and Methods section 2.4). The chromatography 
fractions were subjected to NAP-5 concentration and lyophlization. In-
soultion trypsin digestion was performed (Materials and Methods section 
2.9.1) with the variations in volumes of reagents shown in Figure 7.2. 
Dermal Papilla Culture Supernatant
(7mL)
CS-1 (3.5mL)
+
H-7G-Sepharose
CS-2 (3.5mL)
+
Sepharose
CS-1 FT1CS-1 H-7G-Sepharose
CS-1 H7G-Sepahrose OB CS-1 H7G-Sepharose EB
CS-2 FT2CS-2 Sepharose
CS-2 Sepharose OB CS-2 Sepharose EB
+
H-7G Sepharose
CS-2 FT3CS-2 H-7G-Sepharose
CS-2 H-7G-Sepharose OB CS-2 H-7G-Sepharose EB
0.3M NaCl
2M NaCl
0.3M NaCl
2M NaCl
0.3M NaCl
2M NaCl
Pre-clearing
Of non-specific 
proteins
2hr 4C, spin 2hr 4C, spin
2hr 4C, spin
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Figure 7.2 Trypsin digestion for H-7G-Sephadex chromatography 
fractions. 
7.3 Results 
7.3.1 LC-MS/MS of Dermal Papilla Culture Supernatant Fractions 
Significant but not complete depletion of abundant proteins was observed in 
spectra and increased numbers of peaks were detected. Most of the peptides 
were removed from beads during elution with 0.3M and 2M salt buffer as 
depicted by the HPLC profiles (Figure 7.3A and B). The HPLC profile for the 
fraction ‘CS-1 H-7G Sepharose OB’ (beads mixed in culture supernatant 1 
and on-bead trypsinized) shows discrete peaks hence more proteins (47) 
detected by LC-MS/MS where 3271 compounds were scheduled for 
fragmentation out of 6911 leading to the identification of MMP-1, MMP-2 and 
MMP-3 along with TIMP-1 with Mascot scores > 30 (Figure 7.3). The HPLC 
profile for ‘CS-2 Sepharose OB’ (sepharose mixed with culture supernatant 2 
and on-bead trypsinized) and the one after elution using 0.3M and 2M salt 
buffer (Figure 7.3C and D) show half the intensity observed in ‘CS-1 H-7G- 
Sepharose OB’ and ‘CS-1 H-7G-Sepharose EB’ (panels A and B). 
Identification of comparatively lower number of proteins (9 and 2 in CS-2 
Sepharose OB and CS-2 Sepharose EB, respectively) suggests some 
proteins do bind to matrix. For the fraction ‘CS-2 Sepharose OB’ (Figure 
7.3C) the number of compounds scheduled to MS/MS was 2561 out of 6810 
but identification of just 9 proteins suggests that most of the compounds were 
Samples 
        8M Urea        50mM DTT 100mM IAC    HPLC H2O       Trypsin 
SM             (Lyophilized) 20 μL             2 μL      2μL           112μL         5μL 
FT             (Lyophilized) 30 μL             3 μL      3μL             84μL         5μL 
SFCS E1a+b+c (Lyophilized) 30 μL             3 μL      3 μL             84μL         5μL 
SFCS E2a+b (Lyophilized) 40 μL             4 μL      4 μL            112μL         5μL 
SFCS E2c  (Lyophilized) 20 μL             2 μL      2μL            112μL         5μL
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not peptides. Similarly, 7138 compounds in the fraction ‘CS-2 Sepharose EB’ 
indicate lack of real signal because only six proteins were identified (Figure 
7.3D). The profiles for ‘CS-2 H-7G-Sepharose OB’ (Figure 7.3E) and ‘CS-2 
H-7G-Sepharose EB’ (Figure 7.3F) shows very high intensity HPLC peaks. 
As described in methods section and shown in Figure 7.1 the ‘CS-2 FT2’ 
cleared culture supernatant by pre-treating proteins with sepharose. The 
comparison of results of beads fractions ‘CS-1 H-7G-Sepharose and ‘CS-2 
H-7G-Sepharose’ (Figure 7.3, equivalent fractions before and after 
sepharose pre-treatment) shows that there is a reduction in the number of 
proteins from 47 to 10. Therefore, pre-clearing method was non-specific and 
did not enhance MMP enrichment. 
Figure 7.3 HPLC profiles and LC-MS/MS results for sepharose pre-
clearing experiment (n=1). 
OB: on-bead trypsin digest; EB: on-bead trypsin digest after elution. Numbers 
is parentheses are Mascot scores and peptides identifying the proteins. 
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7.3.2 ADP/GDP use in HT1080 SFCS 
7.3.2.1 Protein Separation (SDS-PAGE) 
The protein expression for HT1080 SFCS and corresponding 
chromatography fractions was the same before and after adding ADP and 
GDP (Figure 7.4A). The beads collected after the elution of proteins showed 
similar protein profile suggesting proteins did not bind to ADP and GDP. The 
control sepharose beads did not show bound proteins before and after 
adding ADP and GDP (Figure 7.4B). 
Figure 7.4 Protein expression of HT1080 SFCS and chromatography 
fractions after removal of ADP/GDP binding proteins. 
7.3.2.2 LC-MS/MS  
Amongst the 140 identified proteins in the starting material were high 
abundant background proteins such as actin, hemoglobin, serum albumin, 
heat shock proteins, keratins and TIMPs (Table 7.1). Several proteins in the 
0.3M NaCl eluates were identified in the probed and control sepharose, i.e. 
wherein ADP/GDP was added to the HT1080 SFCS prior to the 
chromatography. Those included keratins, serum albumins but none of the 
MMPs were identified. 
H-7G-Sepharose
ADP+ / GDP+
H-7G-Sepharose
ADP- / GDP-
Sepharose
ADP+ / GDP+
Sepharose
ADP- / GDP-
225
150
102
76
38
31
52
24
17
12
225
150
102
76
38
31
52
24
12
A B
190 
Table 7.1 LC-MS/MS of HT1080 SFCS chromatography fractions after 
ADP/GDP suppression of proteins. 
7.3.3 LC-MS/MS for H-7G-Sephadex Fractions 
To analyze the number of proteins binding non-specifically to sephadex, 
HT1080 SFCS was sieved with sephadex and H-7G-Sephadex beads. No 
proteins were eluted and on-bead digestion was performed. LC-MS/MS of 
culture supernatant and the beads did not identify MMPs or TIMPs (Table 
7.2). Since number of proteins was reduced when compared to results 
obtained with sepharose (Chapter 6) so sephadex was considered as better 
matrix than sepharose. 
Table 7.2 Proteins binding non-specifically to H-7G-Sephadex (No 
elution). 
Further experiments were set up to elute proteins from H-7G-Sephadex and 
control sephadex using 0.3 and 5M NaCl buffer {50mM Tris-HCl (pH 7.5); 
0.3M or 5M NaCl; 10mM CaCl2; 0.02% (w/v) Na3N}. In previous experiments 
using sepharose as matrix, 5M NaCl buffer eluted more proteins than 2M 
HT1080 SFCS
LC-MS/MS TIMP-1 TIMP-2
No. of Proteins Mascot Score Peptide # Mascot Score Peptide #
SM 140 37 3 146 4
H-7G-Sepharose ADP+/ GDP+ 0.3M NaCl E 40 - - 62 1
Sepharose ADP+/  GDP+ 0.3MNaCl E 7 - - - -
HT1080 SFCS
(50mL)
BA ELISA LC-MS/MS 
Protein 
(mg/50mL) 
(n=3)
MMP-2 
(ng/50mL) 
(n=3)
No. of Proteins
(n=3)
SM 42.94 149.66 40-69
H-7G-Sephadex ND ND 2-17
Sephadex ND ND 0-14
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NaCl buffer. In view of eluting all proteins possibly trapped in sephadex, 5M 
salt buffer was used. The trypsin-digested samples were then desalted using 
C18 columns followed by lyophilization at 37ºC in evaporator. In one of the 
experiments to elute proteins off the H-7G-Sephadex, elution buffers were 
mixed with beads for 30 minutes before centrifugation. The results are shown 
in Table 7.3 presenting elution of TIMP-1 (Mascot score 57) in 0.3M salt 
buffer and TIMP-2 (Mascot score 68) in 5M salt buffer. Although, any MMP 
could not be identified but there were MMP-14 specific peptide peaks 
observed with a low Mascot score. Detailed list of proteins identified in 
pooled eluate fractions of 0.3M salt buffer (E1a-c) and 5M salt buffer (E2a+b 
and E2c) is shown in Table 7.4. MDH in eluates of 0.3M salt buffer are 
internal control for Olive H-7G and have been reported to bind to the dye. 
Table 7.3 Proteins eluted from H-7G-Sephadex using 0.3M and 5M NaCl 
buffers. 
ND: Not detected 
HT1080
SFCS
BA ELISA LC-MS/MS TIMP-1 TIMP-2
Protein
(mg/50mL)
MMP-2
(ng/50mL) No. of Proteins Mascot Score Peptide # Mascot Score Peptide #
SM 39.71 59.55 69 112 5 86 1
FT ND ND 35 32 2 - -
0.3 M NaCl E1a-c ND ND 4 57 1 - -
5M NaCl E2a+b ND ND 24 - - 68 1
5M NaCl E2c ND ND 8 - - - -
192 
Table 7.4 Proteins in eluates of H-7G-Sephadex. 
SM FT E1-c (0.3M NaCl elution) E2a+b (5M NaCl elution) E2c (5M NaCl elution)
Protein Protein Protein Protein Protein
Serum albumin Alpha-2-antiplasmin Keratin, type II cytoskeletal 1 Serum albumin Serum albumin 
Keratin, type II cytoskeletal 1 Alpha-2-HS-glycoprotein Keratin, type I cytoskeletal 9 Actin, cytoplasmic 1 Inter-alpha-trypsin inhibitor heavy chain H2 
Actin, cytoplasmic 1 Amyloid beta A4 protein Tubulin alpha-1A chain Annexin A2 Histone H2A type 1-A 
Heat shock cognate 71 kDa protein CASP8-associated protein 2 Serum albumin Moesin Histone H3.1t 
Metalloproteinase inhibitor 1 CD44 antigen Histone H2A type 1-B/E Protein disulfide-isomerase A3 Kallikrein-10 
Peptidyl-prolyl cis-trans isomerase A Clusterin Histone H4 Malate dehydrogenase, mitochondrial Histone H1.5 
Inter-alpha-trypsin inhibitor heavy chain H2 Cystatin-C Fibronectin Metalloproteinase inhibitor 2 Cystatin-C 
Alpha-2-HS-glycoprotein Fibulin-1 Actin, cytoplasmic 1 Non-histone chromosomal protein HMG-17 Histone H4 
Clusterin Galectin-3-binding protein Heterogeneous nuclear ribonucleoproteins C1/C2 Inter-alpha-trypsin inhibitor heavy chain H2 
Peroxiredoxin-1 Heat shock cognate 71 kDa protein Histone H2B type 1-B Histone H4 
Cystatin-C Hemoglobin subunit alpha 60S ribosomal protein L6 Thrombospondin-1 
Tubulin alpha-1A chain Hemoglobin subunit beta Histone H2B type 1-C/E/F/G/I Ceramide glucosyltransferase 
Metalloproteinase inhibitor 2 Histone H2A type 1-A Protein disulfide-isomerase A3 Histone H2A type 1-A
Alpha-enolase Inter-alpha-trypsin inhibitor heavy chain H2 Annexin A2 Sulfhydryl oxidase 1 
Sulfhydryl oxidase 1 Inter-alpha-trypsin inhibitor heavy chain H3 Keratin, type I cytoskeletal 10 Malate dehydrogenase, cytoplasmic 
SPARC Keratin, type II cytoskeletal 1 Heterogeneous nuclear ribonucleoproteins A2/B1 Histone H3.1t 
Hemoglobin subunit alpha Kininogen-1 Thrombospondin-1 Transforming growth factor-beta-induced protein ig-h3 
Tubulin beta chain Lactotransferrin Histone H2B type 1-A Keratin, type I cytoskeletal 10 
Vitronectin Liprin-alpha-3 Keratin, type I cytoskeletal 18 Stathmin
Inter-alpha-trypsin inhibitor heavy chain H3 Metalloproteinase inhibitor 1 Ezrin Cystatin-C 
Triosephosphate isomerase Midasin Endoplasmin Kallikrein-6 
Hemoglobin subunit beta Peroxiredoxin-1 Enhancer of polycomb homolog 2 Keratin, type II cytoskeletal 1 
Vitamin D-binding protein POTE ankyrin domain family member E Keratin, type I cytoskeletal 18 
Neurosecretory protein VGF Probable 3-hydroxymethyl-3-methylglutaryl-CoA lyase 2 Olfactomedin-like protein 3 
Galectin-3-binding protein Protein MON2 homolog 
Thrombospondin-1 Protein piccolo 
Lactotransferrin Protein TANC1 
Pyruvate kinase isozymes M1/M2 Putative beta-actin-like protein 3 
Glyceraldehyde-3-phosphate dehydrogenase Serum albumin 
Alpha-2-antiplasmin SPARC 
Alpha-2-macroglobulin Sulfhydryl oxidase 1 
78 kDa glucose-regulated protein Thrombospondin-1 
Amyloid beta A4 protein Triosephosphate isomerase
Sperm-associated antigen 1 Ubiquitin 
Kininogen-1 Vitamin D-binding protein 
Elongation factor 2 
WD repeat-containing protein 7 
Cadherin-23 
Keratin, type II cytoskeletal 2 epidermal 
Retinol-binding protein 4 Common between E1a-c and E2a+b 
Histone H2A type 1-D Common between E2a+b and E2c
Stathmin Common among E1a-c, E2a+b and E2c 
Laminin subunit beta-2 
Putative C-type lectin domain-containing protein 
Guanine nucleotide-binding protein subunit alpha-12 
CASP8-associated protein 2 
Keratin, type I cytoskeletal 10 
Keratin, type I cytoskeletal 18 
Rab proteins geranylgeranyltransferase component A 1 
Complement C4-A 
Nucleolin 
Ecto-ADP-ribosyltransferase 4 
Insulin-like growth factor-binding protein 2 
Nebulin 
Abhydrolase domain-containing protein 12B 
Ribosomal protein S6 modification-like protein B 
Macrophage migration inhibitory factor 
Abhydrolase domain-containing protein 15 
Gelsolin 
Kallikrein-6 
Borealin 
Caspase recruitment domain-containing protein 11 
Kinesin-like protein KIF2C 
CD44 antigen 
Tetraspanin-14 
Midasin 
Tax1-binding protein 1 
Zinc finger protein 611 
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7.4 Discussion 
Matrices constitute a major source of non-specific binding. High resolution 
separation is achieved by chromatographic protein purification systems yet 
colloidal contaminants in biological samples such as cell debris often plug 
soft gel matrices such as highly porous sepharose. 
Since dermal papilla cells have been reported to express MMPs in high 
amounts along with other proteins, their culture supernatant was used in the 
current study as a source of MMPs. An attempt was made to deplete high 
abundance proteins by adding un-derivatized sepharose to dermal papilla 
culture supernatant with the aim of filtering out proteins that bind non-
specifically to affinity matrix while increasing the likelihood of binding of 
MMPs to Olive H-7G and identification by MALDI-MS profiling. In addition an 
attempt was made to elute the bound proteins. The resulting fractions were 
assayed for the presence and purity of the target of interest. The results 
showed that depletion of high abundance proteins also removed low 
abundance proteins including MMPs. However, the comparison of results of 
beads fractions ‘CS-1 H-7G-Sepharose and ‘CS-2 H-7G-Sepharose’ (Figure 
7.3, equivalent fractions before and after sepharose pre-treatment) showed 
that there is a reduction in the number of background proteins from 47 to 10. 
Dadvar et al developed an enrichment protocol by using a combination of 
pre-clearing and competitive blocking of proteins in mouse lung tissue lysate 
with nucleotides (ADP and GDP) which reduced the binding of nucleotide 
binding proteins (especially serum albumin) to the beads (Dadvar et al., 
2009). Therefore, we opted for this strategy and used high concentration 
ADP and GDP to suppress nucleotide binding proteins (Actin, endoplasmin, 
tubulin) in the HT1080 SFCS before pull-down affinity assay with H-7G-
Sepharose chromatography beads. However, no change was observed in the 
protein expression for HT1080 SFCS and corresponding chromatography 
fractions before and after adding ADP and GDP (Figure 7.4A). It was 
expected that ADP and GDP will engage proteins leaving les number of 
proteins to bind to the chromatography beads. The beads collected after the 
elution of proteins showed similar protein profile suggesting proteins did not 
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bind to ADP and GDP. The control sepharose beads did not show bound 
proteins before and after adding ADP and GDP (Figure 7.4B). These results 
were confirmed when HT1080 SFCS and corresponding chromatography 
fractions were analysed by MALDI-MS/MS. Amongst the 140 identified 
proteins in the starting material were high abundant background proteins 
such as actin, hemoglobin, serum albumin, heat shock proteins, keratins and 
TIMPs (Table 7.1). Several proteins in the 0.3M NaCl eluates were identified 
in the probed and control sepharose, i.e. wherein ADP/GDP was added to 
the HT1080 SFCS prior to the chromatography. Those included keratins, 
serum albumins but none of the MMPs were identified. 
Sepharose has particle size 45-200ȝm (wet) and a fractionation range of 
1x104-4x107 Da for globular proteins (Sigma and GE healthcare). This is 
composed of cross-linked (through lysine or cysteine side chains) beaded 
agarose more resistant to denaturing conditions and thus offers more 
versatility in the choice of sample buffer and eluent. Because of the porosity 
characteristic to the polymer proteins get trapped in it and keep leaching out 
with every elution buffer used. Its brand name is derived from Separation-
Pharmacia-Agarose. Sepharose is a registered trademark of GE Healthcare 
and its common application is gel filtration (separation by size) of 
biomolecules. 
Sephadex has a fractionation range 700-6x106 and bead sizes fall in 
discrete ranges between 20-300μm (Sigma) on the other hand has cross-
linking in its structure resulting in fine pores hence the number of proteins 
getting stuck is lesser. Sephadex has a fractionation range of 1x103-5x103 Da 
and bead size 20-300μm (GE healthcare). Sephadex is a trademark for 
cross-linked polysaccharide dextran gel commonly used for gel filtration in 
bead form. By varying the degree of cross-linking, the fractionation properties 
of the gel can be altered. It was launched by Pharmacia in 1959 and the 
name is derived from separation Pharmacia dextran. The organic chains are 
cross-linked to give a three dimensional network having functional ionic 
groups attached by ether linkages to glucose units of the polysaccharide 
chains. Moreover, sephadex is used in commercially available desalting 
columns, size exclusion chromatography (SEC) or gel permeation 
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chromatography (GPC). Proteins slide alongside the bead structure and only 
proteins having affinity for the ligand immobilized on beads bind hence 
specifically eluted afterwards. One of the most significant reasons sephadex 
was selected is that the Olive H-7G dye binds to hydroxyl groups. To analyze 
the number of proteins binding non-specifically to sephadex, HT1080 SFCS 
was sieved with sephadex and H-7G-Sephadex beads. The number of 
proteins identified when sepharose was used as a matrix higher (from 70-
170) but when sephadex was used it was reduced to 40 so sephadex was 
considered as better matrix than sepharose. However, no MMP was 
identified before or after elution using salt containing buffers (Table 7.2 and 
Table 7.3). A set of experiments was performed changing samples:beads 
ratio but noteworthy differences were not observed.
In conclusion, the strategies adopted in this study did not eradicate the non-
specific binding of proteins to affinity matrices. Hence, further possibilities 
need to be explored. 
CHAPTER 8 
CONCLUSIONS 
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8 Conclusions 
Identification of proteolytic enzyme expression, activity and localization in 
human cancers is important to improving our knowledge of cancer, its 
diagnosis and treatment. The detection and function of these enzymes, 
particularly MMPs, in cancer may result in new diagnostic markers or new 
therapeutic targets. There are contradictory findings with regard to the role 
played by MMPs in promotion and inhibition of the tumour growth as well as 
tumour progression. It is therefore essential to investigate expression profiles 
and associated high proteolytic activity in cancer tissue to improve 
understanding of their role and potential. The purification and isolation of 
biologically active or inactive proteases from complex mixtures remains a 
challenging task, and is a major objective of this study. Quantification of the 
activity state of proteases promises to reveal the functions of proteases in 
homeostasis and in disease states. This will indicate which proteases 
participate in defined pathologies and will help targeting specific proteases 
for disease treatments. 
Owing to the expanding knowledge of complex roles for MMPs both in 
normal and diseased cells, there has been an increasing interest in their 
identification and functional characterization in human. More information 
about the profile of these proteases will prove useful in the molecular 
diagnosis of disease, with the calibration of protease level to disease severity 
or tumour grade enabling more accurate prognosis for patients. It will help 
find out their state (active or latent) at the time of secretion and understand 
their role in tumour progression and metastasis in cancer. The approach 
described will help progress in the detection of endogenous active, latent 
forms of MMPs and complexed with TIMPs in complex proteomes, an 
important objective with many diagnostic applications. This MALDI-MS based 
MMP profile characterization in turn will help monitor the efficacy of a drug 
administered causing changes in MMP quantities being secreted. The 
development of new affinity capture tool for pro-MMPs and their subsequent 
characterization will provide a useful insight into their regulation prior to 
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secretion and possible strategies to stop their activation on the onset of 
disease. 
A major drawback of previous protein purification methods is the lack of 
specificity. One approach to address this problem is to select a relatively 
specific ligand and make use of it as a broad spectrum purifying tool for a 
class of closely related proteases. Keeping this in view, the first aim of the 
study was synthesis of chromatography material by immobilization of 
previously reported MMP ligand Procion Olive H-7G on hydroxyl polymer 
beads. As a supporting matrix, different gel media for immobilization Olive H-
7G were investigated. This project has attempted to profile MMPs by 
combining principles of affinity chromatography and soft ionization high-
throughput MALDI mass spectrometry. This work has focused on human 
recombinant forms and in particular on cell lines which are known sources of 
MMPs. Current identification methods are not specific enough and there is 
the need for a novel more specific one. The rational design for this study 
entails two stages: enrichment of MMPs followed by an assessment of the 
efficiency of chromatography system using MALDI mass spectrometry. This 
study aimed to achieve these goals with a view to demonstrate Olive H-7G 
dye as a potential ligand for MMPs. 
In order for chromatography to perform its role, it was necessary to 
demonstrate MMPs were expressed and active in cell lines. For this, analysis 
of protein expression using proteomic techniques, SDS-PAGE, western 
blotting, Coomassie brilliant blue and silver staining and ELISA based activity 
assays were performed. The MALDI-MS peptide fingerprints/peptide 
signatures of recombinant human MMPs were identified using trypsin (and 
other proteases). To determine which pro-MMPs bind Olive H-7G, the 
chromatography system Olive H-7G-Sepharose was evaluated using 
commercially available latent recombinant human MMPs (Chapter 5). Further 
elucidation of separation potential of Olive H-7G was achieved by LC-MS/MS 
analysis of purified MMPs from serum-free culture supernatant of cancer cell 
lines. 
One of the objectives of studying rhMMPs was to handle the enzymes as 
levels expected to be similar to those occurring in biological samples. 
198 
rhMMPs were analyzed using MALDI-MS for their integrity and show mass 
peaks specific to intact protein. It was anticipated that it might be the 
detergent (Brij-35) which is masking the specific peaks of intact rhMMPs. 
Attempts to remove the detergent from rhMMPs using C4 zip tips were only 
partially successful (MMP-3, MMP-7, MMP-10 and MMP-14) and could not 
be removed in the case of MMP-2, MMP-8, MMP-9, MMP-13 and MMP-16.  
The identification of MMP-8, MMP-13 and MMP-14 (Figure 5.7) in addition to 
previously reported MMPs (MMP-3, MMP-7, MMP-9 and MMP-10) 
highlighted the broad applicability of Olive H-7G. The identification of these 
three new MMPs could be credited to the LC-MS/MS complimentary protein 
identification. Nevertheless, these results are very encouraging and not only 
confirm the previously reported potential of the Olive H-7G affinity for MMP-3, 
MMP-7, MMP-9 and MMP-10 but also for MMP-8, MMP-13 and MMP-14 
reported in this study. Once the affinity of Olive H-7G was confirmed 
(Chapter 5, section 5.3.1 and 5.3.4), a very fundamental information that 
whether bound MMPs to Olive H-7G could be retrieved or not, 0.3M and 2M 
NaCl buffers were used to elute off the endopeptidases. The ELISA assay 
measured 95.01% recovery of the MMP-2 from Olive H-7G immobilized on 
sepharose (Table 5.6) offering a persuasive evidence. This finding appeared 
to be very plausible and suggested that it is worth viewing Olive H-7G as a 
potential probe for purification of MMPs in keeping with the previous studies. 
The results obtained by ELISA quantification proved that the Olive H-7G not 
only bound the rhMMP-2 but also, recovery of the enzyme was possible 
using elution buffers containing right salt concentrations (0.3M and 2M NaCl). 
The major aim of this study was to develop a method for detection of both 
intracellular and secreted MMPs applicable for use with both pre-clinical and 
clinical material. The main output of the project to date has been the 
development of an affinity chromatographic method utilizing the Procion Olive 
H-7G dye ligand and its use to purify secreted and cellular MMPs. The 
present study utilized the affinity of Olive H-7G to purify both inactive and 
active MMPs from a biological matrix and analyzed by proteomic mass 
spectrometry. This methodology was initially performed using MMP-2 as a 
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representative target, due to the previous reports of MMP-2 purification using 
this dye (Okada et al., 1986). In order to develop this methodology the 
HT1080 fibrosarcoma model was used, which was previously demonstrated 
to express high levels of MMPs (Atkinson et al., 2007) particularly MMP-2, 
MMP-9 (Roomi et al., 2009), MMP-14 (Koshikawa et al., 2000; Takino et al., 
2004). Also HT29 cell line was used which has been reported to express 
MMP-7 and MMP-14 in high amounts (Atkinson et al., 2007). Binding of Olive 
H-7G to different support matrices (sepharose, sephadex and magnetic 
beads) to synthesize an affinity system was successful as there was no 
leaching off of the Olive H-7G dye from beads even when the suspension 
was kept for more than 3 months at 4°C. 
Initially, the yield of MMP-2 from chromatography was low (<10%), 
irrespective of the presence of serum or detergent. A substantial amount of 
MMP-2 being present in the flow-through fraction suggested a lack of binding 
of MMP-2 to the column. One explanation could be that MMP-2 is being 
processed prior to the chromatography, either by MMP-2 auto-activation 
(Makowski and Ramsby, 2005) or via the trypsin used for cell harvesting as 
previously suggested (Okada et al., 1992). This proteolysis of MMP-2 was 
unlikely since MMP-2 was detectable by ELISA, which detects both active 
and inactive MMP-2. A more likely explanation was that other non-MMP 
proteins were binding to the Olive H-7G-Matrix chromatography beads 
thereby blocking access of MMP-2, a hypothesis reinforced by the number of 
non-MMP proteins present in the eluates when analyzed by LC-MS/MS 
(Appendix 9). 
Analyses of the starting material and chromatography eluates by SDS-PAGE 
demonstrated that a high level of albumin was present from cells grown in 
serum-containing media, and potentially masking the MMP-2 signal (Figure 
6.6). Therefore, although MMP-2 levels were higher in serum-containing 
culture supernatants, the six-fold lower level of total protein from serum-free 
media meant that this would be advantageous for chromatography and 
reduced contamination from non-MMP proteins in the fractions. In this 
context it is interesting to note that although cells were grown in serum-free 
media that albumin was still present, as identified by its presence by LC-
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MS/MS in NaCl eluate HT1080 SFCS E2a (Appendix 9) with significant 
Mascot scores. The complete removal of albumin is therefore not possible, 
unless cells are grown completely without serum, an unfeasible situation. 
Analysis of cell lysates and their corresponding chromatographic eluates by 
western blotting demonstrated the presence of MMP-2 in these fractions. 
Samples prepared using either salt or urea buffers did not demonstrate 
bands corresponding to either pro- or active MMP-2. Alternatively, a band 
was evident at 35kDa in salt and urea lysates (Figure 6.10G and I) but not 
corresponding eluates, suggesting MMP-2 proteolysis in these systems. In 
contrast, MMP-2 was present with a mass of 72kDa, corresponding to latent 
MMP-2, in lysates and 0.3M salt eluates isolated in DMSO (Figure 6.10H). 
This result therefore indicated the potential for this chromatographic 
methodology to isolate MMP-2, a finding which provides a strong base for 
further optimization of this method and potentially detection of other forms of 
MMP-2 and other MMPs. 
Figure 8.1 Screening rhMMPs for Olive H-7G in present study. 
Reactive dye Olive H-7G was screened for MMPs with asterisk. 
Reactive 
Dye 
H-7G
pro-MMP-1 (Okada, 1986)
pro-MMP-2 (Okada, 1986)
pro-MMP-3 (Okada, 1986)
pro-MMP-7 (Imai,     1995)
pro-MMP-9 (Okada,  1992)
pro-MMP-10                 (Nakamura, 1998)
Polymer
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Western Blotting
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MMP-1*
MMP-2*
MMP-3*
MMP-7*
MMP-8*
MMP-9*
MMP-10*
MMP-11*
MMP-12*
MMP-13*
MMP-14*
MMP-15
MMP-16*
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MMP-23A
MMP-19
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Detect by
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Conversely to cell lysates, initial analysis of MMP-2 in culture supernatant by 
western blotting did not yield positive results from any fraction (results not 
shown). In order to confirm the presence or absence of MMP-2 (and other 
MMPs) in cell culture supernatants, and the previous demonstration that 
MMP-2 can bind to the chromatography material (albeit at a low yield), 
samples were prepared for mass spectrometric analysis. Due to interference 
with MALDI-MS/MS, samples have to be prepared in the absence of Brij-35 
detergent. Following this preparation, samples were once again screened by 
gel chromatography and western blotting to indicate the presence of 
sufficient proteins and any MMP-2 proteins. Unexpectedly, MMP-2 was now 
detectable by western blotting in the culture supernatants (Figure 6.8) and 
cell lysates (Figure 6.10G-I), suggesting that Brij-35 may also interfere with 
antibody recognition of MMP-2. 
Analysis of chromatography fractions by LC-MS/MS demonstrated the 
presence of various proteins in all eluates and fractions (Appendix 9). 
Comparative results were also obtained from four fractions shown in Table 
6.6 from four independent HT1080 serum-free culture supernatants, with the 
identification of common proteins such as placental anti-coagulant protein 
(PAPIV), malate dehydrogenase mitochondrial precursor, lung cancer 
antigen NY-LU-1, serum albumin precursor and protein disulfide-isomerase 
A-3 precursor. Thus demonstrating the reproducibility of this assay. 
Importantly for the aims of this project, signature peptides from MMPs 
(Chapter 4) and related proteins were detectable in chromatographic eluates 
from serum-free culture supernatants, specifically for MMP-2, MMP-14, 
TIMP-1 and TIMP-2 (Table 6.6). The detection of the MMP inhibitors TIMP-1 
(HT1080 SFCS eluates: E1-c and E2a) and TIMP-2 (HT1080 SFCS eluates: 
E1-c, E2a and E2c) strongly supports the utility of this method for 
identification of MMPs, particularly considering that these proteins are central 
to activation protein complex of MMPs. 
This is the first demonstration that this methodology has applicability for 
detection of MMPs. The membrane-bound MMP-14 was identified from both 
eluates from 0.3M salt (HT1080 SFCS E1-c) and 2M salt (HT1080 SFCS 
E2c). This either supports the suggestion that MMP-14 is bound weakly to 
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the beads, or implies that MMP-14 was present at high levels and so 
exceeds the capacity of the chromatography beads. The detection of MMP-
14 in culture supernatant rather than its expected localization within the 
cellular membrane was an unexpected observation. One explanation for this 
is that MMP-14 is cleaved from the membrane during sample processing, 
either as a consequence of trypsinization during routine cell culture or due to 
MMP-14 mediated auto-conversion (Rozanov et al., 2008), thereby 
appearing in the supernatant. Alternatively, MMP-14 is also known to exist in 
a soluble form, albeit at low levels, and so this may reflect this observation 
(Hakulinen et al., 2008). Interestingly, although MMP-2 was not detected in 
many of analyses, the fact MMP-2 requires both MMP-14 and TIMP-2 
binding for its activation (Butler et al., 1998; Sounni et al., 2003), and the 
detection of both these species in the chromatography, may imply that MMP-
2 was present but not directly bound to the chromatography beads and so 
undetected in most attempts. This is a hypothesis that obviously needs 
further investigation. Since TIMPs inhibit all the MMPs (Murphy and Nagase, 
2008a), this suggests that other MMPs complexed with TIMPs are not being 
detected for the same reason. An interesting observation was the elution of 
TIMP-1 and TIMP-2 with EDTA containing elution buffers (Table 6.8 and 
Table 6.10) suggesting TIMPs might have more affinity towards Olive H-7G 
and the binding is reversed by EDTA. This highlights use of the dye ligand 
under discussion for the purification and identification of TIMPs. 
These results therefore strongly support that Procion Olive H-7G (also known 
as Dyematrex Reactive Green A) is a suitable chromatography medium for 
purifying MMPs. This is in agreement with the previous studies indicating the 
binding of this dye to several pro-MMPs but also extends these studies by 
demonstrating that this dye can actually be used for isolation of further MMPs 
and has strong potential for affinity chromatography of MMPs from biological 
systems. With optimization of the chromatography procedures, it is hoped 
that other MMPs can also be detected. The data would have been more 
compelling if non-specific binding of proteins could be resolved completely. 
In conclusion, this study has highlighted the challenges encountered in whole 
cell and culture supernatant based assays, particularly the issues of 
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sensitivity and specificity. From the results of the present work, it is 
concluded that simultaneous use of different protein separation techniques 
(MudPIT) performed at protein extraction level (cell fractionation) at protein 
isolation level (affinity chromatography) and at peptide level (nHPLC) allows 
MS and MS/MS analysis for MMP identification. The presence of detergent 
and albumin poses a problem in data interpretation in whole cell and culture 
supernatant based assays and was found to be detrimental in mass 
spectrum data acquisition. The results obtained so far are encouraging for 
the identification of latent and possibly active forms of MMPs by LC-MS/MS 
analysis (Table 5.5). 
This study has acknowledged the challenges of developing a robust 
purification and identification method for MMPs exploiting the protease 
binding ability of Olive H-7G. Issues of selectivity and sensitivity within the 
context of techniques (MALDI-MS) utilized which by implication do not bode 
well for the low abundance protein identification. Hence, demonstration of 
non-specific proteins and lack of selectivity of Olive H-7G it is unlikely to 
translate the MMP purification success within clinical settings and further 
work needs to be done. Monitoring active MMPs using approaches described 
in this study will prove valuable in terms of our understanding of cancer and 
its treatment. 
This study aimed to evaluate a previously commercially available method in 
conjunction with proteomics methods. Procion Olive H-7G dye was used as 
part of a series of chromatography steps used to purify pro-MMPs in the 80’s 
and 90’s but before proteomics techniques were widely available and before 
affinity capture had been re-introduced as a valuable method to enrich LAP 
for MS-based identification in the 00’s. This project represents an opportunity 
to evaluate the traditional affinity purification method in conjunction with a 
modern LC-MALDI proteomics strategy to characterize a therapeutically 
important group of proteins in cancer samples. As opposed to previous 
studies, Olive H-7G was screened against more MMPs from various classes 
to find its broad range selectivity (Figure 8.1). The primary objective of this 
project is to develop affinity based methods, based on common 
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physicochemical and functional properties, for unambiguous detection by 
proteomic profiling of human pro-MMPs within a range of biological samples. 
One of the outcomes of the approach described will help to progress in the 
detection of endogenous active and latent forms of MMPs in complex 
proteomes, an important objective with many diagnostic applications. It will 
help find out their state (active or latent) at the time of secretion and 
understand their role in tumour progression and metastasis in cancer. A long 
term outcome of MALDI-MS based MMP profile characterization proposed in 
this study is that it will help monitor the efficacy of a drug administered 
causing changes in MMP quantities being secreted. The development of new 
affinity capture tool for pro-MMPs and their subsequent characterization will 
provide a useful insight into their regulation prior to secretion and possible 
strategies to stop their activation on the onset of disease. 
In summary, major findings of the study are: 
 Pro-MMPs bind to H-7G-Sepharose chromatography beads. 
 H7-G also binds other proteins (MDH) specifically as previously 
reported. 
 Chromatography matrices constitute a major source of non-specific 
protein binding and no single type of bead is ideally suited. 
 MMPs purified from biological sources and identified by LC-MS/MS 
are: 
ND: Not detected 
Cell Line MMPs Identified 
HT1080
Culture supernatant MMP-2MMP-14
Cell extract ND
HT29
Culture supernatant MMP-7 (SM)
Cell extract ND
Dermal papilla Culture supernatant
MMP-1
MMP-2
MMP-3 (Beads)
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Future Work 
• Potential use of signature peptides from pro- and active region for 
each MMP in MRM analysis in future studies. 
• Introducing structural changes in Procion Olive H-7G dye so as to 
improve its selectivity towards MMPs. 
• Since Olive H-7G is a small molecule, it might have a better chance of 
binding to smaller peptide molecules instead of larger 3D proteins. 
One possible approach can be affinity purification of peptides of MMPs 
using Olive H-7G instead of MMP affinity chromatography because of 
the difference in molecular sizes between protein and peptide. 
• Introducing structural modifications (phosphorylation or glycosylation) 
in MMP’s highly conserved region and see if the Olive H-7G dye has 
better specificity for phosph- or glyco- peptides. 
• Design and synthesis of inhibitor based analogues as an alternative 
method for increased selectivity towards MMPs and reduce non-
specific binding. 
• Use of other affinity based ligands such as Procion Red HE-3B to 
compare its efficiency with Olive H-7G ligand. 
• Identification of pro- or active form of MMP with greater sequence 
coverage using more than one digestion enzymes for increased 
confidence in protein identification from the MALDI-MS and database 
searching. 
• Determination of changes in MMP levels under stressed physiological 
conditions, during tumourigenesis or following drug treatment. 
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Appendices 
Appendix 1 Buffer compositions. 
SDS-PAGE running buffer (10X) 
Western blot transfer buffer (10X) 
Loading dye 
Components
Tris-Base 30g
Glycine 144g
SDS 5g
dH2O Upto 1L
Components
Tris-Base 84.4g
Glycine 225.2g 
dH2O 400mL 
Methanol 100mL for 1X 
Components Final Conc.
Tris-HCl 0.1M
Glycerol 5%
dH2O -
SDS 0.10%
Bromophenol 0.01%
ȕ-mercaptoethanol 1%
222 
TBS (10X) 
CAB dialysis buffer (10X) 
Appendix 2 Cell lines origin. 
Components
Tris-Base 6g
NaCl 43g
dH2O Upto 500mL
Components 
Tris-Base (pH 7.6) 30.3g
NaCl 58.4g
CaCl2 0.74g
NaN3 (20%) 50mL
dH2O Upto 500mL
Cell Line Origin/ Source Reference
HT1080
Fibrosarcoma arising 
adjacent to the acetabulum of 
a 35 year old Caucasian 
male.
Rasheed et al., 
1974.
HT29
Colorectal adenocarcinoma
from a 44-year-old Caucasian 
female.
J. Natl. Cancer Inst. 
59: 221-226, 1977.
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Appendix 5 Experimental m/z of rhMMPs including 
signature peptides. 
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-10 MMP-13 MMP-14
m/z m/z m/z m/z m/z m/z m/z m/z m/z
830.55 843.38 707.21 1065.46 714.28 714.26 733.15 717.20 715.32
836.53 1158.47 817.75 1105.47 733.19 733.16 875.31 719.20 817.79
873.51 1184.57 862.37 1113.47 735.18 735.17 897.34 795.34 824.98
879.50 1201.46 886.43 1129.45 748.29 741.33 942.32 1045.52 841.61
915.48 1223.47 905.37 1156.47 791.29 750.46 988.37 1085.48 860.94
954.49 1223.48 924.28 1165.35 804.36 823.33 992.34 1087.47 878.91
958.44 1266.47 926.28 1175.38 847.41 824.29 997.37 1089.54 880.91
960.54 1295.59 961.40 1177.37 942.36 867.30 1009.36 1129.49 890.87
1072.48 1401.47 991.41 1180.40 1007.42 873.33 1022.34 1131.49 892.86
1115.45 1403.53 1005.39 1208.35 1045.55 959.27 1041.41 1133.56 894.89
1127.51 1418.57 1006.37 1227.27 1047.39 977.36 1085.41 1145.42 911.37
1132.69 1461.56 1049.40 1229.31 1096.38 997.35 1090.36 1173.51 1010.37
1176.78 1587.54 1068.27 1290.29 1105.45 999.29 1129.44 1175.51 1032.35
1213.38 1603.51 1090.51 1321.42 1111.40 1001.41 1133.51 1177.58 1034.36
1216.46 1608.45 1093.42 1364.41 1124.47 1041.41 1135.41 1207.32 1053.37
1220.70 1651.44 1101.50 1452.51 1126.43 1044.42 1160.35 1217.52 1058.39
1232.41 1653.48 1126.39 1468.49 1129.51 1061.19 1173.46 1219.52 1083.89
1259.42 1670.51 1133.50 1577.53 1133.59 1065.34 1174.41 1221.60 1101.86
1264.71 1673.49 1137.44 1601.48 1135.40 1085.41 1177.53 1261.54 1103.85
1275.38 1728.47 1143.42 1609.51 1154.40 1089.52 1217.45 1263.54 1243.48
1308.72 1732.39 1178.43 1620.52 1162.54 1129.46 1221.55 1265.62 1271.42
1352.72 1837.76 1181.46 1634.53 1167.44 1133.54 1251.50 1305.56 1287.50
1396.71 1880.76 1185.52 1639.49 1174.43 1152.55 1261.49 1307.56 1303.43
1440.70 1901.64 1186.42 1765.42 1177.61 1166.45 1265.55 1309.64 1313.49
1484.71 2107.71 1188.30 1791.40 1183.41 1167.36 1298.38 1320.51 1320.45
1572.70 2114.78 1190.29 1862.50 1188.36 1173.48 1308.51 1349.58 1325.42
1682.28 2146.70 1205.33 1879.53 1217.50 1177.56 1313.41 1351.58 1331.52
1792.29 2150.66 1207.33 1941.44 1221.63 1184.40 1349.53 1353.65 1335.47
1798.64 2154.63 1225.48 1943.44 1238.38 1214.46 1351.53 1357.50 1342.43
1835.25 2178.64 1237.57 2383.50 1252.51 1216.39 1353.61 1363.51 1356.49
1840.24 2182.72 1267.23 2630.74 1261.57 1217.48 1358.43 1382.42 1375.41
1857.26 2223.75 1269.40 2704.63 1263.58 1221.58 1359.46 1393.59 1377.38
1897.21 3017.91 1294.58 2738.83 1265.65 1227.39 1370.43 1395.59 1399.49
1900.22 3309.91 1310.58 2748.16 1295.51 1246.30 1372.43 1397.67 1402.51
1313.52 2772.33 1305.59 1261.51 1393.54 1437.61 1419.55
1315.54 2786.83 1309.66 1265.60 1397.62 1439.61 1424.49
1317.59 2793.01 1314.43 1305.53 1437.55 1441.69 1432.54
1337.58 2802.80 1316.42 1309.61 1441.63 1457.66 1463.57
1356.50 2815.24 1349.61 1322.43 1467.45 1476.57 1765.47
1358.50 2829.82 1353.68 1328.49 1481.56 1481.63 2383.55
1399.50 2843.82 1389.61 1345.51 1484.52 1483.63 2410.78
1401.54 2848.73 1393.63 1353.63 1525.59 1485.70 2497.79
1418.40 1395.62 1388.52 1565.48 1525.64 2625.83
1420.40 1397.71 1391.53 1569.61 1527.64 2706.77
1445.58 1426.47 1393.56 1595.51 1529.72 2953.95
1463.59 1437.65 1397.65 1613.64 1538.48 2975.93
1489.59 1439.64 1437.58 1617.63 1569.66 2985.92
1492.57 1441.73 1440.58 1638.55 1571.66 2996.93
1553.56 1467.54 1481.59 1657.63 1573.74
1596.55 1468.54 1485.66 1671.41 1591.47
234 
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-10 MMP-13 MMP-14
m/z m/z m/z m/z m/z m/z m/z m/z m/z
1615.46 1481.67 1532.55 1701.65 1608.49
1691.61 1485.75 1569.61 1819.62 1613.68
1713.64 1522.51 1611.41 1842.62 1615.68
1734.61 1525.69 1619.46 1885.61 1617.76
1753.52 1529.76 1672.44 1898.51 1638.62
1755.53 1535.53 1680.61 2063.64 1651.49
1775.75 1565.50 1701.60 2120.62 1657.70
1815.42 1569.71 1794.59 2136.74 1659.71
1838.67 1573.79 1798.62 2142.68 1661.78
2064.74 1578.54 1837.56 2176.56 1670.40
2073.80 1612.46 1856.49 2179.68 1672.41
2107.75 1613.73 1858.50 2192.59 1701.71
2122.84 1617.81 1921.57 2198.69 1705.79
2165.84 1657.75 1938.57 2200.75 1741.62
2184.75 1661.83 1952.77 2235.58 1745.74
1701.77 1983.47 2249.59 1749.81
1705.85 1997.99 2254.50 1789.75
1724.63 2012.54 2498.81 1793.82
1737.61 2055.53 2596.81 1833.77
1745.79 2069.76 2635.84 1837.84
1749.87 2074.45 2704.70 1988.67
1767.63 2077.46 2871.88 1997.68
1780.62 2091.25 2899.37 2011.51
1786.54 2105.78 2913.94 2043.69
1804.68 2148.77 2931.97 2073.41
1828.67 2167.68 2956.33 2136.72
1890.68 2169.69 2962.96 2174.54
1926.70 2178.67 2970.94 2416.29
1974.70 2464.16 2975.85 2431.70
2017.70 2478.67 3032.85 2437.94
2072.73 2540.58 3092.88 2460.10
2103.79 2646.59 3119.84 2474.70
2134.64 2665.76 3247.92 2488.70
2136.66 2720.81 3526.09 2493.61
2146.76 2920.81 3749.21 2495.62
2156.74 3013.83 3759.14 2552.81
2187.71 3025.70 2555.50
2204.76 3039.20 2557.52
2208.67 3053.69 2559.03
2210.68 3108.98 2568.80
2266.66 3115.59 2575.89
2270.59 3123.78 2584.78
2272.58 3152.17 2594.75
2309.82 3166.78 2600.92
2319.81 3174.93 2637.76
2402.88 3185.68 2657.68
2822.98 3674.97 2885.94
3033.93 2986.82
3233.18 3049.73
3320.20 3131.86
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Appendix 6 Mass peaks of Brij-35. 
Brij-35 (0.05%) Brij-35 (0.05%)
m/z m/z
745.14 1425.45
781.25 1441.42
789.15 1469.47
825.25 1485.44
833.16 1513.49
869.26 1529.46
877.17 1557.50
913.28 1573.48
921.18 1601.52
941.30 1617.50
957.29 1645.53
965.19 1661.52
985.30 1689.55
1001.29 1705.54
1009.20 1749.56
1029.31 1793.56
1045.30 1837.59
1053.21 2241.60
1073.33 2285.61
1089.31 2329.62
1097.22 2373.64
1117.34 2417.65
1133.32 2461.67
1141.24 2505.68
1161.35 2549.69
1177.33 2593.70
1185.25 2637.72
1205.36 2681.73
1221.34 2725.75
1229.27 2769.76
1249.38 2813.78
1265.35 2857.79
1293.39 2901.81
1309.37 2945.82
1337.41 2989.84
1353.39 3033.85
1381.43 3077.87
1397.40
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